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Abstract 
This research to develop and validate the BILAG-2004 index for the assessment of 
disease activity in patients with SLE had involved several validation studies. 
The reliability of this index was shown in 2 exercises, as assessed by level of agreement, 
kappa statistic, ICC and disagreement between physicians. This study also highlighted the 
importance of training in ensuring optimal performance of the index. This index had construct 
validity as higher scores in the index were significantly associated increasing ESR, decreasing 
C3, decreasing C4, elevated anti-dsDNA antibody and increasing SLEDAI-2000 scores. Active 
disease scores were significantly associated with increase in therapy, confirming the criterion 
validity of the index. Sensitivity to change was demonstrated as changes in the score of the index 
were differentially related to change in therapy, with greater change in score having greater 
predictive power. Rasch analysis showed that this index had a good fit to the Rasch model, 
indicating that it is a unidimensional ordinal scale index with internal construct validity. 
 The validation studies led to revisions of the index to ensure it had face and content 
validity. The results of this research have shown that the revised BILAG-2004 index is valid for 
use to assess SLE disease activity.  
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Chapter 1     Introduction 
 
 
Systemic lupus erythematosus (SLE) is a multi-system auto-immune disorder which is 
characterised by the production of numerous auto-antibodies. The term ‘lupus’ is a Latin word 
that literally means wolf. How this disease became associated with this animal is not known, 
but it has been suggested that the skin rash resembled a wolf’s bite. For many centuries, this 
disease was recognised as a chronic disease of the skin until the late 19th century, when its 
systemic manifestations were first described (Smith et al. 1988). In the modern era, this 
disease is one of the most common multi-system autoimmune diseases (Jacobson et al. 1997). 
 
1.1 Epidemiology 
Although individuals of all ages can be affected, this is predominantly a disease of 
women of child-bearing age with a female-to-male ratio of around ten to one (10:1). A 
community-based study during 1991 in the Birmingham and Solihull area of the West 
Midlands found a point prevalence of 1 in 2000 and incidence of 6.8 per 100,000 per year 
amongst adult women. It had been noted that it was much more common amongst women 
who were of Afro-Caribbean (prevalence rate 111.8/100,000, incidence 25.8/100,000/year) 
and South Asian descent (prevalence rate 46.7/100,000, incidence 20.7/100,000/year) as 
compared to Caucasian women (prevalence rate 20.7/100,000, incidence 4.3/100,000/year) 
(Johnson et al. 1995).  
This disease has been reported worldwide but there are differences in the incidence, 
prevalence, pattern of organ involvement and severity of the disease among different ethnic 
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groups (Pons-Estel et al. 2004; Alarcon et al. 2002; Alarcon et al. 1999; McCarty et al. 1995; 
Serdula et al. 1979). This has been illustrated in a cross sectional study comparing SLE 
patients seen at three university rheumatology centres in Birmingham, Brazil and Sweden 
using a standard protocol in which there were differences in the severity and pattern of organ 
involvement among the different nationalities (Johnson et al. 1994). The incidence and 
prevalence of the disease appears to be on an increasing trend (Uramoto et al. 1999). 
Prior to the advent of corticosteroids, this disease was considered a fatal disease with a 
5-year survival rate of less than 55% (Merrell et al. 1955). Over the last few decades, the 
survival has improved considerably with 10-year survival rate of around 90% and this most 
likely reflects increased detection of milder disease and improvement in the management of 
the disease (Cervera et al. 2003; Abu-Shakra et al. 1995). Despite this improvement in 
survival, SLE patients have a much lower life expectancy than that of the general population 
with an average of fourfold increased risk of death and this is most pronounced in those under 
the age of 45 years (Moss et al. 2002). Similar mortality results were obtained from an 
analysis of the Birmingham SLE cohort (Leung MH, MSc thesis, University of Birmingham 
2002). 
 
1.2 Immunopathology 
 Multiple abnormalities of the innate and adaptive immune system are involved in the 
pathogenesis of SLE. It is characterised by excessive B-cells stimulation leading to 
autoantibody production, abnormal T-cell function, impaired clearance of immune complexes 
(resulting in deposition in tissues), complement activation and defective cellular apoptosis. 
However, these abnormalities are not uniform and there are likely to be differences between 
 3
patients and within the same patient at different time points or stages of the disease, resulting 
in considerable heterogeneity in its presentation and progress. 
1.2.1 B-cell Abnormalities 
 Auto-reactive B-cells do exist in normal individuals and they produce natural 
autoantibodies (usually of IgM isotype) that do not cause disease or tissue damage. These 
natural autoantibodies do not undergo isotype switching and affinity maturation. In contrast, 
the autoantibodies found in SLE patients have undergone isotype switching and affinity 
maturation. These processes depend on cognate B-cell-T-cell interaction (Figure 1-1).  
B-cells are initially activated in the T zone of the lymph node and at this site, they also 
present the endocytosed antigen to T-cells. This cognate interaction with T-cells is an 
important signal regulating isotype switching and the generation of the germinal centre 
response. The activated B-cells then migrate into the B cell zone to form germinal centres. 
They undergo rapid division and spontaneously mutate the variable region of their antibody 
genes in the dark zone of the germinal centre. The resultant hypermutated B-cells (centrocyte) 
subsequently undergo a series of processes that will determine their survival (Figure 1-2). It 
must be able to recognise and pinocytose surface-bound antigen from follicular dendritic cells 
in the light zone. This antigen is then processed and presented on its surface as part of a class 
II MHC molecule. A further selection step depends on cognate interaction with germinal 
centre T-cells, present in the outer light zone. If the antigen presented by the centrocyte is 
recognised by the T-cell, an interaction (via CD40 and CD40-ligand) is triggered which will 
override the apoptosis programme in the centrocyte and the cell then becomes either a mature 
memory B-cell, or a plasmablast which can differentiate into a antibody producing plasma 
cell, or it may recirculate within the germinal centre leading to further affinity maturation. 
Failure to recognise the antigen on the surface of the follicular dendritic cell or interaction 
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with the T-cell in the outer light zone will lead to apoptosis and deletion of the centrocyte 
(Salmon et al. 1999).  
Figure 1-1: Development of high affinity B-cells in a germinal centre (reproduced from 
Salmon and Gordon 1999). B, B-cell; CB, centroblast; CC, centrocyte; FDC, follicular 
dendritic cells; mB, memory B-cell; PC, plasma cell; T, T-cell. 
 
Figure 1-2: The process of selecting memory B-cells in a germinal centre (reproduced 
from Salmon and Gordon 1999). 
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In SLE, there is failure of peripheral tolerance with the presence of auto-reactive T-
cells and follicular dendritic cells presenting autoantigens that allow the survival and 
expansion of auto-reactive B-cells leading to production of autoantibodies (Yurasov et al. 
2005). 
 There is evidence that SLE B-cells are not just innocent bystanders producing large 
amounts of autoantibodies under the influence of auto-reactive T-cells, but they play a more 
central role in the pathophysiology of SLE. T-cell independent mechanisms of autoantibody 
production have been described in which DNA is able to induce immunoglobulin class 
switching from IgM to IgG in B-cells. This is mediated through Toll-like receptor-9 and 
interleukin-10, and subsequent antibody production is mediated through B-cell receptor and 
B-cell activating factor (BAFF) (He et al. 2004). Toll-like receptors are pattern recognition 
receptors that initiate the innate immune response, with toll-like receptor-9 being involved in 
triggering activation of B-cells. 
There are intrinsic defects in SLE B-cells leading to aberrant signal transduction and 
exaggerated response to stimuli, resulting in B-cell hyperactivity that is a striking feature of 
SLE. Another contributing factor is increased production of BAFF by dendritic cells, that 
stimulates B-cell survival and maturation. These B-cells can activate T-cells through aberrant 
expression of stimulatory molecules (such as CD40L, CD80 and CD86) on the surface 
membrane or through its function as efficient antigen-presenting cells (Pugh-Bernard et al. 
2006). In addition, activated B-cells secrete pro-inflammatory cytokines and some of these 
(such as interleukin-6 and interleukin-10) have a stimulatory and positive feedback effect on 
B-cells in an autocrine manner.  
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1.2.2 T-cell Abnormalities 
 Auto-reactive T-cells are detectable in SLE patients and also in the normal population 
(Hoffman et al. 1993). Normally, these T-cells have low affinity for autoantigens and are 
prevented from expanding by regulatory mechanisms. However in SLE, there appears to be a 
breakdown in immune tolerance that allows pathogenic auto-reactive T-cells to escape into 
the periphery and expand. T-cells that are reactive to several nuclear antigens (including 
DNA, histones and small nuclear ribonucleoprotein) have been found in peripheral blood of 
SLE patients. Upon recognition of autoantigens presented by antigen-presenting cells, these 
T-cells play an important role in autoantibody production by assisting class switching and 
affinity maturation of auto-reactive B-cells (as described in the previous section), and also 
produce cytokines (such as interferon-α, interferon-γ, interleukin-4 and interleukin-10) which 
promote autoantibody production (Hoffman 2004). 
Furthermore, SLE T-cells have a hyperexcitable phenotype similar to that of B-cells. 
Aberrant T-cell receptors (TCR) have been found in a large proportion of SLE patients that 
have a lower excitation threshold than the normal TCR (Enyedy et al. 2001). In addition, there 
is increased quantity of lipid rafts on the T-cell membrane (Jury et al. 2004). These lipid rafts 
are cholesterol and gangliosides enriched membrane microdomains. They play an important 
role in assembly of many cell membrane-associated signalling complexes. In SLE, these rafts 
also appeared to be clustered in a large fraction of T-cells despite the absence of obvious 
stimuli. This phenotype may contribute to the heightened sensitivity of TCR signalling 
observed in SLE. 
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1.2.3 Abnormalities in Apoptosis 
 Apoptosis or programmed cell death is a normal physiological phenomenon which is 
an active, tightly regulated process leading to ordered destruction of cells. This avoids the 
release of intracellular contents into extracellular microenvironment that would lead to an 
inflammatory response. During this process, a variety of intracellular components, including 
nuclear components such as nucleosomes (containing DNA), Ro and La, are clustered at the 
surface of the apoptotic cells (Casciola-Rosen et al. 1994). These components do not normally 
encounter the immune system as the apoptotic cells are rapidly cleared by phagocytic cells. 
The complement system also helps in clearing apoptotic cells through complement receptor-
mediated phagocytosis, as C1q can bind to these cells which triggers complement activation 
and deposition of C3 and C4 on these cells. C-reactive protein (CRP) also plays a role as it 
binds to apoptotic cells in a calcium-dependent manner and augments the classical pathway of 
complement activation, but it protects the apoptotic cells from the assembly of the terminal 
complement components (Gershov et al. 2000). Furthermore, CRP-enhanced opsonisation and 
phagocytosis of apoptotic cells by macrophages is associated with the expression of anti-
inflammatory cytokine transforming growth factor β. 
 In SLE, there is defective clearance of apoptotic cells due to defective phagocytosis 
from altered maturation of phagocytes (Blanco et al. 2001). This defect is further hampered 
by deficiency in complement components (congenital or acquired) that is common in SLE. As 
a result, there is fragmentation of the apoptotic cells with release of apoptotic blebs containing 
intracellular antigens (autoantigens). These autoantigens can be taken up and processed by 
dendritic cells and presented to T and B cells, triggering the induction of autoantibodies that 
leads to loss of peripheral tolerance. Furthermore, these autoantigens can stimulate the 
immune system to produce more autoantibodies and can bind to existing autoantibodies to 
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form immune complexes that get deposited within tissues causing inflammatory reactions. 
Apart from that, autoantibodies that are present in SLE may bind to surface of apoptotic cells 
and the resulting antibody-mediated phagocytosis may trigger secretion of pro-inflammatory 
cytokines (Rovere et al. 1999). The resultant disease flare causes more apoptosis and 
consumption of complement components, further exacerbating the problem. 
 
1.2.4 Autoantibodies and Immune Complexes 
One of the hallmark features of SLE is the presence of autoantibodies. More than 100 
autoantibodies have been described in SLE that target various autoantigens including nuclear 
antigens, cytoplasmic antigens and phospholipid-associated antigens (Sherer et al. 2004). The 
common autoantibodies in SLE, being present in more than 25% of patients, are anti-ssDNA 
(single-stranded DNA), anti-dsDNA (double-stranded DNA), anti-Ro, anti-poly ADP ribose 
polymerase, anti-histone/nucleosomes, and antiphospholipid antibodies. These autoantibodies 
can be broadly divided into organ-specific autoantibodies (such as anti-neuronal antibody, 
anti-platelet antibody) and non-organ-specific autoantibodies (such as antinuclear antibodies). 
The most well recognised autoantibodies associated with SLE are anti-nuclear antibodies and 
anti-double stranded DNA (anti-dsDNA) antibodies. Most of these autoantibodies are of IgG 
subtype, following isotype switching, and have the capacity to cause tissue damage.  
Immune complexes are formed when autoantibodies bind to their target antigens. They 
may be formed within the circulation resulting in circulating immune complexes, or locally 
when the autoantibodies bind to antigens within tissues. Normally, immune complexes are 
cleared rapidly from the circulation by the mononuclear phagocyte system and this prevents 
tissue deposition of immune complexes that would otherwise results in inflammation and 
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damage. In SLE, there is impaired clearance of immune complexes by mononuclear 
phagocyte system (Lobatto et al. 1988). 
The complement system also plays an important role as activation of the classical 
complement pathway by the immune complexes aids the clearance of immune complexes by 
phagocytes. Furthermore, activated complement components that are bound to the immune 
complexes inhibit immune complex interaction and prevent extension of immune complex 
lattice (Johnson et al. 1987). This leads to smaller immune complexes and reduced immune 
precipitation (that facilitates tissue deposition). This complement-mediated mechanism of 
immune complex clearance and prevention of immune precipitation is defective in 
hypocomplementaemia, which is common in SLE. 
 
1.2.5 Complement System Abnormalities 
 Following the deposition of immune complexes in tissues, there is activation of the 
classical complement pathway and this generates pro-inflammatory fragments of complement 
proteins (C3a, C4a and C5a). These complement activation products attract and activate 
leucocytes which release various pro-inflammatory mediators resulting in inflammatory 
infiltrate. Activation of the complement system results in consumption of complement 
components leading to reduced plasma levels of classical pathway complement proteins. In 
addition, up to one third of SLE patients have anti-C1q autoantibodies (which are associated 
with lupus nephritis) that bind to activated C1 complex (bound to immune complexes) which 
further amplify complement activation (Walport 2002). 
Paradoxically, hereditary deficiency of classical complement components is associated 
with a strong predisposition to developing SLE. The complement system plays an important 
role in maintaining immune tolerance to prevent the development of autoimmunity as it 
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assists with the rapid clearance of immune complexes and apoptotic cells (Walport 2002). 
Furthermore, it may play a role in the negative selection of auto-reactive lymphocytes that is 
activated through opsonisation of autoantigens by C4b or C3b (via complement receptors) 
(Prodeus et al. 1998). In addition, decreased serum complement C3 and C4 levels (hereditary 
or acquired) prevent formation of soluble immune complexes and so promotes deposition and 
persistence of immune complexes in tissues (Schifferli et al. 1985).  
 
1.2.6 Cytokine Abnormalities 
 Cytokines have been studied extensively in human and murine SLE. A large number 
of cytokines have been linked to SLE immunopathology. It is beyond the scope of this section 
to review all the cytokines studied to date and this area has been reviewed comprehensively 
by Crow and Kirou (Crow et al. 2007). This section will focus on the key cytokines involved 
in SLE which are interferon-α, interleukin-10, interleukin-6 and tumour necrosis factor-α 
(TNF-α). 
 The high level of interferon-α expression is one of the first cytokine abnormalities 
described in SLE. This increased expression is further substantiated by the observation that 
the treatment of malignancies and hepatitis C with recombinant interferon-α occasionally 
results in the development of SLE (Ioannou et al. 2000). Recently, it has been found that there 
is a characteristic up-regulation of interferon-α gene expression, which is known as the 
interferon-α gene signature, in the peripheral blood mononuclear cells of SLE patients 
(Baechler et al. 2003). It is produced predominantly by plasmacytoid dendritic cells following 
stimulation with immune complexes containing apoptotic cells or nuclear fragments via Fc-
gamma receptor-IIA (FcγRIIA) (Lovgren et al. 2004; Bave et al. 2003). Interferon-α induces 
differentiation of monocytes into efficient antigen-presenting cell capable of presenting 
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autoantigens, and promote survival and differentiation of activated T and B lymphocytes. 
When produced in abundance, this cytokine favours the development of auto-reactive immune 
response. The level of gene expression and serum levels of interferon-α correlated with SLE 
disease activity and severity (Kirou et al. 2005; Bengtsson et al. 2000). 
 There is increased production of interleukin-10 in SLE patients (Llorente et al. 1994) 
and this comes from several sources including B-cells, T-cells and monocytes. The serum 
level of this cytokine had been found to be correlated with SLE disease activity (Houssiau et 
al. 1995). It is a potent stimulator of B-cell proliferation and differentiation, thus promoting 
production of autoantibodies. This cytokine also has anti-inflammatory effects in which it 
inhibits a range of functions in both T-cells and macrophages. The effect on T-cells may have 
accounted for some of the T-cell abnormalities seen in SLE as some of these abnormalities 
were restored following treatment with anti-interleukin-10 monoclonal antibody (Llorente et 
al. 2000). 
Interleukin-6 is a pleiotropic cytokine with wide range of effects in immune 
regulation, inflammation, haematopoiesis and oncogenesis. Serum interleukin-6 levels are 
increased in SLE and correlated with disease activity (Spronk et al. 1992). Furthermore, its 
production has been detected at sites of affected organs in SLE: cerebrospinal fluid (Hirohata 
et al. 1990), renal glomeruli (Horii et al. 1993) and skin (Nurnberg et al. 1995). It is a pro-
inflammatory cytokine that promotes B-cell maturation to plasma cells and secretion of 
immunoglobulins. Therefore, it appears to play an important role in B-cell hyperactivity that 
is characteristic of SLE. 
TNF-α is another pro-inflammatory cytokine with pleiotropic effects on a variety of 
cells. The levels are increased in SLE and appears to correlate with disease activity 
(Studnicka-Benke et al. 1996). The precise role this cytokine play in SLE is not clear but it is 
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likely to be involved in the immunopathology as TNF-α has been demonstrated within lesions 
of lupus nephritis (Herrera-Esparza et al. 1998) and anti-TNF-α therapy has been used in an 
open label study for the treatment of active disease with clinical improvement of arthritis and 
nephritis (Aringer et al. 2004). 
 
1.3 Aetiopathogenesis 
 The aetiopathogenesis of SLE is not completely understood but is complex involving 
the following factors: 
  1. Genetic factors 
  2. Environmental factors 
  3. Hormonal factors 
 
1.3.1 Genetic Factors 
 The genetic basis of SLE is supported by the ethnic differences in disease incidence 
and prevalence, and the tendency of this disease to aggregate in families. The degree of 
familial clustering, as measured by risk ratio of sibling recurrence as compared to the 
population, has been estimated to be as high as 29 (Alarcon-Segovia et al. 2005). Twin studies 
has revealed a higher concordance rate in monozygotic twins (at least 24%) than dizygotic 
twins (at least 2%) (Deapen et al. 1992). Therefore, SLE is considered a complex genetic trait 
in which there is lack of direct correlation between a phenotype and a genotype. This trait 
could be either due to the same genotype resulting in different phenotypes or different 
genotypes can result in the same phenotype. This is further complicated by the definition used 
to define SLE in research setting, which is dependent on fulfilling 4 of 11 American College 
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of Rheumatology (ACR) criteria (Hochberg 1997; Tan et al. 1982), making SLE a disease 
with heterogeneous phenotypes. 
 Genetic factors are major determinant of susceptibility to the disease and possibly 
contribute to the disease severity as well. The important genetic associations of SLE are: 
1. Major histocompatibility complex (MHC) 
2. Hereditary complement deficiency 
3. Immunoglobulin receptors (Fcγ receptors) 
4. Cytotoxic T lymphocyte antigen-4 (CTLA-4) 
5. Programmed cell death-1 (PD-1) 
6. Mannose-binding lectin (MBL) 
 
 The human MHC region is located in chromosome 6 which encodes the human 
leucocyte antigen (HLA) genes and many other genes that are involved in self/non-self 
recognition, antigen presentation and immune regulation. There has been consistent 
association of HLA-DR2 and HLA-DR3 with SLE in Northern European population, 
conferring a two-fold relative risk with each allele (Graham et al. 2002). This region encodes 
the MHC class II molecules that are involved in antigen presentation to T-cells.  
 Homozygous hereditary deficiency of the early components of the classical 
complement pathway is very strongly associated with development of SLE. There is a 
hierarchy of the prevalence and severity in the association, with C1q deficiency having the 
worst risk (more than 90%) and severity, followed by C4 (risk of 75%) and C2 (risk of 10%) 
deficiencies (Walport 2002). The C1q genes are located in chromosome 1 while the genes for 
C4 and C2 are within the MHC class III region of chromosome 6. 
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 Another strong genetic association with SLE has been described for allelic variants of 
Fcγ receptor (FcγR) genes. FcγRs are a family of glycoprotein receptors that are expressed on 
the surface of leucocytes and bind to the Fc portion of IgG molecules, playing an important 
role in clearance of immune complexes. Three classes of these receptors have been identified 
(FcγRI, FcγRII and FcγRIII) and they vary in their binding capacity for IgG, their preferences 
for IgG isotypes, the cell types that express them and the intracellular signal they elicit. 
FcγRII and FcγRIII are low-affinity receptors that bind to polymeric IgG in immune 
complexes. Polymorphisms of FcγRIIA and  FcγRIIIA have been associated with SLE and 
development of lupus nephritis (Karassa et al. 2003a; Karassa et al. 2003b; Norsworthy et al. 
1999). These polymorphisms resulted in less efficient binding and clearance of immune 
complexes. 
 PD-1 and CTLA-4 are cell surface receptors that are structurally related, belonging to 
the CD28 co-stimulatory receptor family. PD-1 is expressed on activated T-cells and B-cells, 
while CTLA-4 is found on activated T-cells. Activation of both these receptors results in 
negative regulatory effects on the immune response. Polymorphisms of PD-1 (Prokunina et al. 
2002) and CTLA-4 (Lee et al. 2005a) genes have been associated with SLE. 
 The lectin pathway leads to complement activation without the need for the presence 
of immunoglobulin. It is initiated when MBL binds to repetitive carbohydrate moieties (such 
as mannose, N-acetyl-D-glucosamine and N-acetyl-mannosamine) which are present in 
abundance in various micro-organisms. MBL is structurally similar to C1q and MBL variant 
alleles, which result in its deficiency, are associated with increased risk of SLE, in similar 
fashion to hereditary complement deficiency (Lee et al. 2005b). 
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1.3.2 Environmental Factors 
 Environmental factors probably play a role in triggering the autoimmune process in a 
genetically susceptible individual. Broadly, these factors are: 
  1. Ultraviolet light  
  2. Infections  
  3. Drugs 
  4. Heavy metals and chemicals 
Ultraviolet light exposure has been well known to trigger flares of SLE and 
photosensitivity is a characteristic manifestation. The use of sun screen that protects against 
ultraviolet light has been shown to be effective in preventing ultraviolet-induced lupus 
erythematosus (Herzinger et al. 2004). Furthermore, ultraviolet-light exposure via a tanning 
device has been associated with the development of SLE in a previously healthy individual 
(Fruchter et al. 2005). Ultraviolet light results in apoptosis of keratinocytes and expression of 
autoantigens such as Ro, La, RNP and Sm on the surface of apoptotic cells (Casciola-Rosen et 
al. 1994). Impaired clearance of these apoptotic cells could lead to the induction of 
autoantibodies. In SLE patients, autoantibodies could bind to these exposed autoantigens with 
a resultant increase in interferon-α production and flare of disease activity (Reefman et al. 
2007). 
 It is also a common clinical observation that infections can trigger SLE flares and may 
precede the development of autoantibodies and SLE. A number of infectious agents have been 
linked to SLE, but Epstein-Barr virus (EBV) infection is the best studied. It has been shown 
that more lupus patients had evidence of past EBV infection as compared to controls in both 
paediatric and adult age groups (James et al. 2001; James et al. 1997). The exact mechanisms 
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remained uncertain but many viruses induce production of proteins with epitopes that are 
similar to self-antigens. As a result, antibodies produced against the viral proteins could cross-
react with self-antigens. These opsonised self-antigens would then be phagocytosed and 
presented to T-cells and B-cells resulting in loss of immune tolerance. Additionally, viruses 
could alter infected cells and increase their antigenicity. Apart from that, infection leads to an 
increase in cell death and apoptosis of cells of immune system which may drastically increase 
the amount of autoantigen available to activate an immune response (Salmon et al. 1999). 
Furthermore, viral infection induces production of interferon-α which promotes activation of 
the immune system and worsening of SLE disease activity. 
 More than 100 drugs have been implicated in causing drug-induced lupus, with 
procainamide and hydrallazine being the best studied. These drugs inhibit DNA methylation 
in T-cells and induce autoreactivity (Cornacchia et al. 1988). DNA methylation refers to the 
post-synthetic methylation of cytosine bases in DNA to form methylcytosine. Promoters of 
active genes are hypomethylated and methylation renders the genes inactive. Therefore, DNA 
methylation suppresses gene expression. T-cells with hypomethylated DNA over-express 
lymphocyte function-associated antigen 1 (LFA-1) which contributes to development of 
autoreactivity (Richardson et al. 1994). 
Several heavy metals and chemicals have been reported to be associated with SLE, 
and these includes mercury, crystalline silica, gold, cadmium, vinyl chloride, hydrazines, 
pesticides and hair dyes. Among these, the most compelling epidemiologic data exist for 
crystalline silica and mercury (Cooper et al. 2004; Parks et al. 2002). However, the precise 
mechanisms of initiating autoimmunity by these agents remain unclear. 
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1.3.3 Hormonal Factors 
 It is not surprising that oestrogen plays a role in the expression of SLE given the 
strong gender bias towards the female sex in this disease and the timing of disease onset that 
occurs predominantly after puberty. There is also the increased risk of flare during pregnancy 
which is a physiological state of high oestrogen levels (Ruiz-Irastorza et al. 1996), although 
this has not been found uniformly in all studies. In addition, the use of oestrogen-containing 
contraceptive pill and postmenopausal oestrogen replacement has been associated with an 
increased risk of developing SLE in some studies (Sanchez-Guerrero et al. 1997; Sanchez-
Guerrero et al. 1995). 
Oestrogen has immunomodulatory effects as oestrogen receptors (which are nuclear 
receptors) are expressed in most cells of the immune system. The hormone-receptor complex 
binds to DNA at specific sequences along the target genes that stimulate or suppress gene 
transcription depending on the target cells. Oestrogen has stimulatory effects on B-cells and 
may rescue autoreactive B-cells from normal mechanism of tolerance, resulting in enhance 
production of autoantibodies. The effect of oestrogen on T-cells are less well studied but 
current evidence suggest it has stimulatory effects in SLE (Lang 2004). 
  
1.4 Clinical Features 
SLE is a chronic disease that is characterised by periods of exacerbations with a 
variable course. It is a multi-system disease that can affect any part of the body, resulting in a 
diverse range of clinical manifestations as shown in Table 1-1. Furthermore, involvement of a 
system could result in a variety of manifestations, which adds to its complexity. For example, 
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apart from the classical discoid rash or malar rash that are typical lupus rash, there are many 
other cutaneous manifestations such as bullous lesion, maculopapular rash, psoriasiform 
subacute cutaneous rash, annular subacute cutaneous rash, subcutaneous nodule of lupus 
panniculitis and cutaneous vasculitis. Similarly, involvement of the nervous system could 
result in many possible manifestations which include acute confusional state, psychosis, 
delusion, cognitive dysfunction, stroke-like syndrome, transverse myelopathy and peripheral 
neuropathy. 
Table 1-1: Cumulative incidence of SLE manifestations (Adapted from Dubois’ Lupus 
Erythematosus, 7th edition). 
Manifestations Cumulative Incidence (%) 
Positive Antinuclear Antibodies > 95 
Fatigue/Malaise 80 – 90 
Arthritis/Arthralgia/Myalgia 80 – 90 
Mucocutaneous lesions  70 – 90 
Positive Anti-double stranded DNA antibodies 60 – 70 
Anaemia 50 – 70 
Leucopenia 40 – 60 
Low complements C3 and/or C4 40 – 60 
Pleurisy/Pericarditis 40 – 60 
Fever 50 
Cognitive dysfunction 50 
Renal involvement 40 – 60 
Hypergammaglobulinaemia 30 – 40 
Anti-Sm antibody 10 – 30 
Thrombocytopenia 20 – 30 
Psychosis 10 – 30 
Seizures 10 – 20 
 
Recently, involvement of the gastrointestinal tract (such as intestinal vasculitis, 
pancreatitis, cholecystitis, hepatitis, abdominal serositis, intestinal pseudo-obstruction and 
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malabsorption) and eye (such as keratitis, scleritis, uveitis and vaso-occlusive retinopathy) 
have become increasingly recognised (Sivaraj et al. 2007; Sultan et al. 1999). Although these 
manifestations are uncommon, it is critical to recognise them early to enable early institution 
of immunosuppressive therapy, as they carry significant morbidity and mortality.  
A hallmark feature of this disease is the production of variety of autoantibodies. The 
most well recognised autoantibodies associated with SLE are anti-nuclear antibodies and anti-
dsDNA antibodies. Some of these antibodies are specific to SLE such as anti-dsDNA and 
anti-Sm, hence are useful as diagnostic markers. The other characteristic immunological 
manifestations are the formation of immune complexes and activation/consumption of 
complement.  
As there are myriad of possible manifestations with SLE and most of these 
manifestations are not specific to the disease itself, it is not surprising that the clinical 
presentation of this disease could mimic other medical or surgical conditions. Therefore, it is 
not uncommon for it to be confused with other conditions such as infection and fibromyalgia 
as the clinical presentation can be similar. Furthermore, as any organ system may be involved, 
this disease may present in variable combinations of organ system manifestations that can 
vary between patients and within the same patient over time. All this can lead to a delay in the 
diagnosis of the disease or identification of a flare in the disease with potentially disastrous 
consequences. 
The American College of Rheumatology (ACR) has devised a classification criteria 
for SLE that was developed for clinical trials and research studies (Table 1-2) (Hochberg 
1997; Tan et al. 1982). There are 11 criteria and any 4 or more criteria are required for the 
classification of SLE. However, it should be noted that this classification criteria were not 
intended for diagnostic purposes. This is demonstrated in a study which revealed that over 
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50% of patients with SLE did not fulfil the criteria at a particular point in time, although the 
majority eventually did after several years (Levin et al. 1984). Apart from that, the criteria set 
is heavily weighted towards mucocutaneous manifestations and there are some important 
omissions such as kidney biopsy and activation of complements (Petri et al. 2004a). The 
classification criteria are currently in the process of being revised, to take into account these 
concerns. 
Table 1-2: The 1997 ACR revised criteria for classification of SLE. 
Criterion Definition 
Malar rash Fixed malar erythema, flat or raised 
Discoid rash Erythematous-raised patches with keratotic scaling and follicular plugging; 
atrophic scar may occur in older lesions 
Photosensitivity Skin rash as an unusual reaction to sunlight, by patient history or physician 
observation 
Oral ulcers Oral or nasopharyngeal ulcers, usually painless, observed by physician 
Arthritis Non-erosive arthritis involving two or more peripheral joints, characterised 
by tenderness, swelling or effusion 
Serositis 1. Pleurisy (convincing history of pleuritic pain or rub heard by physician 
or evidence of pleural effusion) 
or 
2. Pericarditis (documented by ECG, rub or evidence of pericardial 
effusion) 
Renal disorder 1. Persistent proteinuria (>0.5 g/day or >3+) 
or 
2. Cellular casts of any type 
Neurological 
disorder 
1. Seizures (in absence of other causes) 
or 
2. Psychosis (in absence of other causes) 
Haematological 
disorder 
1. Haemolytic anaemia 
or 
2. Leucopaenia (< 4000/ml on two or more occasions) 
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or 
3. Lymphopaenia (<1500/ml on two or more occasions) 
Immunological 
disorder 
1. Anti-double-stranded DNA 
or 
2. Anti-Sm 
or 
3. Positive finding of antiphospholipid antibodies based on (a) abnormal 
serum level of IgG or IgM anticardiolipin antibodies, (b) positive test for 
lupus anticoagulant using a standard method, or (c) a false positive 
serological test for syphilis known to be positive for at least 6 months 
Antinuclear 
Antibodies 
An abnormal titre of antinuclear antibody by immunofluorescence or an 
equivalent assay at any time and in the absence of drugs known to be 
associated with “drug-induced lupus syndrome” 
 
1.5 Outcomes in SLE 
 Outcomes in SLE can be described by three domains, namely disease activity, 
accumulated damage and health status of patients (Isenberg et al. 1999). Disease activity is 
defined as immune-mediated disease process that is potentially reversible as opposed to 
damage which is an irreversible process or ‘scarring’. The assessment of disease activity will 
be discussed further in Section 1.7. 
 Mortality is the ultimate form of damage from the disease and remains an important 
outcome measure that is used to inform the management of patients with SLE. With 
improvement in management of SLE, the survival of patients with the disease has improved 
substantially. As such, other measures of damage have become necessary to complement the 
mortality statistic in this chronic disease. A validated scale has been developed for this 
purpose and is known as Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology damage index (SLICC/ACR DI) (Gladman et al. 2000a; Gladman 
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et al. 1997; Gladman et al. 1996). This index looks at damage that has developed since the 
diagnosis of SLE and this is regardless of attribution, whether it is due to disease activity, its 
therapy or intercurrent illness. It divides the items of damage into 12 organ systems (Ocular, 
Neuropsychiatric, Renal, Pulmonary, Cardiac, Peripheral Vascular, Gastrointestinal, 
Musculoskeletal, Skin, Gonadal Failure, Diabetes Mellitus and Malignancy). Its score ranges 
from 0 indicating no damage up to a possible maximum of 47 and this accumulates over time. 
A multi-national study of more than 1000 patients, who were followed-up longitudinally, 
showed that higher SLICC/ACR DI scores were at higher risk of death (Gladman et al. 
2000a). In another study, early renal damage (within 1 year of diagnosis) as assessed using 
this index was predictive of development of end-stage renal failure while pulmonary damage 
was predictive of mortality at 10 years after diagnosis (Stoll et al. 1996). 
 Health status of the patient or health-related quality of life (HRQOL) is the person’s 
sense of physical, emotional and social well-being associated with the disease or its treatment. 
This provides the patient’s perspective of the impact of the disease. It is usually assessed 
using a self-completed questionnaire. HRQOL can be measured using generic instruments 
that are applicable to various diseases, such as Medical Outcomes Study Short Form 36 (SF-
36) and European QoL. However, these generic instruments may not capture certain aspects 
(such as sleep disturbance, sexual functioning, body image and impact on the family) that are 
relevant to SLE and hence may not be sufficiently responsive in clinical trials. As a result, 
HRQOL instruments that are specifically designed for SLE, have been developed recently 
such as SLEQOL (Leong et al. 2005) and LupusQOL (McElhone et al. 2007). 
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1.6 Treatment 
 The treatment of SLE is directed towards the control of disease activity, prevention of 
development of damage and management of complications. This section is not intended to be 
a comprehensive review on the treatment of SLE. The focus of this section is on the principles 
of treatment to control disease activity, thereby preventing development of long term 
complications and mortality from uncontrolled immune-mediated tissue damage. There are 
numerous options available for the treatment of SLE disease activity, which can be 
categorised into: 
1. Symptomatic 
2. Antimalarials  
3. Prasterone 
4. Thalidomide 
5. Dapsone 
6. Retinoids 
7. Corticosteroids  
8. Immunosuppressives/Cytotoxics 
9. Immunoglobulins 
10. Plasmapheresis 
11. Rituximab 
Treatment is tailored to the patient and the major determinant of therapeutic option 
used is the level of disease activity that can be divided broadly into mild, moderate and 
severe. Severe disease activity is defined as manifestations that are life threatening or cause 
significant organ dysfunction such as seizures, nephrotic syndrome or inability to perform 
activities of daily living due to inflammatory arthritis. In contrast, mild disease activity refers 
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to minor manifestations that only cause some discomfort and the patient is able to continue 
with his/her daily routines. 
Severe disease activity requires aggressive therapy with high dose corticosteroids 
(more than 20 mg/day of prednisolone or equivalent) and usually together with an 
immunosuppressives. Thus far, clinical trials in severe disease activity have been for lupus 
nephritis and have shown efficacy of cyclophosphamide (Austin, III et al. 1986), 
mycophenolate mofetil (Ginzler et al. 2005) and intravenous methylprednisolone (in 
combination with intravenous cyclophosphamide) (Illei et al. 2001). However, the efficacy in 
these studies has been defined based on renal outcome only (such as reduction in proteinuria 
and reduction in worsening of renal function). Intravenous immunoglobulins and 
plasmapheresis are mainly used in those with life-threatening complications. Recently, 
rituximab which is a chimeric monoclonal antibody against CD20 that causes depletion of B-
cells, has shown promise in the treatment of severe disease activity (Isenberg 2006). 
 Moderate disease activity is usually treated with lower doses of corticosteroids (up to 
20 mg/day prednisolone or equivalent). In addition, immunosuppressives are commonly used 
concomitantly with corticosteroids. Antimalarials have been shown to be safe and effective 
with mucocutaneous manifestations and inflammatory arthritis, hence can be used instead of 
immunosuppressives for these manifestations (D'Cruz 2001). For certain manifestations, local 
treatment with corticosteroids (and occasionally immunosuppressives) could be used such as 
intra-articular injection of methylprednisolone for inflammatory synovitis or topical 
corticosteroids for discoid rash. Thalidomide, retinoids and dapsone are reserved for treatment 
of refractory lupus rash. Prasterone is an androgen which has been shown recently to have 
steroid-sparing properties and to reduce the number of SLE flares (Petri et al. 2004b; Petri et 
al. 2002). 
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Mild disease activity usually only requires symptomatic treatment such as analgesia or 
non-steroidal anti-inflammatory drugs (NSAIDs). Not uncommonly, antimalarials or topical 
corticosteroids, with their good safety profile, are also used for milder mucocutaneous or 
musculoskeletal manifestations that are recurrent or persistent. 
 Despite the availability of numerous therapeutic options, it is surprising that there has 
not been a new treatment approved for use in SLE by the drug authorities in United States of 
America and Europe for the past 20 years. This has been due to the scarcity of randomised 
placebo-controlled trials that are adequately powered. One of the main reasons for this is the 
difficulty in designing and conducting clinical trials in SLE (Mukhtyar et al. 2007; Dall'Era et 
al. 2006). This reflects the complexity and multi-system nature of this disease which makes 
objective assessment of disease activity difficult and challenging. With the development of 
several promising new agents, there is a pressing need for this issue to be addressed quickly in 
order to assess these therapies with the greatest likelihood of success.  
 
1.7 Assessment of Disease Activity 
As with most human attributes, SLE disease activity cannot be measured directly. 
What is being measured is the observed phenomenon that allows us to infer the existence of 
these attributes. Standardised and objective assessment of disease activity is crucial as it 
allows for comparison of results of studies between different centres and enables multicentre 
studies to be conducted (Mukhtyar et al. 2007). This is essential in clinical trials to determine 
the efficacy of any particular treatment and to compare different therapeutic approaches.  
Before a measure can be used as a marker of disease activity, it needs to undergo 
rigorous validation process to ensure that it is biologically relevant, reliable, reproducible and 
sensitive to change (Singh et al. 2006; Illei et al. 2004a). This is imperative as any measure 
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that lacks validity is measuring a characteristic (in whole or part) other than that which is 
intended. In general, these markers can be in the form of biological markers (biomarkers) or 
composite clinical disease activity indices. 
 
1.7.1 Biomarkers 
A biomarker is defined as a genetic, biological, biochemical or molecular 
characteristic that reflects a biological process (which in this context is disease activity), and 
can be evaluated qualitatively or quantitatively. With numerous abnormalities of the immune 
system having been identified, numerous candidate markers have been proposed as 
biomarkers of disease activity. The most widely used classical markers of disease activity are 
the serum anti-dsDNA antibodies and complement C3 and C4 levels. 
There is a divergent view on the usefulness of anti-dsDNA antibodies and complement 
C3 and C4 levels in predicting SLE disease activity with some studies showing good 
association between these classical markers and disease activity, while other studies indicate 
that these classical markers are of little value. This difference in opinion is mainly the result 
of difference in study design used, difference in the type of organ involvement in recruited 
patients and different definition of disease activity being employed in the studies. Two Dutch 
longitudinal studies (Ter Borg et al. 1990; Swaak et al. 1986; Swaak et al. 1982) in which 
anti-dsDNA and complement C3 and C4 levels in patients were measured at close intervals (4 
to 6 weekly) demonstrated that exacerbation in disease activity were preceded by rapid 
increase in anti-dsDNA levels (over a mean period of 8 to 10 weeks), peaking at the time of 
exacerbation and this was followed by rapid reduction in the levels. A more gradual reduction 
in complement C3 and C4 levels (over a period of up to 24 weeks) was also noted to precede 
the flares. The association with flare was stronger for anti-dsDNA antibodies compared to 
 27
complement levels. Patients with stable levels of anti-dsDNA antibodies were much less 
likely to have a flare of disease activity. In these two studies, the flares were predominantly 
renal involvement and it was noted that all renal flares were preceded by increase in anti-
dsDNA levels. The definition of flare used in these two studies were well defined but 
unfortunately had not been validated (Ter Borg et al. 1990; Swaak et al. 1986; Swaak et al. 
1982).  
Similar results were obtained in another prospective longitudinal study in which 
patients were assessed monthly and disease activity was measured using several composite 
clinical activity indices and physician’s global assessment (Ho et al. 2001b). However, 
decreasing complement levels were only predictive of renal and haematological flares (Ho et 
al. 2001a). In a study by Esdaile et al, changes in anti-dsDNA antibodies and complement 
levels were not found to be good predictors of flare (Esdaile et al. 1996). However, anti-
dsDNA antibodies and complement levels were measured at the time of flare and around 3, 6 
and 9 months prior. The definition of flare was an increase of at least 6 in the modified 
SLEDAI score (after excluding 9 items), which was scored retrospectively. This study also 
highlighted the difference in the results between cross sectional and longitudinal evaluation of 
these markers. Cross sectional study of these markers found that patients with renal flare 
tended to have higher anti-dsDNA levels and lower C3 levels, in contrast to longitudinal 
assessments where there was no association between these markers and flare. 
Despite the differences in the results, what can be concluded from these studies is that 
longitudinal changes in anti-dsDNA and complement levels are probably more helpful than a 
single estimation in predicting flares. Rapid increase in anti-dsDNA levels is useful in 
predicting flares of disease activity in some but not all patients. Therefore, it is of greatest use 
when it is measured frequently (every 4 to 6 weeks). Decreasing complement C3 and C4 
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levels are also predictive of flares but its association is weaker when compared to anti-dsDNA 
and the decrease is much more gradual. It has been consistently shown that increasing anti-
dsDNA and decreasing complement levels are strongly associated with lupus nephritis. 
As serum complement levels represent the dynamic state of complement synthesis and 
consumption, the levels may not reflect the true status of complement activation which is a 
feature of active disease. Firstly, there is a wide variation in normal serum complement levels 
among different individuals (partly due to genetic polymorphisms). Secondly, there is a 
control in the balance of synthesis and consumption of complement proteins whereby 
increased consumption is counterbalanced by an increase in synthesis that is variable between 
individuals. Additionally, many of the complement proteins are acute phase reactants and as 
such, there will be an increase in the synthetic rate in response to inflammatory stimuli. The 
drawbacks of serum complement levels led to the rationale that plasma levels of complement 
activation products (such as C3a, C4a, C5a, C3d, C4d, C5b-9, Ba and Bb) would be better 
marker of disease activity. Complement split products, particularly of the alternative and 
terminal complement pathway activation, had been shown to be more useful in predicting 
flare of disease activity than C3 and C4 levels (Buyon et al. 1992). However, these assays 
have not been widely adopted outside of a research setting as accurate measurement of 
complement activation products is hampered by the instability and short half-lives of these 
activation products, whereby complement activation can easily occur in vitro after blood 
sampling. Apart from that, complement activation is not specific to SLE disease activity but 
also occurs in other inflammatory conditions such as infection (Sturfelt et al. 2005). This may 
have contributed to the inconsistent results on the utility of complement split products with 
disease activity from other studies (Mollnes et al. 1999). 
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Numerous cytokines have been studied with regards to its association with disease 
activity, which has been reviewed thoroughly by Ilei et al (Illei et al. 2004b). Data on a few 
cytokines have shown promise, namely interferon-α, soluble interleukin-2 receptor and 
soluble TNF receptors, but further studies (particularly with larger number of patients and in a 
longitudinal fashion) are required to confirm the utility of these cytokines as markers of 
disease activity. One of the major drawbacks of cytokines as markers of disease activity is 
that they have pleiotropic effects with stimulatory and inhibitory effects on different cells of 
the immune system. Furthermore, the production of these cytokines is context dependent 
varying with many factors such as stage of the disease (advanced versus early), presence of 
organ damage, type of organ involvement, treatment status and ethnicity. This does limit the 
usefulness of cytokines as reliable markers of disease activity. 
Other potential markers of disease activity which require further confirmatory studies 
include erythrocyte or reticulocyte bound C4d (Liu et al. 2005; Manzi et al. 2004) and 
circulating CD27high plasma cells (Jacobi et al. 2003) 
 Although a large number of studies have described potential markers of disease 
activity, none of them has fulfilled the criteria of a validated biomarker to date. The majority 
of these studies were not designed to validate the marker as a biomarker. Many of the studies 
are cross sectional, which is inadequate as longitudinal studies are required to demonstrate 
that the marker can be used to monitor disease activity in individual patients. It is critical that 
the marker is studied across different patient population characteristics, such as ethnicity, 
organ involvement, treatment status and stage of disease (early versus late). The definitions of 
active disease used have not been uniform across studies to date and standardised assessment 
of disease activity was not used in many studies, making comparison of results difficult and 
probably contributed to the conflicting results. A large number of studies also lack the 
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statistical rigor necessary for valid conclusions. Last, but not least, many of the bioassays used 
to measure the marker are not standardised resulting in conflicting results from different 
laboratories (Illei et al. 2004a). 
 
1.7.2 Composite Clinical Disease Activity Indices 
Composite clinical disease activity indices are instruments that combine clinical and 
laboratory parameters in the evaluation of SLE disease activity. Numerous composite clinical 
disease activity indices have been developed to standardise the assessment of disease activity 
in SLE. There are over 60 different disease activity indices that have been described in the 
literature, but most of them have not been validated (Liang et al. 1988). Of these, there are 5 
disease activity indices that have undergone validation: 
1. SLE Disease Activity Index (SLEDAI) (Bombardier et al. 1992) 
2. Systemic Lupus Activity Measure (SLAM) (Liang et al. 1989)  
3. European Consensus Lupus Activity Measurement (ECLAM) (Vitali et al. 
1992) 
4. Lupus Activity Index (LAI) (Petri et al. 1992) 
5. Classic British Isles Lupus Assessment Group Index (Classic BILAG) 
(Hay et al. 1993) 
Broadly, there are two types of disease activity indices. The majority of currently 
available indices are global score indices in which the scores of the individual items within 
the index are summated into a total score that provides an overall measure of disease activity. 
In contrast, individual organ-system score index provides scores for each individual organ-
system within the index reflecting the level of disease activity in these organ-systems. The 
only individual organ-system score index is the Classic BILAG index. Currently, the two 
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indices commonly used in studies and clinical trials are the SLEDAI and Classic BILAG 
indices, which will be discussed further. 
 
SLE Disease Activity Index 
This global score index was developed in 1985 from a meeting in Toronto. The 24 
items (16 of which were clinical) to be included in the index were identified through nominal 
consensus process involving 15 lupus experts, who completed a questionnaire containing a list 
of 37 clinical variables and rated these variables on the importance in measuring disease 
activity. Using 574 paper patient profiles, weighting for each item was determined by multiple 
regression analysis. The weighting used ranged from 1 to 8, giving rise to a total possible 
score of 105 (Bombardier et al. 1992). A manifestation is recorded if it has been present at 
any time over the past 10 days regardless of severity, or whether it has improved or worsened.  
This index had undergone some form of validation. It was shown to be reliable by 
several studies (Hawker et al. 1993; Guzman et al. 1992; Petri et al. 1992; Gladman et al. 
1992; Liang et al. 1989), however these studies suffered from small number of patients (less 
than 40) and incorrect use of simple correlation to assess reliability in one study (Guzman et 
al. 1992). Construct validity of the index was demonstrated as it had good correlation with 
physician’s global assessment and other activity indices (Ward et al. 2000; Gladman et al. 
1994; Guzman et al. 1992; Petri et al. 1992; Gladman et al. 1992; Liang et al. 1989). Once 
again, all the studies except one involved small number of patients (less than 50 patients) and 
paper patient profiles were used in one study (Gladman et al. 1994). Its sensitivity to change 
was demonstrated by several studies which used internal responsiveness methods (discussed 
in section 1.8.4) especially in the form of effect size or standardised response mean (Chang et 
al. 2002a; Fortin et al. 2000; Ward et al. 2000; Brunner et al. 1999; Guzman et al. 1992; Liang 
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et al. 1989). Additionally, Fortin et al used the more robust external responsiveness method 
comparing changes in the index with the corresponding change in physician’s opinion of 
change in patient’s disease status (Fortin et al. 2000). These sensitivity to change studies also 
involved relatively small number of patients (less than 100 patients) 
It was subsequently noted that the original index focused on new or recurrent 
manifestations and failed to capture on-going activity. This led to a revision by the Toronto 
group which allowed the index to capture on-going disease activity in the items of proteinuria, 
rash, alopecia and mucosal ulcers, giving rise to SLEDAI-2000 index (Appendix 3) (Gladman 
et al. 2002). Another group of investigators in the United States, who was involved in the trial 
of oestrogen in SLE, produced another version known as the SELENA-SLEDAI that 
incorporated on-going disease activity in the items rash, alopecia and mucosal ulcers, but also 
made changes to other descriptors such as including vertigo in cranial nerve disorder, 
changing the criteria for proteinuria to include a recent increase of more than 0.5g/day, and 
allowing only one of the features in the descriptor for pleurisy and pericarditis to be present 
for it to be recorded (instead of the combination of features required in the original index such 
as pleuritic chest pain with pleural rub) (Petri et al. 2005). Unfortunately, these two revisions 
have not been formally validated. SLEDAI-2000 had been shown to correlate very well with 
the original SLEDAI index (Gladman et al. 2002), but this was to be expected as SLEDAI-
2000 index is derived from the original SLEDAI index and the majority of the items were 
identical. 
 
Classic British Isles Lupus Assessment Group Index (Classic BILAG) 
The original BILAG index was developed in 1984 through a nominal consensus 
approach by the British Isles Lupus Assessment Group (BILAG) which was a group of 
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rheumatologists with a special interest in the care of SLE patients (Symmons et al. 1988). It 
was developed based on the principle of the physician’s intention to treat, on the premise that 
there was broad agreement among clinicians as to which aspect of the disease required 
treatment with disease-modifying therapy such as corticosteroids or immunosuppressives. 
This first version contained 87 items distributed over 8 systems (Non-specific, 
Mucocutaneous, Neurological, Renal, Musculoskeletal, Cardiorespiratory, Vasculitis and 
Haematological). It had an ordinal scoring scale by design and did not have a global score. 
Disease activity was classified into 4 categories from Grade A to D: 
     Grade A – active disease requiring immediate treatment with disease-modifying therapy 
     Grade B – active disease but less severe than A requiring symptomatic treatment 
     Grade C – stable disease 
     Grade D – inactive disease 
Several issues with the first version were realised such as poor reliability in the 
musculoskeletal and vasculitis systems, inappropriate scoring of Grade B in neurological 
system with migraine headaches, and the inability of the index to differentiate between 
patients with mild stable involvement and those with past involvement of a system. This led 
to revisions of the index and the third revision (version 3 which is now known as the Classic 
BILAG index) was subsequently validated and published (Appendix 2) (Hay et al. 1993). This 
revision involved the following modifications: definition of a time scale, provision of a 
glossary, changes to the scoring scheme and refinement of the definition of items to avoid 
ambiguity. It has 86 items distributed over 8 systems (General, Mucocutaneous, Neurology, 
Musculoskeletal, Cardiorespiratory, Vasculitis, Renal and Haematology) that records 
manifestations occurring over the past month as compared to the month before. As such, this 
is a transitional index that is able to capture changing severity of clinical manifestations as 
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most items in the index (except for laboratory investigations and a few items that are yes/no) 
are recorded, if present, as new, improved, the same or worse over the past month as 
compared to the previous month (see Appendix 2). The scoring of this index had been 
modified so that there were 5 categories of disease activity from A to E: 
    Grade A – very active disease requiring immunosuppressive drugs and/or prednisolone  
                      dose of more than 20 mg daily (or equivalent)  
    Grade B – moderate disease activity requiring lower dose of corticosteroids, antimalarials  
                      or NSAIDs  
    Grade C – stable mild disease 
    Grade D – no current disease activity but the system has previously been affected 
    Grade E – no current or previous disease activity in the system 
The glossary was further expanded in 1999 and minor modifications were made to the scoring 
of renal and neurological systems (Isenberg et al. 2000). Even though this index was 
developed based on the principle of intention to treat, it was devised to capture manifestations 
of disease activity and the treatment has no bearing on the scoring of this index. 
 This index was shown to be reliable in a multi-centre study involving 82 patients in 
which succinct case summary was provided (Hay et al. 1993). The same investigators also 
demonstrated the construct and criterion validity of the index. Criterion validity was assessed 
in a large multi-centre study of 353 patients looking at the agreement between Grade A score 
and commencement or increase in prednisolone (dose of more than 20mg daily) or 
immunosuppressives. However, construct validity was only analysed using data from one of 
the centres that recruited 127 patients and the association between Grade A score with ESR 
and anti-dsDNA antibodies was assessed. The sensitivity to change of this index was shown 
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in two small longitudinal studies (less than 50 patients each) using internal responsiveness 
methods (Ward et al. 2000; Brunner et al. 1999). 
 
1.7.3 Problems with Current Indices 
Despite the availability of numerous disease activity indices, there are key problems 
with them. Apart from the Classic BILAG index, the others indices are not transitional in 
nature. A transitional index is one that allows the change in severity of manifestations to be 
recorded, hence improvement or worsening of manifestations are captured. As a result, in a 
non-transitional index that is not able to differentiate change in severity of manifestations, a 
manifestation that has improved considerably will derive the same score as the same 
manifestation that has worsened significantly. This leads to incorrect scoring with over-
scoring for manifestation that has improved and under-scoring for manifestation that has 
worsened, and potentially the wrong conclusions could be drawn from such an analysis. It is 
an essential requirement for an index to be transitional before it can be used to assess the 
efficacy of therapies.   
Global score which is a feature of most indices could be misleading. Firstly, the 
definitions of different levels of activity (mild, moderate or severe) based on the global score 
has not been established with certainty for global score indices. This is clearly an important 
issue as cut-off scores are used in clinical studies to stratify patients into different levels of 
disease activity and also to determine eligibility for studies, especially in a clinical trial. There 
have been only two studies that have assessed the best cut-off score to define active disease 
for SLEDAI and SLAM indices (Gladman et al. 2000b; Abrahamowicz et al. 1998). Even 
these two studies differ in the results due to methodological differences. The study by 
Abrahamowicz et al used a small sample (n = 30) of abstracted case histories that were 
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assessed by 38 lupus experts and suggested that the best cut-off score based on treatment 
decision for SLEDAI was 6 and for SLAM was 7. The other study by Gladman et al used a 
larger database of 230 patients and based on physician’s global assessment of disease activity, 
determined that the best cut-off score for SLEDAI was 4. However, the physician’s 
assessment of disease activity was done retrospectively from the records and only descriptive 
statistics were used in the analysis with no allowance made for possible correlation between 
repeated observations from the same patient. In addition, the physician’s global assessment of 
disease activity (PGA) is not ideal as the gold standard for disease activity, as several studies 
have shown that PGA is associated with unsatisfactory performance and poor agreement 
between expert physicians (Liang et al. 2004; Wollaston et al. 2004; Brunner et al. 1999; 
Gladman et al. 1994; Gladman et al. 1992). 
Secondly, there are many different permutations that can lead to the same global score. 
To illustrate this, a score of 4 in SLEDAI-2000 can be achieved with arthritis, proteinuria or a 
combination of rash, fever and thrombocytopenia, as the items have different weighted scores 
(see Appendix 3 for details of item weighting). Hence, the same global score over two time 
points does not necessarily mean that the disease activity has remained unchanged. 
Furthermore, the minimal clinically important change for these global score indices has yet to 
be established. This is another important issue as it is required to classify whether the 
patient’s disease activity over time has improved, worsened or remained unchanged. There 
have been a few studies that have tried to address this issue using different methods, but 
unfortunately they were hampered by small sample size (less than 100 patients) (Fortin et al. 
2000), use of simple descriptive statistics for analysis (Gladman et al. 2000b), use of 
abstracted case history (Liang et al. 2004) or use of physician’s global assessment as the gold 
standard for disease activity (Liang et al. 2004; Fortin et al. 2000; Gladman et al. 2000b; Petri 
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et al. 1991). Hence, it is not surprising that all these studies yielded different results with the 
same index as illustrated by the minimal increase in SLEDAI score associated with a 
worsening of disease activity ranging from 3 to 8 across these studies. This could lead to 
problems with misclassification of response and difficulties in the interpretation and analysis 
of results. This may have contributed to the high placebo response seen in the clinical trial of 
prasterone in which SLEDAI was used to assess disease activity (Petri et al. 2004b; Petri et al. 
2002). 
Many of these indices are not comprehensive enough as they are unable to capture 
certain manifestations of active disease that are not included in the index. This is by design as 
they are meant to be easy to use and as a result, only relatively common and/or severe 
manifestations are incorporated into the indices. Unfortunately, there is a major drawback to 
this design due to the resultant misclassification, as patients with manifestations that are not 
captured by the index are wrongly classified as having inactive or less active disease than they 
are actually suffering from. For example, serious SLE manifestations such as myelopathy or 
peripheral neuropathy would not be captured by SLEDAI-2000. Although the Classic BILAG 
index has been designed to be a comprehensive index, it is not immune to such criticism as it 
does not capture most gastrointestinal or ophthalmic manifestations of SLE, which are 
increasingly recognised. 
Apart from these 5 disease activity indices (Classic BILAG, SLEDAI, LAI, SLAM 
and ECLAM), none of the other reported indices have been validated. Although these 5 
indices have been generally accepted as ‘validated’, they have not undergone the 
comprehensive and rigorous validation process that is required of an index before it can be 
said to be truly valid. Many of the validation studies suffered from small sample size, use of 
paper patients, retrospective assessments and inadequate statistical analysis. In addition, the 
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sensitivity to change of these indices has not been adequately assessed. Most of the studies 
have used an internal responsiveness method to demonstrate that these indices are sensitive to 
change (Chang et al. 2002a; Fortin et al. 2000; Ward et al. 2000; Brunner et al. 1999; Guzman 
et al. 1992; Liang et al. 1989). This method only shows that these indices do change with 
time, but this has not been compared to an external standard. Therefore, these changes may 
not be clinically meaningful. It is important that the change in the index over time reflects 
actual change in the clinical status of the patient when the index is used to measure transition 
in clinical states. One study did use an external responsiveness method to assess sensitivity to 
change, comparing the change in the index against the change in an external standard (Fortin 
et al. 2000) but the external standard used was physician’s global assessment which had been 
shown to be unsuitable for this purpose (Liang et al. 2004; Wollaston et al. 2004; Brunner et 
al. 1999; Gladman et al. 1994; Gladman et al. 1992). 
Therefore, the currently available disease activity indices cannot be considered 
adequate for capturing changes in disease activity and require substantial improvement as 
many of them are clearly not good enough for use in a clinical trial setting. 
 
1.8 Development and Validation of the BILAG-2004 Index 
Over the past few years, concerns regarding the Classic BILAG index were raised 
amongst members of BILAG: 
1. It became apparent that this index had some serious omissions, particularly with 
respect to gastrointestinal and ophthalmic manifestations. These have not been well 
studied previously but recent studies suggest that they are more common than 
previously thought and associated with significant morbidity and mortality (Sivaraj et 
al. 2007; Lee et al. 2002; Hallegua et al. 2000).  
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2. The glossary for the index was far too brief and inadequate. Furthermore, much of the 
terminology used was outdated, especially in the neuropsychiatric system where the 
definitions predate the development of the American College of Rheumatology (ACR) 
nomenclature and case definitions for neuropsychiatric lupus syndromes (ACR Ad 
Hoc Committee on neuropsychiatric lupus nomenclature 1999).  
3. Our understanding and perception of the significance of certain features of the disease 
have changed considerably over the last 20 years. For certain severe manifestations 
such as myelopathy, it is now accepted that thrombosis is contributory in addition to 
the inflammatory process and it is not uncommon for these manifestations to be 
treated with anticoagulation (in combination with immunosuppressives and/or 
systemic corticosteroids). 
4. Some of the items are in fact damage items and should not be included, such as 
avascular necrosis, sclerodactyly, telangiectasia and tendon contractures. 
5. Improvement of items scoring Grade A resulted in a decrease in the score to Grade C 
which is inappropriate for such serious manifestations that are still on-going. 
 
Two members of the BILAG (Caroline Gordon and David Isenberg) proposed in 2002 
that the Classic BILAG index needed to be revised, taking into account the above-mentioned 
issues. Conceptual change to the index started in 2003 with all members of BILAG being 
engaged in intensive consultation/discussion about how best to revise the index and the 
preliminary new index was completed in 2004, hence the name ‘BILAG-2004 index’. 
The BILAG-2004 index is based on the Classic BILAG index but with the following 
changes incorporated: 
1. Addition of gastrointestinal and ophthalmic manifestations 
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2. The terminology, glossary and definitions have been updated and improved to reflect 
current understanding of the disease. This includes the incorporation of the ACR 
neuropsychiatric nomenclature/definitions and major revision to the majority of items 
in the other systems. 
3. The scoring scheme has been refined and this includes recognition that anticoagulation 
(in the presence of intensive immunosuppression) may be used to treat active 
manifestations and that improvement in items that score Grade A results in a Grade B 
score (instead of Grade C). 
4. Removal of items that are clearly not due to disease activity such as avascular 
necrosis, tendon contractures, thromboembolism, telangiectasia, calcinosis, 
sclerodactyly, Raynaud’s phenomenon, livedo reticularis and superficial phlebitis. 
5. Redistribution of items in the Vasculitis system into individual systems. 
 
Like its predecessor, the BILAG-2004 index is a transitional index but has more items 
(102 in total) distributed over 9 systems (Constitutional, Mucocutaneous, Neuropsychiatric, 
Musculoskeletal, Cardiorespiratory, Gastrointestinal, Ophthalmic, Renal and 
Haematological). The categorical (ordinal) scoring system is similar to that of the Classic 
BILAG index but with some modification to include an expanded list of treatments that were 
considered appropriate for a certain level of disease activity, as follows: 
    Grade A – very active disease requiring any of the following: 
1. systemic high dose oral corticosteroids (equivalent to prednisolone > 20  
                             mg/day) 
2. intravenous pulse corticosteroids (equivalent to pulse methylprednisolone  
                             ≥ 500 mg) 
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3. systemic immunomodulators (including biologicals, immunoglobulins and  
                             plasmapheresis) 
4. therapeutic high dose anticoagulation in the presence of high dose steroids  
                            or immunomodulators (such as warfarin with target INR of 3 to 4) 
    Grade B – Moderate disease activity requiring any of the following treatment: 
1. systemic low dose oral corticosteroids (equivalent to prednisolone ≤ 20  
                             mg/day) 
2. intramuscular or intra-articular or soft tissue corticosteroids injection  
                             (equivalent to methylprednisolone < 500mg) 
3. topical corticosteroids 
4. topical immunomodulators 
5. antimalarials or thalidomide or prasterone or acitretin 
6. symptomatic therapy (such as NSAIDs for inflammatory arthritis) 
    Grade C – mild disease 
    Grade D – no current disease activity but the system has previously been affected 
    Grade E – no current or previous disease activity in the system 
Before a newly developed index can be used widely, it needs to be validated to ensure 
that it is measuring what it is purported to measure. The validation process can be divided into 
the following processes: 
1. Face and content validity 
2. Reliability 
3. Construct and criterion validity 
4. Sensitivity to change 
5. Predictive validity 
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6. Rasch analysis 
The preliminary BILAG-2004 index had undergone initial validation with a reliability study 
involving 8 patients being assessed by 8 physicians, before work for this thesis began 
(Isenberg et al. 2005). Two reliability exercises were performed and there was good reliability 
for most systems in the index. There was some concern regarding the performance of the 
musculoskeletal system that was felt to be most likely related to inadequacies in the glossary. 
Further changes were made to improve the glossary after the reliability study (Appendix 1). 
 
1.8.1 Face and Content Validity 
Face validity and content validity have overlapping concepts and they go hand in 
hand, hence they are commonly assessed together. Face validity refers to the credibility of the 
index and it assesses whether the index appears reasonable or sensible. Content validity on the 
other hand determines the comprehensiveness of the index and assesses if the index covers all 
aspects of disease activity to be measured. 
The initial phase in the development of an index is usually through consensus 
approach amongst experts in the field to determine the items that should be included in the 
index. This approach was used in the development of the BILAG-2004 index as changes to 
the index were made through a consensus building process involving members of BILAG. 
This was supplemented by distributing the index to members of the SLICC (System Lupus 
International Collaborating Clinics) group and British Society for Rheumatology (BSR) SLE 
Special Interest Group for their comments and opinions. In total, the opinions of 37 lupus 
experts (non-BILAG members) from within and outside United Kingdom were obtained. All 
their comments were reviewed and appropriate changes to the index were made accordingly.  
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However, face and content validity is not a single study but is continually assessed 
throughout the validation process, whereby changes to index are made based on the data 
collected (this is described in detail in the relevant chapters of this thesis). 
 
1.8.2 Reliability 
Reliability or repeatability is the ability of the index to reproduce similar results when 
used repeatedly. Variability in measurements can arise from 3 sources, namely patients, the 
measurement instrument and raters performing the measurement. Patients vary between each 
other, and also within themselves, at different points in time. It is this variability that an 
instrument aims to measure. Variation arising from the measurement instrument 
(measurement error) is a form of systematic error (bias). Variation may also be the result of 
the rater using the measurement instrument. This form of variability may be within the same 
rater (intra-rater variability) or between raters (inter-rater variability). 
Inter-rater variability occurs when two or more raters assess the same patient within a 
very short period of time during which the status of the patient’s condition has not changed. 
Intra-rater variability occurs when a single rater assesses a patient with a stable condition at 
different time points. This is usually difficult to assess due to knowledge bias as the rater 
would remember the previous assessment if the time interval between assessments is short. 
However, if the interval between assessments is considerably longer to avoid this bias, it is 
very likely that the patient’s condition will have changed. Intra-rater variability will contribute 
to inter-rater variability, hence if inter-rater reliability is good then intra-rater reliability can 
also be assumed to be good as well (Brennan et al. 1992). It is for this reason that only inter-
rater reliability will be assessed for the BILAG-2004 index. 
 44
The most common statistical method for assessing inter-rater reliability of categorical 
scale is the kappa statistic (Cohen 1960). The formula for kappa is as follows: 
  Actual agreement (%) – Expected agreement (%) 
100 – Expected agreement (%) 
The numerator is the actual agreement beyond chance while the denominator represents 
potential agreement beyond chance. Therefore, kappa expresses the actual agreement beyond 
chance as a proportion of potential agreement beyond chance. Kappa provides an overall 
measure of agreement between raters and has a value ranging from -1 to 1. There is no 
absolute interpretation of the kappa values but some guidelines have been suggested (Table 1-
3) (Landis et al. 1977). Generally, a value of at least 0.40 is considered to represent acceptable 
agreement. 
Table 1-3: Interpretation of kappa statistic. 
Kappa value Agreement 
< 0.0 
0.00 – 0.20 
0.21 – 0.40 
0.41 – 0.60 
0.61 – 0.80 
0.81 – 1.00 
Poor 
Slight 
Fair 
Moderate 
Substantial 
Almost Perfect 
 
However, kappa is only concerned with agreement and does not take into account 
partial agreement or different degrees of disagreement. All degrees of disagreement are 
treated the same, as complete disagreement. A typical table of agreement is shown in Table 1-
4. The expected frequency in a cell is calculated as the product of the total in the relevant 
column and the total in the relevant row, divided by the grand total. Using the table above as 
an example, E11 = R1 x C1/N, E12 = R1 x C2/N, E21 = R2 x C1/N and so on. The diagonal cells 
of the table (E11, E22, E33 and E44) represent perfect agreement and the further away from this 
diagonal, the greater is the degree of disagreement. As the BILAG-2004 index is an ordinal 
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scale index with decreasing level of activity from Grade A to Grade E, it would be preferable 
to take into account different levels of disagreement. As an example, the disagreement 
between Grade A and Grade B is far less severe than the disagreement between Grade A and 
Grade D. For this purpose, a weighted kappa statistic is used to adjust for the different levels 
of disagreement (Cohen 1968). The expected frequency for each cell is multiplied by a weight 
and the weight ranges from 0 to 1. A weight of 1 represents perfect agreement while 0 
represents total disagreement and any values in between represent partial agreement with 
larger values indicating lesser degree of disagreement.  
Table 1-4: Typical table of agreement. 
Rater 2   
A B C D/E 
Total 
A E11 E12 E13 E14 R1 
B E21 E22 E23 E24 R2 
C E31 E32 E33 E34 R3 
 
 
Rater 1 
D/E E41 E42 E43 E44 R4 
Total C1 C2 C3 C4 N 
 
Another method for assessing reliability is with intra-class correlation coefficient 
(ICC) (Shrout et al. 1979). This is derived from analysis of variance and is the ratio of 
variance between patients to the total variance. ICC is very similar to kappa statistics as ICC 
and weighted kappa (using quadratic weights) are statistically equivalent (Fleiss et al. 1973). 
Although this is primarily designed for continuous data, it can be use for ordinal data by 
transforming the data into a continuous data. The initial reliability study of the preliminary 
BILAG-2004 index had used this statistical method to assess reliability. 
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1.8.3 Construct and Criterion Validity 
Criterion validity determines if this index agrees with the gold standard. As there is no 
gold standard for SLE disease activity, change in therapy is used as the reference standard 
(also known as the criterion) for the validation of the BILAG-2004 index. Construct validity 
determines if this index correlates well with other surrogate measures of disease activity, 
known as constructs. These constructs are not the gold standard, but they are correlates of 
disease activity. A cross sectional study is required for the assessment of construct and 
criterion validity. 
For construct validity, statistical analysis is used to demonstrate the correlation 
between the index and the surrogate measures (constructs). On the other hand, it is the 
agreement between the index and the criterion (reference) that is being assessed in criterion 
validity, by determining the sensitivity, specificity, positive predictive value and negative 
predictive value of the index. Sensitivity is the percentage of patients with active disease that 
are correctly classified by the index (or true positive rate) while specificity is the percentage 
of patients without active disease correctly classified by the index (or true negative rate). 
Positive predictive value is the probability of a patient, classified as having active disease by 
the index, really does have active disease while negative predictive value is the probability of 
a patient, classified as not having active disease by the index, really does have inactive 
disease. 
Receiver operating characteristic (ROC) curve is also commonly used to assess the 
performance of an index in the analysis for criterion validity (Zweig et al. 1993). The ROC 
curve is a plot of true positive fraction (sensitivity) against false positive fraction (1 – 
specificity) (Figure 1-3). An index with perfect discrimination between active and inactive 
disease states has an ROC plot that passes through the upper left corner where the true 
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positive fraction is 1.0 and the false positive fraction is 0. The no-discrimination line is a 45 
degrees diagonal line from the lower left corner to the upper right corner and this represents 
the plot for an index that cannot discriminate between the two states. The closer the plot is to 
the upper left corner, the better is the performance of the index in discriminating between 
active disease and inactive disease. Another way to quantify the performance of the index is 
to calculate the area under the ROC curve which provides a quantitative expression of how 
close the curve is to the perfect one (area = 1.0). 
Figure 1-3: Typical receiver operating characteristic plot. 
 
1.8.4 Sensitivity to Change 
Sensitivity to change or responsiveness of an index implies the ability of the index to 
change with time. There are two forms of responsiveness: internal responsiveness and 
external responsiveness. 
Internal responsiveness is defined as the ability of an index to change over a particular 
time frame. Traditional statistical methods that are used to assess sensitivity to change of 
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several SLE disease activity indices fall into this category and they include paired t-test, effect 
size, standardised response mean and Guyatt’s responsiveness index. The main disadvantage 
of these methods is that the changes in the index do not relate to changes on an external 
measure at individual patient level. Apart from Guyatt’s responsiveness index, the statistics 
only examine the extent of change in the index between two time points. Hence, statistically 
significant change may occur without corresponding change in clinical status and these 
changes may not be clinically meaningful or relevant. Moreover, the comparison is made at 
the population level and may not reflect clinical change at the individual patient level. 
Furthermore, comparison across different studies is difficult as the statistics used are not 
independent of study design (Husted et al. 2000). 
External responsiveness is the extent to which changes in the index over time relate to 
corresponding changes in an external reference measure. It is essential that the selected 
external reference measure represent an accepted indicator of change in the patient’s status. 
Therefore, it is the clinically meaningful change that is being studied. As the statistics are 
based on correlational approach, they characterise the relationship between change in the 
index and change in the external reference at the individual patient level. Therefore the result 
is generalisable across studies, that is the same relationship should be observed in another 
study of similar patients, allowing for comparison. The common statistical approaches used 
are receiver operating characteristic method, regression models and correlation analyses 
(Husted et al. 2000). 
It is important that the change in the index over time reflects actual change in the 
clinical status of the patient when the index is used to measure transition in clinical states, and 
this affects the number of patients that are required to detect significant differences between 
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treatment arms in a clinical trial. Therefore, the more robust external responsiveness method 
is the preferred method to assess sensitivity to change of an index. 
 
1.8.5 Predictive Validity 
This is the ability of the index to predict the occurrence of a future outcome. This 
entails a prospective longitudinal study and the outcome of interest is damage as measured by 
SLICC/ACR damage index. This longitudinal study is designed to determine if greater 
cumulative exposure to active disease according to the BILAG-2004 index would lead to 
development of damage in an inception cohort of SLE patients. 
 
1.8.6 Rasch Analysis 
Measurement scales are commonly used in medical sciences and most of them are 
ordinal scales as they are made up of qualitative items. Traditionally, the rating scale 
responses of these items are assigned discrete numbers of increasing value to reflect the 
increasing quantity of the qualitative responses. Subsequently, the scores for all the items are 
summated into a total or raw score. This raw score is subsequently used as the ‘measure’ in 
statistical analyses. Two assumptions are made when this is done. Firstly, each item is 
assumed to contribute equally to the measure. This implies that all the items are of equal 
importance in the assessment of the construct. Secondly, all the items are measured on the 
same linear scale and the distance between each rating scale point is uniform both within and 
across items. Unfortunately, the validity of these two assumptions has not been tested using 
traditional approaches. The Rasch analysis provides the only means to assess these 
assumptions. 
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The Rasch model is a probabilistic mathematical model that is used to assess 
measurement scale scientifically (Andrich 1988; Rasch 1980). It assumes that the probability 
of a particular response in an item is a logistic function of the severity of the item and the 
patient’s disease activity. Its most basic model is the dichotomous model which is represented 
by the following equation: 
logit = ln ⎟⎠
⎞⎜⎝
⎛
− P
P
1
= β - δ 
where P is the probability of a patient’s given response to an item, β is the patient’s disease 
activity and δ is the severity of the item. It is the logistic transformation of the probabilities 
that gives rise to a linear scale, with logit being the basic unit of this scale. An implicit 
assumption of this model is that there is a hierarchical ordering of the items in the index, 
which means that the data forms an ordinal scale. This model has the properties of 
fundamental measurement which are additivity of the scale (logit being the basic unit), and 
specific objectivity as the equation allows for item severity and patient’s disease activity to be 
independent of each other (item-person separation). The concept of Rasch measurement can 
be represented by a map of items (within a scale) and patients as shown in Figure 1-4. Using 
the Rasch model, the item and person data undergo logarithmnic transformation which will 
convert ordinal data into a linear (logit) scale. This transformation will provide the estimates 
for item severity and patient’s disease activity in logit scale, which allow both items and 
patients to be displayed on the same map (according to its estimated value). The map in 
Figure 1-4 shows the relative location of 6 patients (in squares labelled A to F) with differing 
levels of disease activity and 8 items (in circles labelled 1 to 8) with differing severity. The 
more severe items and patients with more active disease are located further towards the top of 
the map (more positive logit value). Therefore, item 1 has the highest severity (most difficult 
to achieve) while item 3 being at the other end of the map is the least severe (easiest to 
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achieve). Items 5 and 8 have similar level of severity as they are on the same location on the 
logit scale. Similarly, patient A has the most active disease (being at the top of the map) 
followed by D, B, E, C and F. Data that are performing to the model expectation would be 
located in the white zone and data that do not fit the model (as with item 5) will be in the 
shaded area. 
Figure 1-4: Representation of Rasch measurement using item-person map. (square 
represents person, circle represent item, shaded areas represent data that do not fit the 
Rasch model) 
 
 
Apart from that, this model also confers unidimensionality whereby the index 
measures only one attribute at a time. Measurement scales should strive to achieve this 
property as multidimensional scales have a number of attributes merged into a single generic 
score that makes interpretation difficult. This model is also used to assess internal construct 
validity of the index as unidimensionality infers that the items in the index are measuring the 
same attribute.  
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Unlike traditional statistical analysis where the statistical model tries to fit the data, the 
reverse is the case with Rasch analysis as the data needs to conform to the model. The original 
Rasch model was designed for dichotomous data, but since its publication, the model has been 
expanded for use in other situations.  
 
1.9 Objectives of Research 
The objectives of my thesis were to develop and validate the BILAG-2004 index for 
the assessment of disease activity in SLE with the following aims: 
(a) to ensure that this index has face and content validity 
(b) to determine the inter-rater reliability of this index in routine clinical practice 
(c) to determine the construct and criterion validity of this index 
(d) to determine if this index is sensitive to change 
(e) to determine the predictive validity of this index 
(f) to determine if this index fits the Rasch model 
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Chapter 2     General Methodology 
 
 
The validation of the BILAG-2004 index has involved the following studies: 
1. Reliability study in routine clinical practice 
2. Cross sectional study (construct and criterion validity) 
3. Sensitivity to change study 
4. Predictive validity study 
5. Rasch analysis 
All these studies involved multiple centres in United Kingdom and had received multi-centre 
research ethical approval from Hull and East Riding Research Ethics Committee as well as 
approval from local research ethics committees of all participating centres. These studies were 
carried out in accordance with the Helsinki Declaration and written consent was obtained 
from patients. Patients with SLE who satisfied the revised ACR criteria for classification of 
SLE were recruited from both in-patients and out-patients (Hochberg 1997; Tan et al. 1982). 
Patients were excluded from the study if they were pregnant, under age of 18 years or unable 
to give valid consent. 
The specific details of each study are described in subsequent relevant chapters. This 
chapter provides descriptions of certain aspects of methodology and analysis which are 
common to multiple chapters. 
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2.1 Definition of Change in Therapy 
Change in therapy was used as the reference standard for disease activity in the cross 
sectional study (for criterion validity) and in the sensitivity to change study (which is a 
longitudinal study). The definition used for both studies was similar, however there was a 
slight but important difference. In the cross sectional study, change in therapy was the 
difference in treatment after the patient was assessed as compared to the treatment that the 
patient was on prior to the assessment. In other words, it was the change in the treatment 
following the assessment. In contrast, change in therapy in the sensitivity to change study was 
the difference in treatment after the patient was assessed at the index visit, as compared to the 
therapy after the previous visit (or change in treatment between two consecutive visits).  
The medications of interest were immunosuppressives, antimalarials, corticosteroids, 
biological therapy, topical corticosteroids, topical immunosuppressives, intravenous 
immunoglobulins, plasmapheresis, anticoagulation, prasterone, dapsone, thalidomide and 
retinoids. NSAIDs were not included, as they were commonly used for several other 
indications (for pain relief in non-SLE conditions) and could be obtained over the counter as 
non-prescription medication. 
Three categories of change were defined, namely ‘no change’, ‘increase in therapy’ or 
‘decrease in therapy’. Change in therapy was classified into two categories for the purpose of 
analysis, namely ‘increase in therapy’ and ‘no increase in therapy’. Therefore, no increase in 
therapy represents a combination of ‘no change’ and ‘decrease in therapy’. This was chosen 
as increase in therapy was seen as a marker of disease activity. A robust definition for change 
in therapy was used. 
Increase in therapy was defined as any increase in the medications of interest 
regardless of any concomitant reduction in other medications. Decrease in therapy was 
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defined as any decrease in the medications of interest without any concomitant increase in 
other medications. However, change in therapy was not just a simple change in the dose of the 
medications. The following special circumstances had to be taken into account: 
1. Dosing levels based on body weight 
2. Step-down switch of immunosuppressive therapy 
3. Gradual escalation of immunosuppressive therapy following initiation 
4. Increase in immunosuppressive therapy for steroid-sparing effect 
5. Initiation of anticoagulation for active SLE disease 
6. Reduction or discontinuation of therapy due to side effects 
 
Dosing Levels 
For some immunosuppressives, different dosing levels based on body weight were 
considered in the definition of change in therapy (Table 2-1). A change in therapy was 
deemed to have occurred when there had been a change in the dosing level of these 
medications. These levels were based on clinical judgement and experience. 
Table 2-1: Dosing levels of medications used for defining change in therapy. 
Medications Level 1 Level 2 Level 3 
Azathioprine < 1 mg/kg/d 1 - 2.4 mg/kg/d ≥ 2.5 mg/kg/d 
Mycophenolate < 2 g/d 2 g/d > 2 g/d 
Ciclosporin A < 2 mg/kg/d 2 - 3 mg/kg/d > 3 mg/kg/d 
Tacrolimus < 0.10 mg/kg/d 0.10 - 0.15 mg/kg/d > 0.15 mg/kg/d 
Methotrexate < 10 mg/wk 10 - 15 mg/wk > 15 mg/wk 
Oral Cyclophosphamide < 1 mg/kg/d 1 - 2 mg/kg/d > 2 mg/kg/d 
 
For medications that were not listed in Table 2-1, a simple change in dose would constitute a 
change in therapy. 
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Change in Immunosuppressives 
A switch in immunosuppressive therapy was generally considered as an increase in 
therapy except in the situation of changing cyclophosphamide to azathioprine, methotrexate 
or ciclosporin. This was because it was common practice to make such a change once the 
disease was under control, as prolonged cyclophosphamide therapy was associated with 
significant toxicity (step-down phase). In fact, this step-down phase was equivalent to a 
reduction in therapy as the discontinuation of cyclophosphamide was considered as a decrease 
in therapy while the initiation of the other immunosuppressive was not considered an increase 
in this circumstance. In the case of change from cyclophosphamide to mycophenolate mofetil, 
the situation was clarified with the local investigator as to whether the change was a result of 
failed cyclophosphamide (indicating increase in therapy) or as a step-down phase (indicating 
no increase in therapy).  
 
Immunosuppressives for Steroid-Sparing Effect 
If an immunosuppressive agent was started for its steroid-sparing effect, this was not 
considered to be an increase in therapy.  
 
Anticoagulation for Active Disease 
Anticoagulation needed to be initiated for reason of active disease (which was 
clarified with the local investigator) and in the presence of immunosuppressives or high dose 
corticosteroids before it was considered an increase in therapy. 
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Escalation of Immunosuppressive Dose 
As most immunosuppressives have potential toxicity, it is common practice to start at 
a low dose and gradually escalate to the target dose. To take this into account, any increase in 
the dose of immunosuppressives within the first 3 months of initiation was considered as part 
of an escalation plan to achieve the target dose and not as an increase in therapy. Similarly, it 
was also common practice to reduce corticosteroids dose gradually during this period as part 
of the escalation plan. Therefore, any concomitant reduction in corticosteroids dose during the 
escalation phase was not considered as a reduction in therapy.  
 
Reduction of Therapy due to Side Effects 
If any medication was decreased or discontinued due to side effects, this was not 
considered to be a reduction in treatment.  
 
2.2 Common Statistical Analysis 
Overall BILAG-2004 and overall Classic BILAG scores were used in the analysis in 
several of the studies. These overall scores were determined by the highest score achieved by 
any system in the respective index. BILAG-2004 and Classic BILAG scores of D and E were 
combined together as both of them indicate inactivity. Therefore, four categorical overall 
scores were possible (A, B, C and D). 
The majority of the patients in the cross sectional and sensitivity to change studies 
contributed more than one observation to the respective studies as there were repeated 
observations over time from the same patients. In both of these studies, patients who had more 
active and severe disease were more likely to be seen and assessed more frequently, thereby 
contributing more observations compared to patients with stable or mild disease. Therefore, 
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observations from the same patient were more likely to be correlated and independence of 
these observations could not be assumed. To account for the repeat observations from the 
same patients, robust variance estimation (Huber/White/sandwich variance estimator) was 
used instead of the standard variance estimation in the logistic regression analyses (Williams 
2000).  
All statistical analyses were performed using Stata for Windows (Stata Corporation, 
Texas). The specific details of the analysis used in the various validation studies will be 
described in subsequent relevant chapters. 
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Chapter 3     Reliability Study in Routine Clinical Practice 
 
 
3.1 Abstract 
Objectives:  
1. To determine the inter-rater reliability of the BILAG-2004 and SLEDAI-2000 indices 
2. To compare the ability of the BILAG-2004 and SLEDAI-2000 indices to capture 
disease activity  
Methods:  
SLE patients were recruited from 11 centres and were assessed by 2 raters separately in 
routine clinical practice. Disease activity was determined using the BILAG-2004 index. Two 
exercises were performed: changes were made after the first exercise (E1) and training was 
provided to the raters before the second exercise (E2). SLEDAI-2000 index was also used in 
E2. E1 and E2 involved 12 and 14 raters respectively. Reliability was assessed using level of 
agreement, kappa statistic, intraclass correlation coefficient (ICC) and analysis of 
disagreement. Ability to detect disease activity was assessed by determining the number of 
patients with high activity on the BILAG-2004 index (overall score A or B) but low SLEDAI-
2000 score (< 6) and number of patients with low activity on the BILAG-2004 index (overall 
score C, D or E) but high SLEDAI-2000 score (≥ 6). Treatment of these patients were 
analysed and increase in therapy was used as the reference standard for active disease. 
Results:  
Ninety seven patients were recruited for both exercises. There was improvement in 
agreement, kappa statistics and ICC, with reduction in major disagreements from E1 to E2. 
Reliability was further improved by removing poorly performing items. Only 93 patients in 
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E2 had SLEDAI-2000 assessments. There were 43 patients (46.2%) with a difference in 
SLEDAI-2000 score between the 2 raters and this difference was ≥ 4 in 19 patients (20.4%). 
Agreement for each of the items in SLEDAI-2000 was between 81.7 – 100%. Thirty five 
patients (37.6%) had high activity on BILAG-2004 but low SLEDAI-2000 score, of which 
48.6% had their therapy increased. There were 5 patients (5.4%) with low activity on BILAG-
2004 but high SLEDAI-2000 score.  
Conclusions:  
The BILAG-2004 and SLEDAI-2000 indices are reliable to assess SLE activity. SLEDAI-
2000 index appears to be less able to detect active disease requiring increased therapy than the 
BILAG-2004 index. 
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3.2 Objectives 
1. To determine the inter-rater reliability of the BILAG-2004 index in routine clinical 
practice 
2. To determine the inter-rater reliability of the SLEDAI-2000 index in routine clinical 
practice 
3. To compare the ability of the BILAG-2004 and SLEDAI-2000 indices to capture 
disease activity  
 
3.3 Introduction 
As discussed in Chapter 1, SLE is a complex multi-system autoimmune disease with 
diverse immunological and clinical manifestations. Assessment of disease activity poses a 
challenging problem as any organ system can be affected and it is well known that SLE may 
mimic manifestations of other diseases. As there is no single biomarker that adequately 
reflects disease activity, numerous composite clinical indices have been developed for the 
assessment of disease activity (Liang et al. 1988). The two most commonly used disease 
activity indices in clinical studies are the Classic BILAG and SLEDAI indices. Over time, 
several deficiencies were noted with both of these indices and they were revised resulting in 
the BILAG-2004 and SLEDAI-2000 indices, respectively.  
To-date, almost all the validation studies of the SLEDAI index involved the original 
index and SLEDAI-2000 had not been fully validated (Chang et al. 2002a; Chang et al. 
2002b; Ward et al. 2000; Gladman et al. 1994; Guzman et al. 1992; Petri et al. 1992; Gladman 
et al. 1992; Liang et al. 1989). The SLEDAI-2000 index was only validated retrospectively 
 62
against the SLEDAI index which showed that SLEDAI-2000 correlated with its predecessor 
(Gladman et al. 2002).  
The preliminary BILAG-2004 index had been subjected to an initial validation with 
reliability study (Isenberg et al. 2005). Two reliability exercises were performed, in which 8 
patients were assessed on each occasion by 8 rheumatologists in a specially designed research 
clinic. The results showed that most of the systems had good reliability but there was concern 
regarding the performance of the Musculoskeletal system, which was most likely related to 
inadequacies in the glossary. Changes were made to improve the glossary after the study. 
In this chapter, I will present the results of a much larger inter-rater reliability study of 
the BILAG-2004 and SLEDAI-2000 indices in routine clinical practice. The performance of 
both of these indices was also compared with regards to their ability to detect disease activity 
requiring an increase in therapy. 
 
3.4 Methods 
This was a multi-centre cross sectional study involving 11 centres in the United 
Kingdom. Recruited SLE patients were assessed separately by the local rheumatologist and an 
external physician (CSY). This study was performed in the setting of routine clinical practice 
and the medical records were available to both of the raters. Disease activity was assessed 
using the BILAG-2004 index. Raters were also asked to record any anomalies or difficulties 
encountered with the index during the study. After the study in each centre, there was 
discussion between the raters on the difference in scoring between the two raters, and issues 
related to the face and content validity of the index and its glossary. 
Two reliability exercises were performed. During the first exercise (E1), several issues 
with the glossary of the index were identified and it was noted that several raters were 
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insufficiently familiar with the index resulting in errors on using the index. Following this, 
changes were made to the glossary of the BILAG-2004 index. A second exercise (E2) using 
the revised BILAG-2004 index was planned a few months later and it was decided that for 
this exercise, SLEDAI-2000 index (Gladman et al. 2002) would also be used to assess disease 
activity as a comparison. Prior to the second exercise, training was provided to the raters to 
familiarise them with both the revised BILAG-2004 and SLEDAI-2000 indices. Twelve 
patients were involved in both of the exercises. The first exercise involved 12 raters while the 
second exercise involved 14 raters. 
 
3.5 Analysis 
For the purpose of analysis, the BILAG-2004 index scores of D and E were combined 
together as both of them indicate inactivity. For each system, inter-rater reliability of the 
BILAG-2004 index was assessed using kappa statistic (unweighted and weighted) based on a 
simple two way tabulation of external versus local rater scores (Cohen 1968; Cohen 1960). In 
addition, a pooled within centre intraclass correlation coefficient (ICC) was calculated for 
each system through the use of numerical scores for each categorical grade (A=9, B=3, C=1 
and D/E=0) (Stoll et al. 1997). The ICC used in this analysis was a slight generalisation of the 
ICC equation [2,1] given by Shrout and Fleiss (Shrout et al. 1979). An overall ICC for the 
index was calculated using the summated numerical scores of all systems. Calculations of 
ICC were performed by Dr Elizabeth Allen.  
Confidence intervals (CI) were calculated for kappa statistics and ICCs. As BILAG-
2004 scoring has more than 2 categories, a bootstrap technique with 1000 replications was 
used to estimate a 95% confidence interval for kappa statistic. Bootstrap technique is a 
computer-intensive method used to estimate parameters and confidence intervals for models, 
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which require fewer assumptions about the distribution of the data than parametric methods 
(Davison et al. 2007). It infers the distribution of the population from the distribution of the 
sample data and derives estimates by making repeat random samples of the same size as the 
original sample from the data itself. However, there is replacement of the sample using the 
computer in which any observation can be sampled more than once. This replacement is 
important to avoid random permutation of the original data that would result in the same 
estimate as the original data. The confidence intervals are estimated from the variability 
derived from this sampling. 
Percentages of assessments on which both raters agreed were calculated, as was a 
weighted level of agreement. The weighting used to calculate the weighted level of agreement 
and weighted kappa statistic reflects the judgement of the raters on the severity of the possible 
disagreements and is as follows:  
Table 3-1: Weighting used to calculate weighted agreement and weighted kappa 
statistic. 
Rater 1  
Arbitrary weight A B C D/E 
A 1.0 0.75 0.25 0 
B 0.75 1.0 0.5 0 
C 0.25 0.5 1.0 0.5 
 
 
 
Rater 2 
D/E 0 0 0.5 1.0 
 
As Grades A and B represented active disease and Grades D and E indicated inactivity, it was 
decided that this difference in scoring between raters would be considered total disagreement 
(weighting score of zero). Similarly, with Grade C indicating mild disease, the score 
difference between raters of A and C was considered as minor agreement of about 25% and 
hence the weighting of 0.25. This weighting system is similar to the one used in the reliability 
study of the Classic BILAG index (Hay et al. 1993). An acceptable level of agreement was set 
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at the level of at least 70%. As for kappa statistic, the acceptable value was that of at least 
0.40 (Landis et al. 1977). With ICC and weighted kappa statistic being equivalent statistically, 
the acceptable value for ICC was the same as kappa statistic (Fleiss et al. 1973). 
With active disease being represented by scores of A and B and the other grades (C, D 
and E) indicating minimal activity, disagreements in scoring between the raters were 
classified into major disagreement and minor disagreement. Major disagreement in scoring 
was defined as scores of A by one rater and C or D or E by the other rater, or scores of B by 
one rater and D or E by the other. Minor disagreement was defined as a score difference of A 
and B, or score difference of B and C, between raters. Score difference of C and D or E was 
generally regarded as acceptable level of disagreement. 
The reliability of SLEDAI-2000 index was assessed using the level of agreement for 
each item in the index. The ability to detect disease activity was assessed by determining the 
number of patients with discordant BILAG-2004 and SLEDAI-2000 scores. These discordant 
scores can be divided into those with high activity on the BILAG-2004 index (overall score of 
A or B) but low SLEDAI-2000 score (less than 6), and those with low activity on the BILAG-
2004 index (overall score of C or D or E) but high SLEDAI-2000 score (6 or more). The 
overall BILAG-2004 score for a patient was determined by the highest score achieved by any 
system in the index. Treatment of these patients was analysed and increase in corticosteroids, 
antimalarials or cytotoxic therapy was used as the reference standard for active disease. 
Assessment by the external rater was used for this analysis to avoid rater effect and to 
minimise bias as treatment decisions were made by the local rater. Analysis with different 
SLEDAI-2000 cut-off scores for definition of active disease was also performed. 
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3.6 Results 
Ninety seven patients were recruited for both of the exercises. The demographics of 
the patients are summarised in Table 3-2. 
Table 3-2: Demographics of patients recruited into the reliability exercises. 
Patient Characteristics Exercise 1 Exercise 2 
Female sex (%) 
Mean age in years (range) 
Ethnicity (%) 
    Caucasian 
    Afro-Caribbean 
    South Asian 
    Oriental 
    Others 
Mean disease duration in years (range) 
89.7 
42.3 (18.5 – 82.2) 
 
74.2 
8.2 
13.4 
0 
4.1 
9.4 (0 – 32.1) 
90.7 
43.7 (17.7 – 75) 
 
68.0 
15.5 
11.3 
1.0 
4.1 
10 (0 – 34.8) 
 
The distribution of disease activity across the systems for both exercises as assessed 
by the local physician using the BILAG-2004 index is summarised in Table 3-3 and Table 3-
4. 
Table 3-3: Distribution of disease activity across systems for Exercise 1 using the 
BILAG-2004 index as assessed by local physician. 
System A (%) B (%) C (%) D (%) 
Constitutional 1.0 11.3 52.6 35.1 
Mucocutaneous 5.1 19.6 25.8 49.5 
Neuropsychiatric 8.2 1.0 24.7 66.0 
Musculoskeletal 4.1 13.4 42.3 40.2 
Cardiorespiratory 3.1 8.2 1.0 87.6 
Gastrointestinal 0 1.0 1.0 97.9 
Ophthalmic 0 2.1 2.1 95.9 
Renal  1.1 7.7 14.4 78.4 
Haematological 0 3.4 47.4 46.4 
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Table 3-4: Distribution of disease activity across systems for Exercise 2 using the 
BILAG-2004 index as assessed by local physician. 
System A (%) B (%) C (%) D (%) 
Constitutional 1.0 9.3 51.5 38.1 
Mucocutaneous 3.1 23.7 34.0 39.2 
Neuropsychiatric 4.1 8.2 16.5 71.1 
Musculoskeletal 4.1 18.6 38.1 39.2 
Cardiorespiratory 0 9.3 3.1 87.6 
Gastrointestinal 0 1.0 0 99.0 
Ophthalmic 0 1.0 1.0 97.9 
Renal  4.1 4.1 5.2 86.6 
Haematological 0 10.3 24.7 64.9 
 
The majority of the patients in both exercises had relatively low disease activity 
(Grades C or D) and this was particularly evident in the Gastrointestinal and Ophthalmic 
systems. This remained an issue despite targeted recruitment of patients with active disease 
for the second exercise in view of the clustering of low activity in the first exercise. Even in 
patients with evidence of active disease, most of them had only one system involved while the 
other systems were usually unaffected or minimally affected.  
 
3.6.1 Inter-rater Agreement and Reliability of the BILAG-2004 Index 
 
The results of the first exercise are summarised in Tables 3-5 to 3-7. The details are 
shown in Appendix 5. The overall ICC for the BILAG-2004 index was 0.45 (95% CI: 0.31, 
0.58). There was poor level of agreement (< 70%) in the Constitutional, Mucocutaneous and 
Musculoskeletal systems, while the kappa was low (< 0.40) in Constitutional, 
Neuropsychiatric, Musculoskeletal, Gastrointestinal and Ophthalmic systems, and, the 
estimated ICC was low (< 0.40) in Constitutional, Neuropsychiatric, Cardiovascular, 
Gastrointestinal and Ophthalmic systems. The low kappa and ICC values despite excellent 
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agreement in Ophthalmic and Gastrointestinal systems were due to clustering of inactivity in 
these systems in most patients. 
The presence of large number of major disagreements (0.44 per patient) was rather 
worrying with the majority of them in Constitutional, Mucocutaneous, Neuropsychiatric, 
Musculoskeletal and Cardiorespiratory (Table 3-7). Further analysis into the disagreements 
revealed that most of them (98.6%) could be attributed to non-scale factors (not related to the 
index). Almost all the non-scale factors were related to the raters. It was evident that there 
were numerous recording errors (misclassification), such as recording of features that were 
not due to SLE (for example painful knee effusion from osteoarthritis), and errors in 
interpretation of the terms used in the index (usually the result of not referring to the 
glossary), for example scoring moderate inflammatory arthritis as severe inflammatory 
arthritis. These errors could be attributed to insufficient familiarity with the BILAG-2004 
index. 
Table 3-5: Agreement for each system in the BILAG-2004 index for Exercise 1. 
System Agreement 
% 
Weighted Agreement 
% 
Constitutional 48.5 69.6 
Mucocutaneous 69.1 80.4 
Neuropsychiatric 74.2 84.0 
Musculoskeletal 51.6 72.4 
Cardiorespiratory 90.7 92.0 
Gastrointestinal 96.9 97.4 
Ophthalmic 95.9 96.9 
Renal 96.9 98.5 
Haematological 91.5 95.7 
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Table 3-6: Kappa statistic (unweighted and weighted) and ICC of each system in the 
BILAG-2004 index for Exercise 1. 
System Kappa 
(95% CI) 
Weighted Kappa 
(95% CI) 
ICC 
(95% CI) 
Constitutional 0.18 
(0.05, 0.31) 
0.18 
(0.06, 0.33) 
0.09 
(0, 0.21) 
Mucocutaneous 0.50 
(0.36, 0.65) 
0.55 
(0.41, 0.71) 
0.40 
(0.26, 0.53) 
Neuropsychiatric 0.36 
(0.18, 0.55) 
0.38 
(0.20, 0.59) 
0.34 
(0.20, 0.47) 
Musculoskeletal 0.26 
(0.13, 0.39) 
0.35 
(0.22, 0.49) 
0.43 
(0.30, 0.56) 
Cardiorespiratory 0.53 
(0.25, 0.78) 
0.58 
(0.33, 0.82)) 
0.18 
(0.06, 0.32) 
Gastrointestinal -0.01 
(-0.02, 0) 
-0.01 
(-0.03, 0) 
0 
(0, 0.11) 
Ophthalmic 0 
(0, 0) 
0 
(0, 0) 
0 
(0, 0.11) 
Renal 0.91 
(0.79, 1) 
0.94 
(0.84, 1) 
0.97 
(0.96, 0.98) 
Haematological 0.84 
(0.71, 0.94) 
0.85 
(0.74, 0.93) 
0.75 
(0.65, 0.82) 
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Table 3-7: Analysis of disagreement in scoring of the BILAG-2004 index between raters 
in Exercise 1. 
Disagreements Total Systems 
A and C or D 13     Neuropsychiatric     5 
    Mucocutaneous       4 
    Cardiorespiratory    3 
    Constitutional          1 
B and D 30 
    
     
    Constitutional         8 
    Musculoskeletal     8 
    Mucocutaneous      6 
    Cardiorespiratory   3 
    Gastrointestinal      2 
    Ophthalmic            2  
    Neuropsychiatric    1 
A and B 6 
 
    Musculoskeletal    4 
    Mucocutaneous     1 
    Cardiorespiratory  1 
B and C 22 
 
    Musculoskeletal   11 
    Mucocutaneous      6 
    Constitutional        3 
    Cardiorespiratory   1 
    Haematological      1 
 
Several issues with the glossary and definitions were identified and changes were 
recommended as follows: 
1. There was no clear guidance in the form and glossary on the differentiation of activity 
and damage due to SLE. This resulted in misclassification of items, with features that 
were due to damage being recorded as disease activity. Hence, a clear indication that 
only features due to activity are to be recorded was needed in the form and glossary. 
Apart from that, guidance on the differentiation of activity from damage was provided. 
2. New episodes of manifestations that occurred in the last 4 weeks and not in the 
previous 4 weeks were being recorded as ‘new’ even if they had improved 
significantly prior to the assessment. It was noted that this would result in over-scoring 
of the given manifestations as it would be uncommon for physicians to increase 
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therapy in this situation. It was therefore more appropriate that in this situation, the 
item should be recorded as ‘improving’ instead of ‘new’, which would result in a 
lower score provided that the item fulfilled the criteria for improving. 
3. Many items in the index had not been adequately qualified or quantified in the 
glossary and this had resulted in different thresholds or interpretations being used by 
individual raters. The definitions of items in the index were re-examined and changes 
were made accordingly to the glossary. 
4. There was confusion in the interpretation of the term polyarthritis which was used in 
the item ‘severe polyarthritis’. It was commonly misunderstood to mean the 
conventional definition which was involvement of 5 or more joints, while in the 
BILAG-2004 index this referred to severe involvement of 2 or more joints. Therefore, 
the item ‘severe polyarthritis’ was rephrased into ‘severe arthritis’. 
In view of the above results in Exercise 1 which was less than satisfactory, a repeat 
exercise was conducted using the revised BILAG-2004 index incorporating the above 
changes. Training was provided to the raters to familiarise them with the index before the 
second exercise. The training was in the form of correspondence and a short briefing before 
the start of the second exercise in each centre, to ensure familiarity with the items and the 
glossary definitions.  
The results of the second exercise are summarised in Tables 3-8 to 3-10, with details 
in Appendix 4. 
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Table 3-8: Agreement for each system in the BILAG-2004 index for Exercise 2. 
Systems Agreement 
% 
Weighted Agreement 
%  
Constitutional 53.6 75.3 
Mucocutaneous 72.2 84.3 
Neuropsychiatric 80.4 86.9 
Musculoskeletal 56.7 77.3 
Cardiorespiratory 90.7 92.3 
Gastrointestinal 99.0 99.0 
Ophthalmic 99.0 99.0 
Renal 95.9 97.9 
Haematological 88.7 94.3 
 
Table 3-9: Kappa statistic (unweighted and weighted) and ICC of each system in the 
BILAG-2004 index for Exercise 2. 
Systems Kappa 
 
(95% CI) 
Weighted 
Kappa 
(95% CI) 
ICC 
 
(95% CI) 
Constitutional 0.24 
(0.12, 0.39) 
0.31 
(0.18, 0.44) 
0.63 
(0.51, 0.74) 
Mucocutaneous 0.58 
(0.46, 0.70) 
0.65 
(0.52, 0.76) 
0.46 
(0.31, 0.60) 
Neuropsychiatric 0.46 
(0.26, 0.65) 
0.50 
(0.30, 0.70) 
0.80 
(0.71, 0.86) 
Musculoskeletal 0.34 
(0.20, 0.48) 
0.47 
(0.32, 0.59) 
0.55 
(0.41, 0.66) 
Cardiorespiratory 0.44 
(0.12, 0.76) 
0.45 
(0.08, 0.75) 
0.38 
(0.23, 0.53) 
Gastrointestinal 0 
(0, 0) 
0 
(0, 0) 
0.08 
(0, 0.23) 
Ophthalmic 0.66 
(0, 1) 
0.49 
(0.33, 0.82) 
0.20 
(0.05, 0.35) 
Renal 0.80 
(0.57, 0.96) 
0.88 
(0.71, 0.97) 
0.99 
(0.98, 0.99) 
Haematological 0.79 
(0.66, 0.89) 
0.82 
(0.71, 0.91) 
0.86 
(0.80, 0.90) 
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Table 3-10: Analysis of disagreement in scoring of the BILAG-2004 index between 
raters in Exercise 2. 
Disagreements Total Systems 
A and C or D 1 
 
    Musculoskeletal  1 
B and D 26 
    
    Constitutional        3 
    Musculoskeletal    3 
    Mucocutaneous     5 
    Cardiorespiratory  6 
    Gastrointestinal     1 
    Ophthalmic           1 
    Neuropsychiatric  7 
A and B 7 
 
    Musculoskeletal   3 
    Mucocutaneous    3 
    Neuropsychiatric  1 
B and C 32 
 
    Musculoskeletal  13 
    Mucocutaneous   10 
    Constitutional       7 
    Haematological    2 
 
The overall ICC for this second exercise was 0.67 (95% confidence interval: 0.54, 
0.76). There was low kappa in the Constitutional, Gastrointestinal and Ophthalmic systems 
while the level of agreement for all systems was acceptable when weighted agreement was 
considered. The ICC was low in the Cardiorespiratory, Gastrointestinal and Ophthalmic 
systems. The low kappa and/or ICC values despite good agreement in Ophthalmic and 
Gastrointestinal systems were due to clustering of inactivity in these systems in most patients. 
In general, there was improvement in the level of agreement, kappa and ICC from Exercise 1 
to Exercise 2. There were also far fewer major disagreements (0.28 per patient) than in 
Exercise 1.  
It was also noted in both exercises that some items in the index consistently had rather 
poor agreement between raters, and these items were: 
1. Fatigue in the Constitutional system 
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2. Lupus migraine/cluster/tension headache in the Neuropsychiatric system 
3. Mood disorder (depression/mania) in the Neuropsychiatric system 
4. Anxiety disorder in the Neuropsychiatric system 
5. Arthralgia/Myalgia in the Musculoskeletal system 
A repeat analysis of these three systems (Constitutional, Neuropsychiatric and 
Musculoskeletal) with the above items removed was performed. The results are summarised 
in Table 3-11 and Table 3-12 
With the removal of these items, there was substantial improvement in the level of 
agreement in both of the exercises. The kappa statistic and ICC values generally improved 
slightly for Exercise 1. As for Exercise 2, there were large increases for both kappa statistic 
and ICC values for the Neuropsychiatric system, but these modifications resulted in a large 
decrease in the ICC value of the Constitutional system due to increased homogeneity of the 
population studied with removal of the item fatigue. There were noticeable increases in the 
width of some confidence intervals after the modifications which changed the extent of the 
heterogeneity in the observed scores. More importantly, there were far fewer major 
disagreements in the Constitutional and Neuropsychiatric systems. However, in the 
Musculoskeletal system, there was a 2 to 3 fold increase in the number of major 
disagreements following the removal of the arthralgia/myalgia item. Therefore, the items 
fatigue, lupus migraine/cluster/tension headache, mood disorders and anxiety disorder were 
removed from this index while the item arthralgia/myalgia was retained. 
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Table 3-11: Analysis of level of agreement, kappa statistic, ICC and disagreements 
between raters in Exercise 1 for the Constitutional, Neuropsychiatric and 
Musculoskeletal systems before and after removal of some items (fatigue, lupus 
migraine/cluster/tension headache, mood disorder, anxiety disorder and 
arthralgia/myalgia) 
Systems Before Modifications After Modifications 
Constitutional 
     Agreement (unweighted, %) 
     Kappa (unweighted) 
     Kappa (weighted) 
     ICC (95% CI) 
 
     A and C or D disagreement 
     B and D disagreement 
     A and B disagreement 
     B and C disagreement 
 
48.5 
0.18 
0.18 
0.09 (0, 0.21) 
 
1 
8 
0 
3 
 
82.5 
0.19 
0.26 
0.24 (0.11, 0.38) 
 
0 
3 
0 
2 
Neuropsychiatric 
     Agreement (unweighted, %) 
     Kappa (unweighted) 
     Kappa (weighted) 
     ICC (95% CI) 
 
     A and C or D disagreement 
     B and D disagreement 
     A and B disagreement 
     B and C disagreement 
 
74.2 
0.36 
0.38 
0.34 (0.20, 0.47) 
 
5 
1 
0 
0 
 
91.8 
0.40 
0.44 
0.35 (0.21, 0.48) 
 
5 
1 
0 
0 
Musculoskeletal 
     Agreement (unweighted, %) 
     Kappa (unweighted) 
     Kappa (weighted) 
     ICC (95% CI) 
 
     A and C or D disagreement 
     B and D disagreement 
     A and B disagreement 
     B and C disagreement 
 
51.6 
0.26 
0.35 
0.43 (0.30, 0.56) 
 
0 
8 
4 
11 
 
74.2 
0.35 
0.39 
0.41 (0.27, 0.54) 
 
0 
17 
3 
3 
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Table 3-12: Analysis of level of agreement, kappa statistic, ICC and disagreements 
between raters in Exercise 2 for the Constitutional, Neuropsychiatric and 
Musculoskeletal systems before and after removal of some items (fatigue, lupus 
migraine/cluster/tension headache, mood disorder, anxiety disorder and 
arthralgia/myalgia) 
Systems Before Modifications After Modifications 
Constitutional 
     Agreement (unweighted, %) 
     Kappa (unweighted) 
     Kappa (weighted) 
     ICC (95% CI) 
 
     A and C or D disagreement 
     B and D disagreement 
     A and B disagreement 
     B and C disagreement 
 
53.6 
0.24 
0.31 
0.63 (0.51, 0.74) 
 
0 
3 
0 
7 
 
81.4 
0.20 
0.31 
0.37 (0.22, 0.52) 
 
0 
1 
0 
2 
 
Neuropsychiatric 
     Agreement (unweighted, %) 
     Kappa (unweighted) 
     Kappa (weighted) 
     ICC (95% CI) 
 
     A and C or D disagreement 
     B and D disagreement 
     A and B disagreement 
     B and C disagreement 
 
80.4 
0.46 
0.50 
0.80 (0.71, 0.86) 
 
0 
7 
1 
0 
 
91.8 
0.59 
0.62 
0.60 (0.47, 0.71) 
 
0 
6 
1 
0 
Musculoskeletal 
     Agreement (unweighted, %) 
     Kappa (unweighted) 
     Kappa (weighted) 
     ICC (95% CI) 
 
     A and C or D disagreement 
     B and D disagreement 
     A and B disagreement 
     B and C disagreement 
 
56.7 
0.34 
0.47 
0.55 (0.41, 0.66) 
 
1 
3 
3 
13 
 
77.3 
0.42 
0.49 
0.82 (0.74, 0.87) 
 
1 
14 
3 
2 
 
3.6.2 Inter-rater Agreement of SLEDAI-2000 Index 
 
Only data from 93 patients in Exercise 2 were available for this analysis as there was 
no SLEDAI-2000 scoring by the local rater in 4 patients. There were 43 patients (46%) with a 
difference in the total SLEDAI-2000 score between the 2 raters. Of these, 19 patients (20%) 
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had score difference between raters of 4 or more. There was good level of agreement in the 
items of SLEDAI-2000, ranging from 81.7% to 100% (Table 3-13). However, all the clinical 
items with perfect agreement (items 1, 2, 4, 5, 6, 10 and 19) had null score by both raters. 
Table 3-13: Level of agreement between raters for items in SLEDAI-2000 index. 
Item Descriptor Agreement (%) 
1 Seizure 100 
2 Psychosis 100 
3 Organic brain syndrome 98.9 
4 Visual disturbance 100 
5 Cranial nerve disorder 100 
6 Lupus headache 100 
7 Cerebrovascular accident 98.9 
8 Vasculitis 98.9 
9 Arthritis 89.3 
10 Myositis 100 
11 Urinary casts 100 
12 Haematuria 100 
13 Proteinuria 100 
14 Pyuria 100 
15 Rash 84.9 
16 Alopecia 81.7 
17 Mucosal ulcers 87.1 
18 Pleurisy 98.9 
19 Pericarditis 100 
20 Low complement 100 
21 Increased DNA binding 100 
22 Fever 98.9 
23 Thrombocytopenia 100 
24 Leukopenia 100 
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3.6.3 Ability to Detect Disease Activity 
 
There were 54 patients (58.1%) with high activity according to the BILAG-2004 index 
(overall score of A or B) and of these, 29 patients (53.7%) had their therapy increased while 5 
patients (9.3%) had their therapy reduced. However, there were far fewer patients (24 
patients, 25.8%) with high activity according to SLEDAI-2000 index (score of 6 or more) and 
of these, 14 patients (58.3%) had their therapy increased whereas 2 patients (8.3%) had their 
therapy reduced. 
Thirty five patients (37.6%) had high activity on the BILAG-2004 index but low 
SLEDAI-2000 score, whereas there were only 5 patients (5.4%) with low activity on the 
BILAG-2004 index but high SLEDAI-2000 score (Table 3-14). This difference was 
statistically significant (p=0.015). When data from the local rater were used, there were more 
patients (41, 44.1%) with high activity on BILAG-2004 but low SLEDAI-2000 score and less 
patients (4, 4.3%) with low activity on BILAG-2004 but high SLEDAI-2000 score. 
Table 3-14: Cross tabulation of BILAG-2004 and SLEDAI-2000 scores for patients 
recruited into the study. 
 SLEDAI-2000 
Score ≥ 6 
SLEDAI-2000 
Score < 6 
Total 
Overall BILAG-2004 
Score of A or B 
19 35 54 
Overall BILAG-2004 
Score of C or D or E 
5 34 39 
Total 49 44 93 
 
The treatment of these patients with discordant BILAG-2004 and SLEDAI-2000 
scores is summarized in Tables 3-15 and 3-16.  
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Table 3-15: Treatment analysis of patients with high BILAG-2004 and low SLEDAI-
2000 scores with different cut-off scores used to define active disease with SLEDAI-2000. 
 Treatment 
Increased 
Treatment 
Reduced 
Treatment 
Not Changed 
BILAG-2004 A or B and SLEDAI-
2000 < 10 (n = 37) 
 
18 (48.7%) 
 
4 (10.8%) 
 
15 (40.5%) 
BILAG-2004 A or B and SLEDAI-
2000 < 9 (n = 37) 
 
18 (48.7%) 
 
4 (10.8%) 
 
15 (40.5%) 
BILAG-2004 A or B and SLEDAI-
2000 < 8 (n = 35) 
 
17 (48.6%) 
 
3 (8.6%) 
 
15 (42.9%) 
BILAG-2004 A or B and SLEDAI-
2000 < 7 (n = 35) 
 
17 (48.6%) 
 
3 (8.6%) 
 
15 (42.9%) 
BILAG-2004 A or B and SLEDAI-
2000 < 6 (n = 35) 
 
17 (48.6%) 
 
3 (8.5%) 
 
15 (42.9%) 
BILAG-2004 A or B and SLEDAI-
2000 < 5 (n = 30) 
 
15 (50%) 
 
3 (10%) 
 
12 (40%) 
BILAG-2004 A or B and SLEDAI-
2000 < 4 (n = 16) 
 
9 (56.3%) 
 
0 
 
7 (43.7%) 
BILAG-2004 A or B and SLEDAI-
2000 < 3 (n = 16) 
 
9 (56.3%) 
 
0 
 
7 (43.7%) 
BILAG-2004 A or B and SLEDAI-
2000 < 2 (n = 16) 
 
2 (50%) 
 
0 
 
2 (50%) 
BILAG-2004 A or B and SLEDAI-
2000 = 0 (n = 4) 
 
2 (50%) 
 
0 
 
2 (50%) 
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Table 3-16: Treatment analysis of patients with low BILAG-2004 and high SLEDAI-
2000 scores with different cut-off scores used to define active disease with SLEDAI-2000. 
 Treatment 
Increased 
Treatment 
Reduced 
Treatment 
Not Changed 
BILAG-2004 C or D or E and 
SLEDAI-2000 ≥ 6 (n = 5) 
 
2 (40%) 
 
0 
 
3 (60%) 
BILAG-2004 C or D or E and 
SLEDAI-2000 ≥ 5 (n = 5) 
 
2 (40%) 
 
0 
 
3 (60%) 
BILAG-2004 C or D or E and 
SLEDAI-2000 ≥ 4 (n =  11) 
 
2 (18.2%) 
 
2 (18.2%) 
 
7 (63.6%) 
BILAG-2004 C or D or E and 
SLEDAI-2000 ≥ 3 (n = 11) 
 
2 (18.2%) 
 
2 (18.2%) 
 
7 (63.6%) 
BILAG-2004 C or D or E and 
SLEDAI-2000 ≥ 2 (n = 14) 
 
2 (14.3%) 
 
2 (14.3%) 
 
10 (71.4%) 
BILAG-2004 C or D or E and 
SLEDAI-2000 ≥ 1 (n = 15) 
 
2 (13.3%) 
 
2 (13.3%) 
 
11 (73.3%) 
 
Of those patients with high activity on the BILAG-2004 index but low SLEDAI-2000 
scores, 48.6% had their treatment increased. On the other hand, 60% of those with low 
activity on the BILAG-2004 index but high SLEDAI-2000 scores had their therapy reduced or 
unchanged. The results were similar when data from the local rater were used (data not 
shown).  
I looked at the effect of using different cut-off scores used to define active disease 
with SLEDAI-2000 (Tables 3-15 and 3-16). With a lower cut-off SLEDAI-2000 score, the 
number of patients with high activity on the BILAG-2004 index but low SLEDAI-2000 scores 
became less, particularly when the cut-off score was 4 or below. However, the proportion of 
these patients who had their therapy increased remained the same (around 50%). Even at the 
SLEDAI-2000 score of zero, there were 4 patients (4.3%) with high activity on the BILAG-
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2004 index and 2 (50%) of them had their therapy increased. The lowering of the cut-off 
SLEDAI-2000 scores did not make any difference in the number of patients with low activity 
on the BILAG-2004 index but high SLEDAI-2000 scores who had their therapy increased. 
Therefore, it appears that SLEDAI-2000 index is less able to capture active disease requiring 
increased therapy as compared to the BILAG-2004 index. 
 
3.7 Discussion 
These studies had demonstrated that the BILAG-2004 index (with some 
modifications) was reliable for assessing disease activity in SLE. They were performed in the 
setting of routine clinical setting that should be close to actual clinical practice. All the raters 
involved were consultants or senior specialist registrars experienced in the care of patients 
with SLE. This design was based on the one used in the reliability study of the Classic 
BILAG index (Hay et al. 1993). However, this study involved more patients (97 versus 50) 
and more raters (14 versus 7). Furthermore, the agreement and reliability of the index in this 
study was assessed using several measures (kappa statistic, ICC, level of agreement and major 
disagreements) instead of depending solely on kappa statistic, which was the case in the study 
by Hay et al (Hay et al. 1993). This fact is important as there is no single measure that 
captures all aspects of reliability and agreement.  
The main drawback of kappa statistic as an overall measure of performance is its 
dependence on marginal frequencies which are the row and column totals in the typical table 
of agreement. Kappa statistic does not perform well when there is a zero total or when there is 
little discrimination or differentiation within the population under study. This statistic gives 
low values for reliability, albeit correctly, but says little about level of agreement.  This was 
the case in the Gastrointestinal, Ophthalmic and Constitutional systems as there was 
 82
clustering of patients in Grade D or E, resulting in low kappa statistic values when there was a 
corresponding good level of agreement. Apart from that, the kappa statistic is affected by the 
number of categories in the measurement scale (Maclure et al. 1987). With more categories, it 
is more difficult to classify subjects correctly and lower kappa statustic value is the usual 
result.  
The ICC is similarly a measure of reliability designed primarily to assess the ability to 
distinguish patients from each other. Thus it, like kappa statistic, is affected by the 
homogeneity of the population studied. With a more heterogeneous population, the value of 
ICC will be higher. Hence, it is possible to have good agreement with low reliability if the 
population studied lacks variability (homogeneous). This feature contributes to the drop in the 
ICC value for the Constitutional system in Exercise 2 when the item fatigue was omitted 
resulting in a more homogeneous population. 
These studies identified four items (fatigue, lupus migraine/cluster/tension headache, 
mood disorders and anxiety disorder) demonstrating poor agreement between raters and their 
removal resulted in rather large improvement in agreement and reduction in major 
disagreements. Their removal seems appropriate as it is difficult to attribute these items to 
SLE disease activity with certainty and there are specific validated indices available to 
measure them. Further issues relating to face and content validity of the index were identified 
during the second reliability exercise. These issues were minor and did not affect the 
reliability results: 
1. Criteria for defining aseptic meningitis were too stringent and it was recommended 
that this be relaxed to require only those that would be essential for diagnosis (fever, 
headache and abnormal cerebrospinal fluid). 
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2. The definition of demyelinating syndrome required the presence of at least one 
previous event and this would preclude those presenting as the first episode, hence it 
was recommended that this requirement should be omitted. 
3. Definition of cognitive dysfunction required corroborating history from a third party 
which would be difficult to record if the patient attended alone but was able to give a 
good account of it. It was therefore recommended that this requirement be omitted. 
4. It was noted that tenosynovitis was absent from the index and the recommendation 
was to include this along with moderate arthritis and tendonitis. 
5. The criteria for active nephritis were based on the old WHO Classification and it was 
recommended that this should incorporate the latest classification which were the 
WHO Classification 1995 (Churg J et al. 1995) and International Society of 
Nephrology/Renal Pathology Society (ISN/RPS) Classification 2003 (Weening et al. 
2004). 
6. The histological criteria for active nephritis included the clause “since previous 
assessment if seen less than 3 months” which was rather ambiguous and confusing. It 
was recommended that this clause be removed. 
7. The current criteria for proteinuria for Grades A and B which required the proteinuria 
to rise from more than 1g/day (or equivalent) by more than 50% only took into 
consideration deteriorating proteinuria and took no account of stable but significant 
proteinuria. It was recommended that the Grades A and B criteria for proteinuria be 
changed to that of more than 1g/day (or equivalent) that has not improved/decreased 
by 50%. 
8. The current upper threshold of thrombocytopenia (99 x 109/litre) for a score of B in 
Haematology system was deemed to be too high for consideration of steroid or 
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immunosuppressive/cytotoxic therapy. Hence it was recommended that this threshold 
be lowered to 49 x 109/litre. 
The improvement in agreement from Exercise 1 to Exercise 2 is notable. It is likely 
that the improvement in the glossary of the index, omission of ambiguous items and training 
of raters contributed substantially to this improvement. The BILAG-2004 index is a 
comprehensive index with 97 items and clearly, there will be a need for formal training of 
users if this index is to be used in the setting of clinical trials.  
One of the limitations of the reliability study is the clustering of patients with low 
level of disease activity, hence the index has not been tested throughout its full range in 
particular in the Gastrointestinal and Ophthalmic systems which limits the applicability of the 
results of this study. In fact, the reliability of the Ophthalmic system has not been addressed 
adequately in this study as the scoring of most of the items in this system requires the 
assessment by an ophthalmologist. Therefore, the reliability of the Ophthalmic system would 
be best assessed when the two raters are ophthalmologists. The rarity of these manifestations 
will make undertaking such a study very difficult to organise. However, these manifestations 
remain important at an individual level as they do determine the management and outcome. 
This study also represents the first reliability study of SLEDAI-2000 index in routine 
clinical practice and it demonstrates good inter-rater agreement, hence this index is reliable in 
assessment of SLE disease activity which is reassuring. This is consistent with the results of 
reliability studies involving the original SLEDAI index (Hawker et al. 1993; Petri et al. 1992; 
Gladman et al. 1992; Liang et al. 1989). However, the reliability of SLEDAI-2000 index was 
not as good as would be expected with disagreement in the scores between the two raters in 
46% of patients. This is despite training being provided to the raters and the fact that this 
index is considered to be the least complicated disease activity index.  
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As both the BILAG-2004 and SLEDAI-2000 indices were used in the second 
reliability exercise, comparison was made on the ability of these two indices to detect active 
disease requiring increase in therapy. It appears that SLEDAI-2000 is less able to capture 
disease activity when compared to the BILAG-2004 index, which is not surprising as it has 
far fewer items than the BILAG-2004 index (24 versus 97). SLE is a multi-system disease 
that may affect any system and has varied manifestations within patient and between patients, 
hence a comprehensive index is required to capture all aspects of active disease.  
Unfortunately, SLEDAI-2000 fails to capture several clinically important 
manifestations of active disease such as peripheral neuropathy, myelopathy, interstitial 
alveolitis and haemolytic anaemia. Apart from that, some manifestations could not be scored 
in SLEDAI-2000 as the criteria and definitions set out are too stringent. From the experience 
of the physicians involved in this study, there was difficulty in scoring for organic brain 
syndrome, arthritis, pleurisy and pericarditis in SLEDAI-2000 despite patients having these 
manifestations. For example, to score for pleurisy in SLEDAI-2000, the requirements are that 
of ‘pleuritic chest pain with pleural rub, effusion or pleural thickening’. However, it is not 
uncommon for SLE patients with pleurisy to present with just pleuritic chest pain in the 
absence of pleural rub, pleural effusion or pleural thickening. The situation is similar for 
arthritis, pericarditis and organic brain syndrome.  
Other contributing factors include the weighting system used and its inability to 
distinguish the different severity of manifestations. Furthermore, it is unable to detect 
improvement or worsening of a manifestation, as this can only be recorded as either absent or 
present. As an illustration, thrombocytopenia (defined as platelet count less than 100x109 per 
liter) has a weighted score of one. It does not differentiate between severe thrombocytopenia 
(platelet count less than 25x109 per liter) and mild thrombocytopenia (platelet count more 
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than 50x109 per liter). The former would warrant increase in treatment, which is not the case 
for the latter but both would derive the same score in SLEDAI-2000. Due to the weighted 
score of one, patients with only severe thrombocytopenia (platelet count less than 25x109 per 
liter) as its clinical manifestation of disease activity would give a total score of 1 (or 5 if the 
patient also has low complement and elevated anti-dsDNA antibodies) which falls short of the 
cut-off of 6 for active disease (Abrahamowicz et al. 1998). Even with a lower cut-off, 
SLEDAI-2000 index still fails to capture significant numbers of clinically important 
manifestations of active disease. 
In the comparison of the BILAG-2004 and SLEDAI-2000 indices, an overall BILAG-
2004 score was used in the analysis as the BILAG-2004 index was developed as an ordinal 
scale index and not intended for the individual system scores to be summated. It was felt that 
the best way to represent overall disease activity in any individual patient was to use the 
highest score achieved by any system within the index. This seems logical as any patient with 
any system scoring a Grade A or B should be categorised as having active disease regardless 
of how many systems have a score of A or B, and one system with active disease should be 
sufficient to determine the level of therapy required to treat the patient, the premise on which 
the scoring for the index is derived. In fact, using this overall score would create a ceiling 
effect and may actually put the BILAG-2004 index at a disadvantage from an analysis point 
of view. For example, a patient with mild mouth ulcers and mild inflammatory arthritis would 
score Grade C in Mucocutaneous and Musculoskeletal systems, leading to an overall score of 
Grade C but may have therapy increased with hydroxychloroquine or a small increase in 
corticosteroids dose. 
Increased in therapy was used as the reference standard for active disease in the 
absence of a good alternative standard. With this as the benchmark, clinically significant 
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manifestations of active disease (that are being treated) are examined, which makes it very 
unlikely that the BILAG-2004 index is over-estimating disease activity. Although the 
BILAG-2004 index is based on the principle of intention to treat, using change in therapy as 
the reference standard will not bias the analysis in favour of the BILAG-2004 index as actual 
change in therapy does not determine the scoring (only the presence of active manifestations 
will influence the scoring). Furthermore, the scoring of the index was not available to the 
local rater when the treatment decision was made and most investigators were not sufficiently 
aware of the scoring algorithms. To minimise this possible bias further, the external rater 
score was used for analysis as the treatment decisions were made by the local rater. 
The result of the ability to capture active disease needs to be interpreted with caution 
as this is a cross sectional study which only provides a snapshot of disease activity at the time 
of assessment. This does not take into account the level of disease activity prior to the 
assessment and this may explain the reduction in treatment in patients with high activity, if 
the current level of activity represents an improvement from a higher previous level of 
activity such as from Grade A to B in the BILAG-2004 index or SLEDAI-2000 score of 18 to 
10. Other unaccounted factors that will influence treatment decision include treatment history 
(particularly if there has been recent initiation of cytotoxic therapy where further increase in 
therapy is unlikely) and patients’ opinion (such as refusal to increase therapy). One method to 
overcome this is to use physician’s intention of treatment (rather than actual change in 
treatment) but this may bias the result in favour of the BILAG-2004 index as the physician 
may record an intention to increase treatment when manifestations are recorded in the 
BILAG-2004 index. 
Further study with larger number of patients is required to determine the optimal 
SLEDAI-2000 cut-off score for active disease. This assessment is clearly important as it is 
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used in clinical studies to differentiate patients between the two disease states (active or 
inactive) and to determine eligibility for inclusion in clinical trials. This issue will be 
addressed in the cross sectional study. 
Several changes were made to the BILAG-2004 index following the results of the 2 
reliability exercises and the revised index (Appendix 6) was used in the cross sectional and 
longitudinal studies. 
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Chapter 4     Cross Sectional Study 
 
 
4.1 Abstract 
Objectives:  
1. To determine if the BILAG-2004 index has construct and criterion validity.  
2. To compare the sensitivity and specificity of the BILAG-2004, Classic BILAG and 
SLEDAI-2000 indices for the assessment of SLE disease activity. 
Methods:  
SLE patients were recruited in a multi-centre cross sectional study. Data were collected on 
SLE disease activity (the BILAG-2004, Classic BILAG & SLEDAI-2000 indices), 
investigations and therapy. Overall BILAG-2004 and Classic BILAG scores were used in the 
analysis. For construct validity, the constructs used for comparison were ESR, C3, C4, anti-
dsDNA and SLEDAI-2000 scores. For criterion validity, increase in therapy was used as the 
reference standard for active disease. Active disease according to the BILAG-2004 and 
Classic BILAG indices was defined as overall scores of A or B. Receiver operating 
characteristic (ROC) curves were used to determine the best cut-off score for SLEDAI-2000 
index to define active disease. Statistical analyses were based on logistic regression. 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
were calculated.  
Results:  
A total of 369 SLE patients were recruited contributing 1510 assessments. Increasing overall 
BILAG-2004 scores were associated with increasing ESR (p<0.01), decreasing C3 (p<0.01), 
decreasing C4 (p<0.01), elevated anti-dsDNA (p<0.01) and increasing SLEDAI-2000 scores 
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(p<0.01). Increase in therapy was more frequent with higher overall BILAG-2004 scores.  
Active disease scores (overall BILAG-2004 scores of A and B) were significantly associated 
with an increase in therapy (OR 19.3, p<0.01). SLEDAI-2000 had lower sensitivity, 
specificity, PPV and NPV when compared to the BILAG-2004 and Classic BILAG indices. 
The BILAG-2004 and Classic BILAG indices had comparable sensitivity, specificity, PPV 
and NPV. 
Conclusions:  
The BILAG-2004 index has construct and criterion validity. SLEDAI-2000 index does not 
appear to capture active disease requiring increase in therapy as well as the BILAG-2004 or 
Classic BILAG indices. 
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4.2 Objectives 
1. To determine if the BILAG-2004 index has construct validity and criterion validity in 
assessing SLE disease activity. 
2. To compare the sensitivity and specificity of the BILAG-2004, Classic BILAG and 
SLEDAI-2000 indices for the assessment of SLE disease activity. 
 
4.3 Introduction 
With the reliability of the BILAG-2004 index established, the next step in the 
validation process is to determine if this index has construct and criterion validity. Construct 
validity is demonstrated if this index correlates with other surrogate measures (constructs) of 
disease activity. This index has criterion validity if it agrees with the gold standard. As there 
is no gold standard for SLE disease activity, change in therapy is used as the reference 
standard instead. A cross sectional study was designed specifically for this purpose and the 
results are presented in this chapter. 
The SLEDAI-2000 index produces a global numerical score but there is debate about 
the appropriate cut-off score as an indicator of active disease. This is an important issue as it 
is used in clinical studies to differentiate between two disease states (active or inactive) and 
more so, in clinical trials where it is used to determine eligibility. There have been very few 
studies to define the appropriate cut-off score and currently available data have been 
conflicting with one study suggesting a cut-off score of 6 (Abrahamowicz et al. 1998) while 
two others suggested a lower cut-off of 4 (Yee et al. 2007b; Gladman et al. 2000b). In 
addition, all these studies were hampered by either small sample size, abstracted case 
histories, retrospective assessments or limited statistical analysis. This issue is addressed in 
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this cross sectional study by determining the optimal cut-off score for SLEDAI-2000 to define 
active disease requiring increase in therapy. Furthermore, the performances of the BILAG-
2004, Classic BILAG and SLEDAI-2000 indices were compared with regards to sensitivity, 
specificity, positive predictive value and negative predictive value in assessment of SLE 
disease activity. 
 
4.4 Methods 
This was a multi-centre cross sectional study involving 8 centres in the United 
Kingdom. This study commenced in March 2005 and was completed in August 2006. At 
every assessment, data on disease activity, investigations and treatment were collected. 
Disease activity was assessed using the BILAG-2004, Classic BILAG and SLEDAI-2000 
indices. All clinicians involved in this study had been trained to use all three disease activity 
indices. The majority of patients recruited into this study had more than one assessment 
during this period. 
 
4.5 Analysis 
Overall BILAG-2004 and overall Classic BILAG scores were used in the analysis. 
These overall scores were determined by the highest score achieved by any system in the 
respective indices.  
 
Construct Validity 
The constructs used in this validation study were erythrocyte sedimentation rate 
(ESR), complements C3 and C4, anti-dsDNA antibody levels and SLEDAI-2000 score. It was 
expected that the BILAG-2004 index would have a positive correlation or association with 
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ESR, anti-dsDNA antibody and SLEDAI-2000 score (as they increase with disease activity), 
and negative correlation or association with complement C3 and C4 levels (as they fall with 
disease activity).  
The levels of ESR, anti-dsDNA antibody, C3 and C4 were determined locally at the 
respective participating centres. As the laboratory kits used were not the same in all the 
centres, the normal values for anti-dsDNA antibody, C3 and C4 differed between centres. 
Therefore, for the purpose of the analysis, all these constructs were divided into ordinal 
categories as follows: 
(a) ESR – normal (0 – 30), elevated (31 – 60) and markedly elevated (> 60) 
(b) C3 and C4 – normal, low and very low (≤ half of lower normal limit) 
(c) Anti-dsDNA – normal, elevated and very high (> 5 times upper normal limit) 
(d) SLEDAI-2000 scores – inactive (0), mild activity (1 – 3), active (4 – 12) and 
very active (> 12) 
Maximum-likelihood ordinal logistic regression (with robust variance estimation) was 
used to assess construct validity with overall BILAG-2004 score as the outcome variable and 
the constructs as the explanatory variable. The normal or inactive category of the constructs 
was used as the baseline comparator for the other categories. Results were reported in terms 
of odds ratio (OR) with a 95% confidence interval (CI). 
 
Criterion Validity 
Change in therapy was used as the reference standard or criterion for this analysis. In 
this study, change in therapy was the change in treatment following assessment, which was 
the difference in treatment after the patient was assessed, as compared to the treatment that 
the patient was on prior to the assessment. The definition of change in treatment has been 
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described in Chapter 2. Change in therapy was classified into two categories, namely 
‘increase in therapy’ and ‘no increase in therapy’.  
For this analysis, active disease according to the BILAG-2004 and Classic BILAG 
indices was defined as overall scores of A or B. For SLEDAI-2000, receiver operating 
characteristic (ROC) curve analysis was used to determine the optimal cut-off score for active 
disease associated with a change in therapy. This cut-off score was then used for comparison 
with the other indices. 
Maximum likelihood logistic regression (with robust variance estimation) was used 
with change in therapy as the outcome variable and the respective disease activity index score 
as the explanatory variable. The results were reported in terms of odds ratios (OR) with 95% 
confidence intervals (CI). Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) were calculated with the same methodology, but applied only 
to appropriate subsets of patients and with only the intercept term estimated. For calculation 
of sensitivity and its 95% confidence interval, only observations which recorded an increase 
in treatment were used. Specificity, PPV and NPV were calculated using only patients with no 
increase in treatment, active disease and minimally active disease, respectively. 
 
4.6 Results  
A total of 369 SLE patients were recruited and they contributed 1510 assessments for 
the analysis. The demographics of the patients are summarised in Table 4-1. The majority 
(88.6%) of patients had more than one assessment during the study period. The distribution of 
disease activity according to the BILAG-2004, Classic BILAG and SLEDAI-2000 indices is 
summarised in Table 4-2. 
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Table 4-1: Demographics of patients recruited into the cross sectional study (n=369). 
Patient Characteristics  
Female sex (%) 
Mean age in years (SD) 
Ethnicity (%) 
    Caucasian 
    Afro-Caribbean 
    South Asian 
    Oriental 
    Others 
Mean disease duration in years (SD) 
Number of assessments (%) 
    1 
    2 
    3 
    4 
    5 
    6  
    7 or more 
92.7 
41.6 (13.2) 
 
59.9 
18.4 
18.4 
1.4 
1.9 
8.8 (7.7) 
 
11.4 
12.5 
19.8 
18.7 
15.2 
10.0 
8.1 
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Table 4-2: Distribution of disease activity based according to the BILAG-2004, Classic 
BILAG and SLEDAI-2000 indices (n=1510). 
Disease Activity Indices Number (%) 
Overall BILAG-2004 score 
          A 
          B 
          C 
          D/E 
 
98 (6.5) 
390 (25.8) 
721 (47.8) 
301 (19.9) 
Overall Classic BILAG score 
          A 
          B 
          C 
          D/E 
 
95 (6.3) 
435 (28.8) 
834 (55.2) 
146 (9.7) 
SLEDAI-2000 score 
          More than 12 
          4 to 12 
          1 to 3 
          0 
 
28 (1.9) 
539 (35.7) 
419 (27.8) 
524 (34.7) 
 
4.6.1 Construct Validity 
 
The distribution of disease activity according to the BILAG-2004 index and constructs 
(cross tabulated against disease activity) is summarised in Table 4-3. 
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Table 4-3: Cross tabulation of overall BILAG-2004 scores with constructs (ESR, anti-
dsDNA antibody, C3, C4 and SLEDAI-2000 score). 
Overall BILAG-2004 Scores Constructs 
A B C D 
ESR (n=787) 
    Normal (0 – 30) 
    Elevated (31 – 60) 
    Markedly elevated (> 60) 
 
29 
23 
13 
 
158 
60 
25 
 
267 
70 
20 
 
100 
15 
7 
Anti-dsDNA (n=1413) 
    Normal 
    Elevated 
    Very high 
 
49 
25 
15 
 
228 
100 
38 
 
506 
119 
42 
 
216 
66 
9 
C3 (n=1463) 
    Normal 
    Low 
    Very Low 
 
61 
29 
4 
 
279 
100 
4 
 
579 
106 
6 
 
270 
25 
0 
C4 (n=1366) 
    Normal 
    Low 
    Very Low 
 
44 
18 
25 
 
218 
76 
49 
 
467 
132 
51 
 
243 
37 
6 
SLEDAI-2000 (n=1510) 
    Inactive (0) 
    Mild activity (1 – 3) 
    Active (4 – 12) 
    Very active (> 12) 
 
2 
4 
75 
17 
 
22 
93 
264 
11 
 
306 
240 
175 
0 
 
194 
82 
25 
0 
 
Construct - ESR 
ESR values were available for 787 (52.1%) assessments. There was a significant 
association between increasing ESR and higher overall BILAG-2004 scores (Table 4-4). The 
2 degrees of freedom test for an association between overall BILAG-2004 score and ESR was 
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statistically significant (p<0.001). When ESR was analysed as a continuous variable, the 
result was similar (p=0.0002). When only the first visit from each patient was used in the 
analysis, the result was similar (Table 4-5). 
 
Construct - Anti-dsDNA antibody 
Anti-dsDNA antibody levels were available for 1413 (93.6%) assessments. Increasing 
levels of anti-dsDNA were significantly associated with higher overall BILAG-2004 scores 
(Table 4-4). The 2 degrees of freedom test for an association between overall BILAG-2004 
score and anti-dsDNA was statistically significant (p=0.0008). When only the first visit from 
each patient was used in the analysis, the result was similar (Table 4-5). 
 
Construct - C3 and C4 
C3 and C4 levels were available in 1463 (96.9%) and 1366 (90.5%) assessments 
respectively. There was significant association between lower C3 and C4 levels with higher 
overall BILAG-2004 scores (Table 4-4). For both the models, the 2 degrees of freedom test 
were statistically significant (p<0.0001). When only the first visit from each patient was used 
in the analysis, the result was similar (Table 4-5). 
 
Construct - SLEDAI-2000 
SLEDAI-2000 scores were available for all the assessments. Higher SLEDAI-2000 
scores were significantly associated with higher overall BILAG-2004 scores (Table 4-4). The 
3 degrees of freedom test for an association between overall BILAG-2004 score and 
SLEDAI-2000 score was statistically significant (p<0.001). The results were similar when 
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SLEDAI-2000 score was analysed as a continuous variable (p<0.0001). When only the first 
visit from each patient was used in the analysis, the result was similar (Table 4-5). 
Table 4-4: Association of ESR, anti-dsDNA antibody, C3, C4 and SLEDAI-2000 scores 
respectively with higher overall BILAG-2004 scores. 
Constructs Odds Ratio (95% Confidence Interval) 
ESR 
    Normal 
    Elevated (31 – 60) 
    Markedly elevated (> 60) 
 
1.0 
2.1 (1.4, 3.0) 
2.9 (1.4, 6.2) 
Anti-dsDNA Antibody 
    Normal 
    Elevated 
    Very high (> 5 times upper normal limit) 
 
1.0 
1.5 (0.99, 2.1) 
2.7 (1.6, 4.8) 
C3 
    Normal 
    Low 
    Very Low (≤ half of lower normal limit) 
 
1.0 
2.5 (1.8, 3.5) 
5.0 (1.6, 15.5) 
C4 
    Normal 
    Low 
    Very Low (≤ half of lower normal limit) 
 
1.0 
1.7 (1.2, 2.3) 
4.2 (2.5, 6.9) 
SLEDAI-2000 
    No activity (0) 
    Mild activity (1 – 3) 
    Active (4 – 12) 
    Very active (> 12) 
 
1.0 
3.0 (2.1, 4.4) 
20.0 (13.6, 29.5) 
232.7 (108.4, 499.2) 
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Table 4-5: Association of ESR, anti-dsDNA antibody, C3, C4 and SLEDAI-2000 scores 
respectively with higher overall BILAG-2004 scores (when only first visit from each 
patient was used in the analysis). 
Constructs Odds Ratio (95% Confidence Interval) 
ESR 
    Normal 
    Elevated (31 – 60) 
    Markedly elevated (> 60) 
 
1.0 
2.9 (1.6, 5.2) 
5.7 (2.1, 15.4) 
Anti-dsDNA Antibody 
    Normal 
    Elevated 
    Very high (> 5 times upper normal limit) 
 
1.0 
1.4 (0.9, 2.2) 
2.5 (1.1, 5.5) 
C3 
    Normal 
    Low 
    Very Low (≤ half of lower normal limit) 
 
1.0 
2.2 (1.3, 3.6) 
27.8 (2.6, 295.3) 
C4 
    Normal 
    Low 
    Very Low (≤ half of lower normal limit) 
 
1.0 
2.3 (1.3, 4.0) 
3.3 (1.6, 6.6) 
SLEDAI-2000 
    No activity (0) 
    Mild activity (1 – 3) 
    Active (4 – 12) 
    Very active (> 12) 
 
1.0 
3.8 (2.2, 6.4) 
24.6 (13.7, 44.5) 
1386.3 (160.7, 11955.9) 
 
4.6.2 Criterion Validity 
 
Of the 1510 assessments, 342 assessments (22.6%) resulted in an increase in therapy 
while 320 assessments (21.2%) had treatment reduction and 848 assessments (56.2%) were 
not followed by a change in therapy (Table 4-6). There was increasing likelihood of an 
increase in therapy with higher overall BILAG-2004 score (Table 4-7). When only the first 
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visit from each patient was used in the analysis, the result was similar but the strength of 
association (odds ratio) was markedly inflated due the absence of any increase in therapy for 
overall BILAG-2004 score of D (which was the baseline comparator for the other Grades) 
(Table 4-8). 
Table 4-6: Cross tabulation of overall BILAG-2004 scores with change in therapy 
(n=1510). 
Change in Therapy Overall BILAG-
2004 Score Decrease No Change Increase 
D 83 213 4 
C 197 464 61 
B 38 147 205 
A 2 24 72 
 
Table 4-7: Association of increase in therapy with overall BILAG-2004 scores. 
Overall BILAG-2004 Scores Odds Ratio (95% Confidence Interval) 
A 204.9 (65.6, 639.9) 
B 82.0 (29.9, 225.0) 
C 6.8 (2.4, 19.1) 
D 1.0 
 
Table 4-8: Association of increase in therapy with overall BILAG-2004 scores (when 
only the first visit from each patient was used in the analysis). 
Overall BILAG-2004 Scores Odds Ratio (95% Confidence Interval) 
A 4.79 x 108 * 
B 1.4 x 108 (5.3 x 107, 3.7 x 108) 
C 1.3 x 107 (4.8 x 106, 3.7 x 107) 
D 1.0 
* confidence interval could not be estimated 
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4.6.3 Optimal SLEDAI-2000 Cut-Off Score for Active Disease 
 
ROC curves analysis for SLEDAI-2000 as a predictor of increase in therapy are 
summarised by the sensitivities, specificities and area under the ROC curve (AUC) in Table 
4-9 where PPV and NPV values were also provided. The optimal cut-off score for active 
disease is 3 or 4 as both had very similar performance with the best area under the curve. 
Table 4-9: Receiver operating characteristic curves analysis of SLEDAI-2000 index. 
Cut-off 
Score 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
AUC 
2 87.7%  
(83.2, 91.1) 
43.0% 
(38.5, 47.6) 
31.1% 
(27.9, 34.4) 
92.3% 
(89.5, 94.3) 
0.65 
3 71.9%  
(65.8, 77.3) 
70.7% 
(66.1, 75.0) 
41.8% 
(37.5, 46.3) 
89.6% 
(87.2, 91.6) 
0.71 
4 70.8% 
(64.6, 76.3) 
72.2% 
(67.5, 76.4) 
42.7% 
(38.2, 47.2) 
89.3% 
(87.0, 91.4) 
0.71 
5 44.4% 
(38.0, 51.1) 
87.5% 
(84.3, 90.1) 
51.0% 
(45.0, 57.0) 
84.3% 
(81.9, 86.5) 
0.66 
6 42.1% 
(35.9, 48.6) 
88.1% 
(84.9, 90.7) 
50.9% 
(44.7, 57.0) 
83.9% 
(81.4, 86.0) 
0.65 
7 28.4% 
(22.4, 35.1) 
93.3% 
(90.7, 95.2) 
55.4% 
(48.0, 62.6) 
81.6% 
(79.0, 84.0) 
0.61 
8 26.3% 
(20.6, 32.9) 
93.8% 
(91.2, 95.7) 
55.6% 
(47.6, 63.2) 
81.3% 
(78.7, 83.6) 
0.61 
9 17.3% 
(13.1, 22.4) 
96.7% 
(95.1, 97.9) 
60.8% 
(52.0, 69.0) 
80.0% 
(77.4, 82.3) 
0.57 
10 17.3% 
(13.1, 22.4) 
97.0% 
(95.3, 98.1) 
62.8% 
(53.5, 71.1) 
80.0% 
(77.5, 82.3) 
0.57 
 
The ROC curve analysis was repeated using a modified SLEDAI-2000 score that 
excluded the items anti-dsDNA antibody and complements (Table 4-10). The optimal cut-off 
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score for active disease using this modified score was 2. There was improvement in the 
performance of SLEDAI-2000 index with the exclusion of these two items. 
Table 4-10: Receiver operating characteristic curves analysis of SLEDAI-2000 index 
using modified total score excluding the items anti-dsDNA antibody and complements. 
Cut-off 
Score 
Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
AUC 
1 82.7%  
(77.7, 86.9) 
69.6% 
(65.6, 73.4) 
44.4% 
(40.4, 48.4) 
93.2% 
(91.1, 94.9) 
0.76 
2 81.6%  
(76.5, 85.7) 
72.6% 
(68.7, 76.2) 
46.6% 
(42.5, 50.7) 
93.1% 
(91.0, 94.7) 
0.77 
3 57.6% 
(51.2, 63.8) 
86.0% 
(82.6, 88.7) 
54.6% 
(49.0, 60.0) 
87.4% 
(85.0, 89.4) 
0.72 
4 54.1% 
(47.6, 60.4) 
86.9% 
(83.6, 89.7) 
54.7% 
(58.9, 60.4) 
86.6% 
(84.2, 88.7) 
0.71 
5 29.8% 
(24.5, 35.7) 
95.2% 
(93.3, 96.6) 
64.6% 
(57.1, 71.4) 
82.2% 
(79.9, 84.4) 
0.63 
6 28.9% 
(23.7, 34.9) 
95.5% 
(93.6, 96.8) 
65.1% 
(57.4, 72.1) 
82.1% 
(79.7, 84.3) 
0.62 
7 17.5% 
(13.2, 23.0) 
97.4% 
(96.0, 98.4) 
66.7% 
(57.4, 74.8) 
80.1% 
(77.6, 82.5) 
0.57 
8 16.7% 
(12.4, 22.0) 
97.9% 
(96.5, 98.8) 
70.4% 
(60.1, 78.9) 
80.1% 
(77.5, 82.4) 
0.57 
9 10.5% 
(7.5, 14.5) 
99.3% 
(98.7, 99.7) 
81.8% 
(69.4, 89.9) 
79.1% 
(76.6, 81.4) 
0.55 
 
4.6.4 Comparison of Indices 
 
For this analysis, the SLEDAI-2000 cut-off score of 3 was used. Active disease scores 
according to the BILAG-2004 (OR 19.3, 95% CI: 14.1, 26.4), Classic BILAG (OR 19.3, 95% 
CI: 14.0, 26.7) and SLEDAI-2000 (OR 6.2, 95% CI: 4.6, 8.3) indices were significantly 
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associated with an increase in therapy. The sensitivity, specificity, PPV and NPV of the three 
disease activity indices are summarised in Table 4-11.  
The BILAG-2004 and Classic BILAG indices had equivalent sensitivity, specificity, 
PPV and NPV. Consistent with its lower estimated odds ratio, it was apparent that SLEDAI-
2000 had lower sensitivity, specificity, PPV and NPV compared to the BILAG-2004 and 
Classic BILAG indices. The results were not different when SLEDAI-2000 cut-off score of 4 
was used instead of 3. Even when the modified SLEDAI-2000 score that excluded the items 
anti-dsDNA antibody and complements was used (with a cut-off score of 2), the improved 
performance was still not as good as the BILAG-2004 or Classic BILAG indices. 
Table 4-11: Sensitivity, specificity, positive predictive value and negative predictive 
value for increase in therapy of the BILAG-2004, Classic BILAG and SLEDAI-2000 
indices. 
 BILAG-2004 
(95% CI) 
Classic BILAG 
(95% CI) 
SLEDAI-2000 
(95% CI) 
Sensitivity (%) 
Specificity (%) 
PPV (%) 
NPV (%) 
81.0 (76.4, 84.9) 
81.9 (78.4, 85.0) 
56.8 (51.7, 61.7) 
93.6 (91.9, 95.0) 
83.6 (79.1, 87.3) 
79.1 (75.5, 82.3) 
54.0 (58.6, 49.3) 
94.3 (92.6, 95.6) 
71.9 (65.8, 77.3) 
70.7 (66.1, 75.0) 
41.8 (37.5, 46.3) 
89.6 (87.2, 91.6) 
 
4.7 Discussion 
 
The results of this large multi-centre cross sectional study demonstrated that the 
BILAG-2004 index was a valid measure of SLE disease activity as it had construct and 
criterion validity. Its construct validity was confirmed with the expected association between 
this index and ESR, complement C3, complement C4, anti-dsDNA antibody and SLEDAI-
2000 score. The association was strongest with SLEDAI-2000 score as there was a significant 
number of assessments with active disease that did not have high ESR, low C3, low C4 or 
high anti-dsDNA antibody (Table 3-4). The criterion validity of the BILAG-2004 index was 
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confirmed with increasing strength of association between increasing overall BILAG-2004 
score and increase in therapy. 
This study also demonstrated that the optimal SLEDAI-2000 cut-off score for 
definition of active disease linked to the need to increase therapy was 3 or 4. This was 
consistent with the results from our reliability study (Yee et al. 2007a) and another study by 
Gladman et al which used SLEDAI index rather than SLEDAI-2000 index (Gladman et al. 
2000b). However, this is different from the cut-off of 6 that was suggested by Abrahamowicz 
et al (Abrahamowicz et al. 1998). This is most likely related to the difference in the study 
design. This was a prospective study derived from a large number of patients within actual 
clinical practice whereas the earlier study was based on hypothetical situations derived from 
30 abstracted case histories. As such, the result of this study is highly relevant and applicable 
to clinical practice. 
It is not surprising that SLEDAI-2000 index does not capture disease activity requiring 
increase in therapy as well as the BILAG-2004 and Classic BILAG indices. The latter two 
indices are more comprehensive (97 and 86 items respectively) as compared to SLEDAI-2000 
index which has only 24 items. This property (comprehensiveness) is essential to capture all 
aspects of disease activity in a multi-system disease with diverse manifestations.  
One of the drawbacks of SLEDAI-2000 index is the inclusion of anti-dsDNA antibody 
and complement levels. Studies have shown that single estimation of these markers do not 
reflect SLE disease activity well, longitudinal changes in the levels of these markers are much 
more helpful particularly in lupus nephritis (Ho et al. 2001a; Ho et al. 2001b; Esdaile et al. 
1996; Ter Borg et al. 1990; Swaak et al. 1986; Swaak et al. 1982). Furthermore, they are not 
abnormal in a significant proportion of patients with active disease and it is not uncommon for 
them to be abnormal in the absence of disease activity as shown in this study and many other 
 106
studies (Ng et al. 2006; Gladman et al. 2003; Walz LeBlanc et al. 1994; Petri et al. 1991). 
This is reflected in the analysis of this study as the performance of SLEDAI-2000 did improve 
when these two items (anti-dsDNA antibody and complements) were removed. Another 
contributing factor is the weighting system used in SLEDAI-2000 as there appears to be 
excessive weighting for some minor manifestations such as alopecia and mouth ulcers that are 
not always treated. Furthermore, SLEDAI-2000 provides less scope for differentiating the 
severity of manifestations of active disease or indicating any change in the status of disease 
manifestation (improving, worsening or remaining unchanged). 
In this study, no difference in the performance between the BILAG-2004 and Classic 
BILAG indices was demonstrated. This was not unexpected as the main difference between 
the two indices was the addition of ophthalmic and gastrointestinal manifestations in the 
BILAG-2004 index. Active disease manifestations in these two systems were not common in 
this study; there were only 6 assessments (from 5 patients) with Grades A or B score in the 
Gastrointestinal system and 8 assessments (from 3 patients) with Grades A or B score in the 
Ophthalmic system. Even though these manifestations are uncommon, they need to be 
captured as they are important for individual patients in view of the significant morbidity and 
mortality associated with them. 
Overall BILAG-2004 and Classic BILAG scores were used in the analysis as both of 
these indices were developed as ordinal scale index and were not intended for the individual 
system scores to be summated into a global score. The best way to represent overall disease 
activity (as a yes/no dichotomy) for this analysis in any individual patient was to use the 
highest score achieved by any system within the index. This is logical as any patient with any 
system scoring a Grade A or B should be categorised as having active disease (requiring 
therapy in principle) regardless of how many systems have a score of A or B. From an 
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analysis viewpoint, this may put both these indices at a disadvantage as there is a ceiling 
effect and this may underestimate the severity of the illness. For example, a patient with 5 
systems scoring Grade B is equivalent to a patient with just one system scoring Grade B, with 
this analysis. However, for clinical trials and outcome studies, it may be more appropriate to 
consider the number of systems with a given categorical score in the analysis. 
Change in therapy was chosen as the reference standard for disease activity in the 
absence of a better alternative and because it has an operational interpretation. To date, the 
best benchmark to define active disease is the decision as to whether the disease activity 
should be treated. A robust definition of change in therapy was used in this study to account 
for several circumstances whereby therapy was increased for the reasons other than that of 
active disease, and this will minimise the occurrence of misclassification of change in therapy. 
Physician’s global assessment (PGA) had been used previously as a reference standard but 
this had been shown to have unsatisfactory performance with poor agreement between 
physicians in several studies (Wollaston et al. 2004; Gladman et al. 1994; Guzman et al. 1992; 
Gladman et al. 1992).  
Although the BILAG-2004 and Classic BILAG indices were developed based on the 
principle of the physician’s intention to treat, using change in therapy as the reference 
standard should not explicitly bias the analysis in favour of these two indices as change in 
therapy does not determine the scoring of the index. Only the presence of manifestations of 
active disease will influence the scoring. Furthermore, the scoring of these two indices were 
not available to the physician when the treatment decision was made and it would be difficult 
to work out the scoring for both of these indices in routine clinical practice without the 
appropriate reference documentations. 
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One of the limitations of this study is inherent in the cross sectional design in that it 
only accounts for disease activity at the time of assessment. This does not take into account 
the level of disease activity prior to the assessment which will influence the treatment 
decision. The treatment decision regarding a patient with active disease is very different if 
prior disease activity was low (such as a change from Grade D to B) when treatment would be 
increased, as compared to the situation where prior disease activity was high (such as a 
change from Grade A to B) when there would not be an increase in therapy (in fact there 
might be a reduction in therapy). Treatment decision is a complex process which takes into 
account several factors apart from the physician’s intention of treatment. This process 
includes consideration of current therapy, previous therapy (and its response), the patient’s 
opinion (in particular refusal to change therapy as advised) and the presence of co-morbid 
conditions. Unfortunately, it is not possible to model all these factors into the analysis of this 
study. This may explain the relatively low positive predictive value of the BILAG-2004 and 
Classic BILAG indices. On the other hand, the high negative predictive value is reassuring as 
this indicates that increase in therapy is very unlikely in the absence of high disease activity as 
measured by the BILAG-2004 and Classic BILAG indices. 
In conclusion, the BILAG-2004 index is a valid measure of SLE disease activity. It is 
more comprehensive, incorporates up-to-date terminology and has a clearer glossary of 
definitions than the Classic BILAG index. This index also appears to reflect the need to treat 
SLE disease activity better than SLEDAI-2000 index. This study also addressed the use of 
BILAG-2004, Classic BILAG and SLEDAI-2000 indices to define active disease at a single 
time point. It did not address the issue of minimal clinically important change in the scores 
that is relevant to longitudinal studies. This issue will be addressed in the longitudinal study. 
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Chapter 5     Face and Content Validity of Renal System 
 
 
5.1 Abstract 
Objectives:  
Some changes to the scoring scheme of BILAG-2004 renal system were proposed and this 
study was to assess the face and content validity of these changes. 
Methods:  
Data from the prospective multi-centre longitudinal study designed to assess sensitivity to 
change of the BILAG-2004 index were used for this analysis. At every assessment, data were 
collected on disease activity (with the BILAG-2004 index), investigations and therapy. 
Assessments with renal systems score of A, B or C were selected for analysis. Only those 
assessments with urine protein estimation available were used. Assessments where the renal 
system score was lower than other system scores were excluded. The change in therapy 
following these assessments was analysed. 
Results:  
A total of 353 SLE patients were recruited and there were 1771 assessments. Of these, 181 
(10.2%) assessments from 45 patients had renal system score of A, B or C. 130 assessments 
from 36 patients had urine protein estimation and the renal system score was not lower than 
that of any of the other systems. 70 assessments from 26 patients had no other renal factors 
influencing the renal system score. The proposed changes to BILAG-2004 renal system 
scoring did improve the performance of the index when the treatment decision was analysed. 
Conclusions:  
Changes to the scoring scheme of BILAG-2004 renal system were valid.  
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5.2 Objective 
To assess the face and content validity of the proposed changes to the scoring scheme 
for the renal system of the BILAG-2004 index. 
 
5.3 Introduction 
During the course of the longitudinal study (for sensitivity to change), some issues 
related to the scoring of the Renal system of the BILAG-2004 index based on the level of 
proteinuria for Grades A and B were noted (please refer to Renal System scoring scheme in 
Appendix 6). The issues identified were: 
1. Over-scoring of the Renal system due to over-reliance on urine protein dipstick 
despite the presence of other methods of urine protein estimation (24-hours urine 
protein estimation, urine albumin-creatinine ratio and urine protein-creatinine ratio). 
2. The current threshold for improvement (at least 50%) in proteinuria may be too high 
(especially if the assessments are done 4-weekly) resulting in over-scoring of the 
Renal system which is not consistent with treatment decisions. 
3. The current scoring scheme is weighted towards heavy proteinuria (more than 1g/day 
or equivalent) and less severe but significant proteinuria (0.5 to 1g/day or equivalent) 
would score inappropriately low as mild activity (Grade C). 
 
Changes to the scoring of the Renal system for Grades A and B were suggested to take 
account of the issues raised. These changes were: 
1. Urine protein dipstick result would be superseded by other methods of urine protein 
estimation (urine albumin-creatinine ratio, urine protein-creatinine ratio or 24-hours 
urine protein) where available. 
 111
2. A lower threshold of 25% and 33% for definition of improvement in proteinuria may 
be more appropriate 
3. An additional Grade B criterion of urine protein excretion of at least 0.5g/day (or 
equivalent) 
The dataset from the longitudinal study (sensitivity to change study) was used to 
assess the validity of these proposed changes to the Renal system scoring scheme. 
 
5.4 Methods 
Data from the longitudinal study were used to study the effects of these changes. This 
was a multi-centre study designed to assess sensitivity to change of the BILAG-2004 index.  
Patients were followed up prospectively and data were collected for all consecutive visits or 
encounters (inpatient or outpatient) that the patients had with the physician. Data were 
collected on disease activity (as assessed using the BILAG-2004 index), investigations and 
treatment. This study commenced in March 2005 and was completed in April 2007. 
 
5.5 Analysis 
Assessments with Renal system score of Grades A, B or C were selected for this 
analysis, as the proposed changes would have no effect on existing Renal system score of D 
or E (inactivity). Only those assessments with urine protein estimation (24-hours urine protein 
estimation, urine albumin-creatinine ratio or urine protein-creatinine ratio) available were 
used. The change in therapy following these assessments were analysed, which is the 
difference in the treatment the patient was on after the assessment as compared to the 
treatment the patient was on prior to the assessment (similar to that which was used in the 
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cross sectional study). This differed from the definition of change in therapy used in the 
sensitivity to change analysis whereby it was the difference in treatment between two 
consecutive visits.  
Assessments where the Renal system score was lower than that of other system scores 
were excluded as the Renal score would not have been influential on the treatment decision, 
for example an assessment with Renal system score of B and Mucocutaneous system score of 
A would be excluded as the Mucocutaneous system score would be the main determinant of 
treatment decision rather than the Renal system score. On the other hand, an assessment with 
Renal system score of B and Mucocutaneous system score of B would be included as the 
Renal system score would be a major determinant of the decision to treat. 
The aims of these changes were (in order of importance): 
1. Reduction in the number/proportion of Renal system Grade A that is associated with 
decrease in therapy 
2. Reduction in the number/proportion of Renal system Grade B that is associated with 
decrease in therapy, although decrease in therapy was possible if this followed a 
reduction in activity from Grade A 
3. Increase in the number/proportion of Renal system Grade B that is associated with 
increase in therapy  
4. No increase in the number/proportion of Renal system Grade C that is associated with 
increase in therapy, but increase in therapy would be possible if any other system had 
a higher score as a result of down-grading of the Renal system score due to the 
modification 
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5.6 Results 
There was a total of 1767 assessments from 353 patients (the demographics of these 
patients will be presented in the next chapter on the sensitivity to change study). Out of this 
total, 181 assessments (10.2%) had Renal system score of A, B or C and these were derived 
from 45 patients. Of these, 130 assessments (from 36 patients) that had urine protein 
estimation and for which the Renal system score was not lower than any of the other systems, 
were used for this analysis. Seventy assessments (from 26 patients) had no other renal factors 
influencing the Renal system score, such as histology of active nephritis, presence of active 
urinary sediments, deteriorating renal function or presence of nephrotic syndrome. 
With the current Renal system scoring scheme, the treatment for these patients is 
summarised in Table 5-1. 
Table 5-1: Cross tabulation of BILAG-2004 Renal system score (excluding Categories D 
and E) with change in therapy following assessment. 
Change in Therapy Renal System 
Score 
No change Decrease Increase 
Total 
A 11 
(30.6%) 
2 
(5.6%) 
23 
(63.9%) 
36 
B 38 
(56.7%) 
13 
(19.4%) 
16 
(23.9%) 
67 
C 17 
(63.0%) 
9 
(33.3%) 
1 
(3.7%) 
27 
Total 66 
(50.8%) 
24 
(18.4%) 
40 
(30.8%) 
130 
 
Firstly, the effect of urine protein dipstick result not contributing to the Renal system 
score in the presence of other methods of urine protein estimation (24-hours urine protein, 
urine albumin-creatinine ratio or urine protein-creatinine ratio) was assessed. The result is 
summarised in Table 5-2. There was some shift from higher scores (A & B) to lower scores 
(C & D) and there was a reduction in Renal system score of B that was associated with 
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decrease in therapy, although there was slight increase in renal system scores of C with 
treatment increased. 
Table 5-2: Cross tabulation of modified BILAG-2004 Renal system score (in which urine 
protein dipstick result was superseded by other methods of urine protein estimation) 
with change in therapy following assessment. 
Change in Therapy Renal System 
Score 
No change Decrease Increase 
Total 
A 11 
(32.4%) 
2 
(5.9%) 
21 
(61.8%) 
34 
B 32 
(55.2%) 
10 
(17.2%) 
16 
(27.6%) 
58 
C 21 
(58.3%) 
12 
(33.3%) 
3 
(8.3%) 
36 
D 2 
(100%) 
0 0 2 
Total 66 
(50.8%) 
24 
(18.4%) 
30 
(30.8%) 
130 
 
Next, the effect of changing the threshold for definition of improvement in proteinuria 
to 33% and 25% respectively was considered. This was in addition to the criterion whereby 
urine protein dipstick result would be superseded by other methods of urine protein 
estimation. The results are summarised in Tables 5-3 and 5-4. The 25% threshold for 
definition of improvement in proteinuria performed the best when compared to 33% and 50%, 
with reduction in Renal system scores of A and B in which there was decrease in therapy.  
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Table 5-3: Cross tabulation of modified BILAG-2004 Renal system score (in which the 
threshold for definition of improvement in proteinuria was changed to 33% and urine 
protein dipstick result was superseded by other methods of urine protein estimation) 
with change in therapy following assessment. 
Change in Therapy Renal System 
Score 
No change Decrease Increase 
Total 
A 9 
(29.0%) 
2 
(6.5%) 
20 
(64.5%) 
31 
B 31 
(56.4%) 
9 
(16.4%) 
15 
(27.3%) 
55 
C 24 
(57.1%) 
13 
(31.0%) 
5 
(11.9%) 
42 
D 2 
(100%) 
0 0 2 
Total 66 
(50.8%) 
24 
(18.4%) 
30 
(30.8%) 
130 
 
Table 5-4: Cross tabulation of modified BILAG-2004 Renal system score (in which the 
threshold for definition of improvement in proteinuria was changed to 25% and urine 
protein dipstick result was superseded by other methods of urine protein estimation) 
with change in therapy following assessment. 
Change in Therapy Renal System 
Score 
No change Decrease Increase 
Total 
A 9 
(30.0%) 
1 
(3.3%) 
20 
(66.7%) 
30 
B 29 
(54.7%) 
9 
(17.0%) 
15 
(28.3%) 
53 
C 26 
(57.8%) 
14 
(31.1%) 
5 
(11.1%) 
45 
D 2 
(100%) 
0 0 2 
Total 66 
(50.8%) 
24 
(18.4%) 
30 
(30.8%) 
130 
 
The effect of an additional Renal system Grade B criterion of urine protein excretion 
of at least 0.5g/day (or equivalent) that has not improved/decreased by 25% was assessed 
subsequently (Table 5-5). This additional criterion did not appear to have much effect on the 
performance but it did increase the number of Renal system score of B with reduction in 
therapy.  
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Table 5-5: Cross tabulation of modified BILAG-2004 Renal system score (in which the 
threshold for definition of improvement in proteinuria was changed to 25%, additional 
Grade B criterion of urine protein excretion of at least 0.5g/day (or equivalent) that has 
not improved/decreased by 25%, and urine protein dipstick result would be superseded 
by other methods of urine protein estimation) with change in therapy following 
assessment. 
Change in Therapy Renal System 
Score 
No change Decrease Increase 
Total 
A 9 
(30.0%) 
1 
(3.3%) 
20 
(66.7%) 
30 
B 33 
(53.2%) 
13 
(21.0%) 
16 
(25.8%) 
62 
C 22 
(61.1%) 
10 
(27.8%) 
4 
(11.1%) 
36 
D 2 
(100%) 
0 0 2 
Total 66 
(50.8%) 
24 
(18.4%) 
30 
(30.8%) 
130 
 
The results of the above analysis did support the changes that were proposed. 
 
5.7 Discussion 
During the course of the longitudinal study to assess sensitivity to change of the index, 
some issues with the Renal scoring system of the BILAG-2004 index came to light and 
changes were suggested. As these changes would not have made any impact on the way the 
data were collected with the index, the validity of these changes was analysed using this 
dataset by looking at the way patients with disease activity in the Renal system were treated, 
following each assessment.  
The first of these changes was that urine protein dipstick result would be superseded 
by other methods of urine protein estimation. This alteration is appropriate as urine protein 
dipstick measure is a rather crude and inaccurate method of urine protein estimation with a 
tendency to high false positive results which can lead to over-scoring of the Renal system. For 
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example, an increase of urine protein dipstick from 1+ to 2+ (equivalent to a Grade B score) 
with concomitant urine protein excretion increasing from 0.30g/day to 0.45g/day (equivalent 
to a Grade C score) will result in a change in Renal system score from C to B indicating an 
increase in activity, but in practice this change would not constitute a significant change 
requiring an increase in therapy. This was confirmed in the first part of the analysis which 
showed that this change resulted in a shift from higher scores (A or B) to lower scores (C or 
D), leading to a reduction in Renal system score of B with decrease in therapy.  
The second issue was that the threshold for improvement in proteinuria of at least 50% 
was considered to be too high. The dataset was used to look at the effect of changing the 
threshold to 25% and 33% respectively. Although the number of relevant assessments in the 
analysis were small, the reduction in the threshold did appear to improve the performance of 
the index with a reduction in the number of assessments with Renal system scores of A and B 
that had treatment reduced. The threshold for improvement of 25% was considered to have 
performed the best of the three thresholds tested and was felt to be the most appropriate when 
this was discussed in a consensus group reviewing the data, involving members of BILAG 
and 2 nephrologists experienced in the management lupus nephritis (Dr Dwomoa Adu and Dr 
David Jayne). 
It was also noted that the Renal scoring scheme was weighted towards high proteinuria 
(at least 1g/day or equivalent) and less severe but significant proteinuria (between 0.5 to 
1g/day or equivalent) would not be appropriately captured as it would only score Grade C. 
The additional criterion recommended was to capture this significant proteinuria (between 0.5 
to 1g per day or equivalent) as a Grade B score, instead of Grade C. However, this change did 
not have much effect in the analysis. This was not unexpected as this additional criterion 
would only have an effect when there was no other renal factor (such as histology of active 
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nephritis, presence of active urinary sediments and deteriorating renal function) present as 
these other factors would have resulted in a score of A or B. Therefore, it would only have an 
effect in less than 40% of the assessments (70 assessments from 26 patients) when there was 
no other renal factor (histology of active nephritis, presence of active urinary sediments and 
deteriorating renal function) influencing the renal system score. Even though the data did not 
strongly support the inclusion of this additional Grade B criterion, it was considered an 
important and significant omission by members of the BILAG and two nephrologists (Dr 
Dwomoa Ado and Dr David Jayne) in the consensus group discussion.  
Therefore, based on the data presented and the discussions of the consensus group 
comprising members of the BILAG and two nephrologists experienced in the management of 
lupus nephritis, the following changes were made to the BILAG-2004 index: 
1. Urine protein dipstick result is to be superseded by other methods of urine protein 
estimation (urine albumin-creatinine ratio, urine protein-creatinine ratio or 24-hours 
urine protein) where available. 
2. The threshold for definition of improvement in proteinuria is changed from 50% to 
25% 
3. An additional Grade B criterion of urine protein excretion of at least 0.5g/day (or 
equivalent) that has not improved/decreased by 25% 
The new criteria for proteinuria associated with Grades A, B and C of the Renal system is 
summarised in Table 5-6. This revised BILAG-2004 index was used in the sensitivity to 
change study. 
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Table 5-6: New criteria for proteinuria for Grades A, B and C of Renal system for the 
BILAG-2004 index (changes from the old criteria in italic) 
Grade Criteria for Proteinuria 
A Deteriorating proteinuria (severe) defined as   
  (a) urine protein dipstick increased by ≥ 2 levels (to be used only if other  
        methods of urine protein estimation are not available); OR  
  (b) 24-hours urine protein > 1 g that has not decreased (improved) by ≥  
        25%; OR 
  (c) urine protein-creatinine ratio > 100 mg/mmol that has not decreased  
        (improved) by ≥ 25%; OR 
  (d) urine albumin-creatinine ratio > 100 mg/mmol that has not decreased  
        (improved) by ≥ 25% 
B One of the following: 
  (a) Grade A criterion for proteinuria (without fulfilling criteria to score  
        Grade A) 
  (b) urine protein dipstick which has risen by 1 level to at least 2+ (to be used 
        only if other  methods of urine protein estimation are not available) 
  (c) 24-hours urine protein of 0.5 - 1g that has not decreased (improved) by ≥ 
       25% 
  (d) urine protein-creatinine ratio of 50 - 100 mg/mmol that has not  
       decreased  (improved) by ≥ 25%;  
  (e) urine albumin-creatinine ratio of 50 - 100 mg/mmol that has not  
       decreased (improved) by ≥ 25% 
C Mild/Stable proteinuria defined as 
(a) urine protein dipstick ≥ 1+ but has not fulfilled criteria for Grades A & 
B (to be used  only if other  methods of urine protein estimation are not 
available); OR 
(b) 24-hours urine protein > 0.25 g but has not fulfilled criteria for Grades A 
      & B ; OR 
  (c) urine protein-creatinine ratio > 25 mg/mmol but has not fulfilled criteria  
        for Grades A & B; OR  
  (d) urine albumin-creatinine ratio > 25 mg/mmol but has not fulfilled criteria 
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        for Grades A & B 
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Chapter 6     Sensitivity to Change Study 
 
 
6.1 Abstract 
Objectives:  
1. To determine if the BILAG-2004 index is sensitive to change 
2. To compare the sensitivity to change of the BILAG-2004, Classic BILAG and 
SLEDAI-2000 indices 
Methods:  
SLE patients were recruited into a prospective multi-centre longitudinal study. At every 
assessment, data were collected on disease activity (the BILAG-2004, Classic BILAG and 
SLEDAI-2000 indices), investigations and therapy. Overall BILAG-2004 and Classic BILAG 
scores were used in the analysis, as determined by the highest score achieved by any of the 
individual systems. Sensitivity to change was assessed by determining the relationship 
between change in disease activity and change in therapy between two consecutive visits. 
Statistical analyses were based on logistic regression.  
Results:  
A total of 353 SLE patients were recruited and there were 1767 assessments that contributed 
1414 observations for analysis. Changes in the BILAG-2004, Classic BILAG and SLEDAI-
2000 scores were significantly associated with change in therapy. They were differentially 
related to change in therapy, with greater change in score having greater predictive power. 
The BILAG-2004 and Classic BILAG indices had comparable performance when compared. 
SLEDAI-2000 index retained an independent relationship with change in therapy when 
compared to the BILAG-2004 and Classic BILAG indices, respectively. Further analysis 
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showed that changes in SLEDAI-2000 score may be combined with either changes in the 
BILAG-2004 or Classic BILAG indices in explaining change in therapy.  
Conclusions:  
1. The BILAG-2004, Classic BILAG and SLEDAI-2000 indices were sensitive to 
change.  
2. There was no superiority of sensitivity to change in any one of the indices when they 
were compared. 
3. Changes in SLEDAI-2000 score might complement changes in the BILAG-2004 or 
Classic BILAG indices in the analysis of SLE disease activity in a longitudinal study. 
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6.2 Objectives 
1. To determine if the BILAG-2004 index is sensitive to change for the assessment of 
SLE disease activity. 
2. To compare the sensitivity to change of the BILAG-2004, Classic BILAG and 
SLEDAI-2000 indices 
 
6.3 Introduction 
Before the BILAG-2004 index can be used in longitudinal outcome studies of SLE, it 
needs to be shown that it is sensitive to change. This is important when the index is used to 
measure transition in clinical states, and in clinical trials, this would affect the number of 
patients that are required to detect significant effects. 
Sensitivity to change or responsiveness is the ability of the index to change with time. 
There are two forms of responsiveness, namely internal responsiveness and external 
responsiveness (Husted et al. 2000). Internal responsiveness is defined as the ability of the 
index to change over a particular time period. External responsiveness refers not just to the 
ability of the index to change over time but also how the changes in the index relate to the 
corresponding changes in an external reference. Thus, external responsiveness is a more 
robust method of assessing sensitivity to change of an index. 
A longitudinal study was established to determine if the BILAG-2004 index was 
sensitive to change. External responsiveness of the index was assessed in this study. As 
change in therapy was used as the external reference, it is the clinically meaningful change in 
the index that was being studied. In addition, the sensitivity to change of the Classic BILAG 
and SLEDAI-2000 indices were also assessed, and comparison of the three indices was made. 
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6.4 Methods 
This was a multi-centre longitudinal study involving 8 centres in the United Kingdom.    
Recruited SLE patients were followed up prospectively and data were collected for all 
consecutive visits or encounters (inpatient or outpatient) that the patients had with the 
physician. Data were collected on disease activity (as assessed using the BILAG-2004, 
Classic BILAG and SLEDAI-2000 indices), investigations and treatment. This study 
commenced in March 2005 and was completed in April 2007. 
 
6.5 Analysis 
Sensitivity to change analysis was assessed using the method to assess external 
responsiveness as outlined by Husted et al (Husted et al. 2000). The external reference used in 
this study was the change in therapy between consecutive visits, which was the difference in 
treatment after the patient was assessed at the index visit, as compared to the therapy after the 
previous visit. The definition of change in treatment has been described in Chapter 2. Change 
in disease activity was defined as the change in the score of the respective indices between the 
two corresponding consecutive visits. 
For the purpose of analysis, overall BILAG-2004 and Classic BILAG scores as 
determined by the highest score achieved by any of the individual system were used. Scores 
of D and E were combined together as they both indicate inactivity. Therefore, four 
categorical overall scores were possible (A, B, C and D). 
Maximum-likelihood multinomial logistic regression (with robust variance estimation) 
was used to assess external responsiveness with change in therapy as the outcome variable 
and change in disease activity as the explanatory variable. The results were reported in odds 
ratios (OR) with 95% confidence intervals (CI). The baseline comparator for change in 
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treatment used in the analysis was ‘no change in therapy’ whereas for change in disease 
activity, the baseline comparator was ‘no change in activity’ or ‘minimal change in activity’. 
In addition to ‘no change in activity’, ‘minimal change in activity’ for BILAG-2004 and 
Classic BILAG indices included change from Grade D to C, as this change was considered 
minor. For SLEDAI-2000 index, receiver operating characteristic (ROC) curves analysis were 
used to determine the optimal minimal change in score associated with a change in therapy. 
Comparison of indices was undertaken within a common regression model, assessing main 
effects and interactions of the indices as appropriate. 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) were calculated with the same regression methodology, but applied only to appropriate 
subsets of patients and with only the intercept term estimated. For calculation of sensitivity 
and its 95% confidence interval, only observations which recorded an increase in treatment 
were used. Specificity, PPV and NPV were calculated using only patients with no increase in 
treatment, increase in disease activity and no increase in disease activity respectively. 
The relationship between change in SLEDAI-2000 score and change in the BILAG-
2004 index score in its association with change in therapy was studied. In this analysis the 
interaction of the indices were assessed with observations classified into: 
1. Increase in SLEDAI-2000 score only (with minimal change in BILAG-2004 score) 
2. Increase in BILAG-2004 score only (with minimal change in SLEDAI-2000 score) 
3. Increase in both BILAG-2004 and SLEDAI-2000 scores 
4. Decrease in SLEDAI-2000 score only (with minimal change in BILAG-2004 score) 
5. Decrease in BILAG-2004 score only (with minimal change in SLEDAI-2000 score) 
6. Decrease in both BILAG-2004 and SLEDAI-2000 scores 
 126
Similar logistic regression to that of sensitivity to change analysis was used, with change in 
treatment as the outcome variable. The analysis was repeated to define the relationship 
between change in SLEDAI-2000 score and change in Classic BILAG score. 
 
6.6 Results 
A total of 353 SLE patients were recruited and there were 1767 assessments. As 2 
consecutive visits or assessments provided 1 observation, there were 1414 observations 
available for the analysis. The demographics of the patients are summarised in Table 6-1.  
Table 6-1: Demographics of patients recruited into the study (n=353). 
Patient Characteristics  
Female sex (%) 
Mean age in years (SD) 
Ethnicity (%) 
    Caucasian 
    Afro-Caribbean 
    South Asian 
    Oriental 
    Others 
Mean disease duration in years (SD) 
92.9 
40.9 (12.9) 
 
58.1 
20.1 
19.0 
1.4 
1.4 
8.3 (7.9) 
 
There was increase in treatment between consecutive visits in 22.6% of observations 
while 37.3% had therapy decreased, and in 40.1%, there was no change in treatment. The 
distribution of the changes in disease activity according to the three indices and change in 
therapy are summarised in Table 6-2. 
 
 
 
 127
Table 6-2: Cross tabulation of changes in disease activity (according to the BILAG-2004, 
Classic BILAG and SLEDAI-2000 indices) against change in therapy (n=1414). 
Change in Therapy Change in Disease Activity 
Decrease No Change Increase 
Total 
BILAG-2004 
    Decreased (%) 
    No change (%) 
    Increased (%) 
 
194 (52.3) 
280 (36.7) 
53 (18.9) 
 
146 (39.3) 
338 (44.3) 
83 (29.6) 
 
31 (8.4) 
145 (19.0) 
144 (51.4) 
 
371 
763 
280 
Classic BILAG 
    Decreased (%) 
    No change (%) 
    Increased (%) 
 
171 (49.7) 
313 (38.3) 
43 (17.0) 
 
139 (40.4) 
357 (43.7) 
71 (28.1) 
 
34 (9.9) 
147 (18.0) 
139 (54.9) 
 
344 
873 
197 
SLEDAI-2000 
    Decrease ≥ 3 (%) 
    Minimal change (%) 
    Increase ≥ 3 (%) 
 
107 (53.0) 
391 (36.5) 
29 (20.4) 
 
68 (33.7) 
478 (44.7) 
21 (14.8) 
 
27 (13.4) 
201 (18.8) 
92 (64.8) 
 
202 
1070 
142 
 
There was no significant effect of duration of follow-up (p>0.4) but there was a higher 
likelihood of decrease in therapy with greater number of visits (OR 1.10, 95% CI 1.04, 1.16). 
 
6.6.1 Sensitivity to Change of the BILAG-2004 Index 
 
Increase in overall BILAG-2004 score was significantly associated with increase in 
therapy. On the other hand, decrease in overall BILAG-2004 score was significantly 
associated with decrease in therapy and inversely associated with increase in therapy (Table 
6-3). 
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Table 6-3: Sensitivity to change analysis of the BILAG-2004 index determining the 
association of change in overall BILAG-2004 score with change in therapy (n=1414). 
Change in Overall 
BILAG-2004 Score 
Number of 
Observations
Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
No change in activity 763 1.0 1.0 
Increase in activity 280 4.0 (2.9, 5.7) 0.8 (0.5, 1.1) 
Decrease in activity 371 0.5 (0.3, 0.8) 1.6 (1.2, 2.1) 
 
As Grade C was considered as mild activity, a change of grade from D/E (inactivity) 
to C was considered minor. When this change of score from D/E to C was excluded from the 
definition of increase in activity (considered minimal change in activity), increase in overall 
BILAG-2004 scores had a much greater predictive power of increase in therapy (Table 6-4). 
Table 6-4: Sensitivity to change analysis of the BILAG-2004 index after excluding 
change of Grade D/E to C from the definition of increase in activity (n=1414). 
Change in Overall 
BILAG-2004 Score 
Number of 
Observation 
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Minimal change in activity 848 1.0 1.0 
Increase in activity 195 10.7 (6.8, 16.6) 1.1 (0.7, 1.8) 
Decrease in activity 371 0.5 (0.3, 0.8) 1.7 (1.3, 2.2) 
 
Further analysis on the subgroups of changes in score revealed that increase in the 
score to Grade A was more likely than increase in the score to Grade B to be associated with 
increase in therapy, whereas decrease in the score to Grade C or D/E was much less likely to 
have increase in therapy than decrease in the score to Grade B (Table 6-5). Therefore, changes 
in overall BILAG-2004 score were differentially related to change in therapy, with greater 
change in score having greater predictive power. 
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Table 6-5: Analysis on the subgroups of changes in overall BILAG-2004 score and its 
association with change in therapy (n=1414). 
Change in Overall 
BILAG-2004 Score 
Number of 
Observations
Increase in 
Therapy 
Odds Ratio  
(95% CI) 
Decrease in 
Therapy 
Odds Ratio  
(95% CI) 
Minimal change in 
activity 
848 1.0 1.0 
Increase in activity to 
Grade A 
48 16.4 (6.0, 45.0) 0.6 (0.1, 2.8) 
Increase in activity to 
Grade B 
147 9.3 (5.7, 15.3) 1.2 (0.7, 2.1) 
Decrease in activity to 
Grade B 
41 0.7 (0.2, 2.0) 1.9 (0.9, 3.7) 
 
Decrease in activity to 
Grade C or D 
330 0.5 (0.3, 0.8) 1.7 (1.3, 2.2) 
 
6.6.2 Sensitivity to Change of Classic BILAG Index 
 
Increase in overall Classic BILAG score was significantly associated with increase in 
therapy while decrease in overall score was significantly associated with decrease in therapy 
and inversely associated with increase in therapy (Table 6-6). Similar to the BILAG-2004 
index, exclusion of change in the score of D to C from the definition of increase in activity 
increased the predictive power of overall Classic BILAG score on increase in therapy (Table 
6-7). Changes in overall Classic BILAG score were also differentially related to change in 
therapy, with greater change in score having greater predictive power (Table 6-8). 
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Table 6-6: Sensitivity to change analysis of Classic BILAG index determining the 
association of change in overall Classic BILAG score with change in therapy (n=1414). 
Change in Overall 
Classic BILAG Score 
Number of 
Observations 
Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
No change in activity 817 1.0 1.0 
Increase in activity 253 4.8 (3.4, 6.7) 0.7 (0.5, 1.0) 
Decrease in activity 344 0.6 (0.4, 0.9) 1.4 (1.1, 1.8) 
 
Table 6-7: Sensitivity to change analysis of Classic BILAG index after excluding change 
of Grade D/E to C from the definition of increase in activity (n=1414). 
Change in Overall Classic 
BILAG Score 
Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Minimal change in activity 873 1.0 1.0 
Increase in activity 197 9.5 (6.2, 14.4) 0.9 (0.6, 1.5) 
Decrease in activity 344 0.6 (0.4, 0.9) 1.5 (1.1, 1.9) 
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Table 6-8: Analysis on the subgroups of changes in overall Classic BILAG score and its 
association with change in therapy (n=1414). 
Change in Overall 
Classic BILAG Score 
Number of 
Observations
Increase in 
Therapy 
Odds Ratio  
(95% CI) 
Decrease in 
Therapy 
Odds Ratio  
(95% CI) 
Minimal change in 
activity 
873 1.0 1.0 
Increase in activity to 
Grade A 
52 31.3 (9.5, 102.9) 1.5 (0.3, 6.9) 
Increase in activity to 
Grade B 
145 6.6 (4.2, 10.4) 0.9 (0.6, 1.6) 
Decrease in activity to 
Grade B 
40 0.7 (0.3, 1.9) 1.5 (0.8, 3.0) 
 
Decrease in activity to 
Grade C or D 
304 0.7 (0.4, 1.0) 1.5 (1.2, 2.0) 
 
6.6.3 Sensitivity to Change of SLEDAI-2000 
 
Increase in SLEDAI-2000 score was significantly associated with increase in therapy 
(OR 1.2, 95% CI 1.2 – 1.3) and inversely associated with treatment reduction (OR 0.9, 95% 
CI 0.9 – 1.0). When the SLEDAI-2000 score of the previous visit was also included in the 
regression model, both the change in SLEDAI-2000 score and the previous visit SLEDAI-
2000 score were significantly associated with increase in therapy (Table 6-9). Therefore, the 
model with just change in SLEDAI-2000 score was insufficient to explain change in therapy 
(especially treatment increase). 
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Table 6-9: Association between change in therapy with change in SLEDAI-2000 score 
and SLEDAI-2000 score of previous visit. 
 Increase in Therapy 
Odds Ratio*  
(95% CI) 
Decrease in Therapy
Odds Ratio*  
(95% CI) 
Change in SLEDAI-2000 score 1.4 (1.3, 1.5) 0.9 (0.9, 1.0) 
Previous visit SLEDAI-2000 score 1.2 (1.2, 1.3) 1.0 (0.9, 1.1) 
* per unit change in SLEDAI-2000 score 
 
ROC curves analysis with SLEDAI-2000 index as a predictor of increase in therapy, 
to determine the optimal increase in score, is summarised in Table 6-10. When all the 
parameters were considered, the optimal minimal change in SLEDAI-2000 score associated 
with increase in therapy was 1 or 2. However, for the best performance in predicting increase 
in therapy, minimal change in SLEDAI-2000 score of 3 or 4 was preferable as both had better 
positive predictive values (as compared to minimal change of score of 2) although there was a 
compromise in the sensitivity. 
ROC curves analysis was also performed to determine the optimal decrease in score 
that was associated with no increase in therapy (combination of decrease in therapy and no 
change in therapy) as shown in Table 6-11. From the analysis, the optimal decrease in 
SLEDAI-2000 score associated with no increase in treatment was 1 or 2. The results were 
similar when the analysis with decrease in therapy was used instead of no increase in 
treatment (data not shown). 
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Table 6-10: Receiver operating characteristic curves analysis of SLEDAI-2000 index to 
determine the optimal increase in score associated with increase in therapy. 
Increase in 
SLEDAI-2000 
Score 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
≥ 1 47.5% 
(41.7, 53.3) 
82.4% 
(80.0, 84.6) 
44.2% 
(39.0, 49.5) 
84.3% 
(81.7, 86.6) 
≥ 2 45.0% 
(39.5, 50.7) 
84.4% 
(82.2, 86.3) 
45.7% 
(40.4, 51.2) 
84.0% 
(81.5, 86.2) 
≥ 3 28.8% 
(23.8, 34.3) 
95.4% 
(94.0, 96.5) 
64.8% 
(56.8, 72.0) 
82.1% 
(79.6, 84.3) 
≥ 4 26.3% 
(21.5, 31.7) 
95.9% 
(94.4, 96.9) 
65.1% 
(56.5, 72.8) 
81.6% 
(79.1, 83.9) 
≥ 5 14.7% 
(10.6, 19.9) 
98.5% 
(97.4, 99.1) 
73.4% 
(60.8, 83.1) 
79.8% 
(77.2, 82.1) 
≥ 6 13.8% 
(9.8, 19.0) 
98.8% 
(97.9, 99.3) 
77.2% 
(64.5, 86.3) 
79.7% 
(77.1, 82.0) 
≥ 7 9.1% 
(6.1, 13.4) 
99.5% 
(98.7, 99.8) 
85.3% 
(67.7, 94.1) 
78.9% 
(76.4, 81.2) 
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Table 6-11: Receiver operating characteristic curves analysis of SLEDAI-2000 index to 
determine the optimal decrease in score associated with no increase in therapy. 
Decrease in 
SLEDAI-2000 
Score 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
≥ 1 31.7% 
(28.9, 34.7) 
80.6% 
(76.3, 84.3) 
84.8% 
(81.1, 87.9) 
25.7% 
(22.7, 28.9) 
≥ 2 30.3% 
(27.6, 33.3) 
81.9% 
(77.6, 85.5) 
85.1% 
(81.3, 88.3) 
25.6% 
(22.7, 28.7) 
≥ 3 16.0% 
(13.8, 18.5) 
91.6% 
(88.1, 94.1) 
86.6% 
(81.4, 90.6) 
24.2% 
(21.5, 27.0) 
≥ 4 14.9% 
(12.7, 17.4) 
93.1% 
(89.9, 95.4) 
88.1% 
(82.8, 91.9) 
24.2% 
(21.6, 27.1) 
≥ 5 7.2% 
(5.6, 9.2) 
96.6% 
(94.1, 98.0) 
87.8% 
(80.1, 92.8) 
23.3% 
(20.9, 26.0) 
≥ 6 7.0% 
(5.5, 9.0) 
97.2% 
(94.8, 98.5) 
89.5% 
(81.8, 94.2) 
23.4% 
(20.9, 26.1) 
≥ 7 4.7% 
(3.4, 6.4) 
98.1% 
(96.0, 99.1) 
89.5% 
(79.7, 94.8) 
23.1% 
(20.7, 25.8) 
 
When change in SLEDAI-2000 score was defined as minimal increase of 2 to indicate 
worsening and minimal decrease of 2 to indicate improvement (Model A), increase in 
SLEDAI-2000 score was significantly associated with increase in therapy and decrease in 
score was associated with treatment reduction (Table 6-12). The results were very similar if 
the minimal increase in score of 1 or minimal decrease in score of 1 were used instead (data 
not shown).  
With a different model of change in SLEDAI-2000 score using minimal increase of 3 
(Model B, minimal increase of 3 and minimal decrease of 1), increase in SLEDAI-2000 had a 
much stronger association with increase in therapy than Model A (Table 6-13). The results 
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were similar with minimal increase of 4 or minimal decrease of 2 (data not shown). This is 
consistent with the recommendation of using minimal increase in score of 3 or 4 instead of 1 
or 2. 
Table 6-12: Sensitivity to change analysis of SLEDAI-2000 index with Model A of 
change in score (minimal increase of 2 and minimal decrease of 2) (n=1414). 
Change in SLEDAI-2000 
Score 
Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Minimal change 709 1.0 1.0 
Increase ≥ 2 315 4.8 (3.4, 6.9) 1.4 (0.9, 1.9) 
Decrease ≥ 2 390 1.3 (0.9, 1.9) 2.2 (1.7, 2.9) 
 
Table 6-13: Sensitivity to change analysis of SLEDAI-2000 index with Model B of 
change in score (minimal increase of 3 and minimal decrease of 1) (n=1414). 
Change in SLEDAI-2000 
Score 
Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Minimal change 863 1.0 1.0 
Increase ≥ 3 142 10.6 (6.2, 18.1) 1.9 (1.0, 3.5) 
Decrease ≥ 1 409 1.1 (0.7, 1.5) 2.0 (1.5, 2.6) 
 
Further exploratory analysis with alternative models of change in SLEDAI-2000 score 
was performed. Firstly, the magnitude of change was classified into ordinal categories based 
broadly on the minimal increase in score of 3 (for worsening) and minimal decrease in score 
of 1 (for improvement) (Model C): 
1. Minimal change – no change in score or increase in score of less than 3 
2. Increase in score of up to twice the minimal increase in score (3 to 6) 
3. Increase in score of more than twice the minimal increase in score (more than 6) 
4. Decrease in score of up to twice the minimal decrease in score (1 to 2) 
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5. Decrease in score of more than twice the minimal decrease in score (more than 2) 
With this model (Model C), changes in SLEDAI-2000 score were differentially related to 
change in therapy with greater change in score having greater predictive power of change in 
therapy (Table 6-14). 
Table 6-14: Analysis on the subgroups of changes in SLEDAI-2000 score based on 
magnitude of change (Model C) and its association with change in therapy (n=1414). 
Change in SLEDAI-2000 
Score 
Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Minimal change 863 1.0 1.0 
Increase by more than 6 34 35.2 (8.5, 145.5) 2.1 (0.5, 8.3) 
Increase by 3 to 6 108 8.0 (4.6, 14.1) 1.9 (1.0, 3.6) 
Decrease by 1 to 2 207 1.1 (0.7, 1.7) 1.8 (1.3, 2.5) 
Decrease by more than 2 202 1.0 (0.6, 1.6) 2.2 (1.5, 3.0) 
 
Another way to assess change in score was to incorporate SLEDAI-2000 score of the 
previous visit (which had been shown to be important in explaining change in therapy) 
whereby SLEDAI-2000 score is classified into ordinal categories in similar fashion to the 
BILAG-2004 index. The classification of the ordinal categories is based on the cut-off score 
for active disease of 3 (as shown in the cross sectional study): score of less than 3, score of 3 
to 7 and score of more than 7. Similar to the previous analysis, changes in SLEDAI-2000 
score using this categorical model (Model D) were differentially related to changes in therapy 
(Table 6-15). 
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Table 6-15: Analysis on the subgroups of categorical changes in SLEDAI-2000 score 
(Model D) and its association with change in therapy (n=1414). 
Change in SLEDAI-2000 
Score 
Number of 
Observation 
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Minimal change  999 1.0 1.0 
Increase to score of > 7 68 15.5 (6.6, 36.5) 1.2 (0.4, 3.5) 
Increase to score of 3 to 7 120 4.0 (2.5, 6.4) 1.2 (0.7, 2.0) 
Decrease to score of 3 to 7 61 1.8 (0.8, 3.7) 1.8 (1.0, 3.2) 
Decrease to score of < 3 166 0.5 (0.2, 1.0) 1.9 (1.3, 2.7) 
 
Thus far, several models of change in SLEDAI-2000 score had been examined. 
Comparison of these models of change in SLEDAI-2000 score was made using area under the 
ROC curve with increase in therapy as the outcome variable (Table 6-16). The model with 
change in SLEDAI-2000 score as a continuous variable and the SLEDAI-2000 score of the 
previous visit included, had the best performance in explaining increase in therapy while all 
other models performed similarly. 
Table 6-16: Area under the receiver operating characteristic curve for the various 
models of change in SLEDAI-2000 score in explaining increase in therapy. 
Models of change in SLEDAI-2000 Score Area under ROC curve 
Change in score (continuous variable) 0.67 
Change in score (continuous variable) and previous visit 
SLEDAI-2000 score 
0.76 
Model A (minimal increase of 2 and minimal decrease of 2) 0.65 
Model B (minimal increase of 3 and minimal decrease of 1) 0.64 
Model C (based on magnitude of change) 0.65 
Model D (categorical changes) 0.67 
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6.6.4 Comparison of Indices 
(Tables 6-17 to 6-30 at the end of section) 
 
When changes in the score for both the BILAG-2004 and Classic BILAG indices were 
included in a common regression model, increase in the score for both indices were 
significantly associated with an increase in therapy (Table 6-17). However, only decrease in 
BILAG-2004 score was significantly associated with a decrease in therapy, which was not the 
case for decrease in Classic BILAG score. Further comparison of these two indices, by 
assessing the ability of increase in the score of the respective indices in predicting increase in 
therapy, showed that they had similar sensitivity, specificity, PPV and NPV (Table 6-18). 
Comparison was made between changes in BILAG-2004 score and the various models 
of change in SLEDAI-2000 score (Tables 6-19 to 6-24). When changes in the score of both 
the BILAG-2004 and SLEDAI-2000 indices were included within a common regression 
model, both of the indices remained significantly associated with change in therapy, 
regardless of the model of change in SLEDAI-2000 score used in the analysis. Therefore, 
both the BILAG-2004 and SLEDAI-2000 indices retained independent relationships with 
change in therapy when both were included in the regression model. Similarly, changes in the 
score of both Classic BILAG and SLEDAI-2000 indices had independent relationships with 
change in therapy when these two indices were compared (Tables 6-25 to 6-30). 
Therefore, the comparison of the indices did not show that any of the three indices was 
clearly superior with regards to sensitivity to change. In this analysis, the BILAG-2004 index 
had comparable performance to Classic BILAG index. There was some non-overlapping 
relationship with change in therapy when SLEDAI-2000 index was compared with the 
BILAG-2004 and Classic BILAG indices, respectively.  
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Table 6-17: Comparison of the ability of change in BILAG-2004 score and change in 
Classic BILAG score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall BILAG-2004 score 
    Increase (excluding D to C) 
    Decrease  
 
4.7 (2.8, 8.0) 
0.7 (0.4, 1.1) 
 
1.3 (0.7, 2.4) 
1.7 (1.2, 2.4) 
Overall Classic BILAG score 
    Increase (excluding D to C) 
    Decrease 
 
3.2 (1.9, 5.3) 
0.9 (0.6, 1.5) 
 
0.9 (0.5, 1.7) 
1.1 (0.8, 1.5) 
 
Table 6-18: Sensitivity, specificity, positive predictive value and negative predictive 
value for the model of increase in activity, according to the BILAG-2004 and Classic 
BILAG indices, in predicting increase in therapy. 
Indices Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
BILAG-2004 42.2 
(37.0, 47.6) 
94.5 
(92.9, 95.8) 
69.2 
(61.9, 75.7) 
84.8 
(82.4, 87.0) 
Classic BILAG  41.6 
(36.6, 46.7) 
94.1 
(92.6, 95.4) 
67.5 
(60.8, 73.6) 
84.6 
(82.2, 86.8) 
 
Table 6-19: Comparison of the ability of change in BILAG-2004 score and change in 
SLEDAI-2000 score (continuous variable) in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall BILAG-2004 score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
13.0 (4.7, 36.0) 
7.5 (4.4, 12.6) 
0.8 (0.3, 2.6) 
0.6 (0.4, 1.0) 
 
0.7 (0.2, 3.2) 
1.4 (0.8, 2.4) 
1.6 (0.8, 3.1) 
1.5 (1.2, 2.0) 
Change in SLEDAI-2000 score 
(continuous variable) 
1.1 (1.0, 1.2) 0.9 (0.9, 1.0) 
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Table 6-20: Comparison of the ability of change in BILAG-2004 score and change in 
SLEDAI-2000 score (continuous variable) with previous visit SLEDAI-2000 score, in 
predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall BILAG-2004 score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
8.4 (4.0, 11.5) 
6.7 (4.0, 11.5) 
0.3 (0.1, 1.2) 
0.6 (0.3, 0.9) 
 
0.7 (0.2, 3.1) 
1.4 (0.8, 2.3) 
1.5 (0.8, 3.0) 
1.5 (1.1, 2.0) 
Change in SLEDAI-2000 score 
(continuous variable) 
Previous visit SLEDAI-2000 score 
1.2 (1.1, 1.3) 
 
1.2 (1.1, 1.3) 
0.9 (0.9, 1.0) 
 
1.0 (0.9, 1.1) 
 
Table 6-21: Comparison of the ability of change in BILAG-2004 score and Model A of 
change in SLEDAI-2000 score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall BILAG-2004 score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
12.8 (4.5, 36.0) 
6.7 (4.0, 11.1) 
0.6 (0.2, 1.9) 
0.5 (0.3, 0.9) 
 
0.6 (0.1, 2.6) 
1.1 (0.7, 2.0) 
1.5 (0.8, 2.8) 
1.4 (1.1, 1.9) 
SLEDAI-2000 score 
    Increase (≥ 2) 
    Decrease (≥ 2) 
 
2.4 (1.6, 3.5) 
1.6 (1.1, 2.5) 
 
1.4 (1.0, 2.0) 
2.0 (1.5, 2.6) 
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Table 6-22: Comparison of the ability of change in BILAG-2004 score and Model B of 
change in SLEDAI-2000 score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall BILAG-2004 score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
11.4 (4.0, 32.6) 
6.1 (3.6, 10.3) 
0.6 (0.2, 1.9) 
0.5 (0.3, 0.8) 
 
0.6 (0.1, 2.5) 
1.1 (0.6, 1.9) 
1.5 (0.8, 2.9) 
1.5 (1.1, 1.9) 
SLEDAI-2000 score 
    Increase (≥ 3) 
    Decrease (≥ 1) 
 
4.4 (2.4, 8.0) 
1.5 (1.0, 2.2) 
 
2.0 (1.1, 3.7) 
1.7 (1.3, 2.3) 
 
Table 6-23: Comparison of the ability of change in BILAG-2004 score and Model C of 
change in SLEDAI-2000 score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall BILAG-2004 score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
9.8 (3.6, 26.9) 
5.2 (3.1, 8.5) 
0.7 (0.2, 1.8) 
0.4 (0.3, 0.8) 
 
0.3 (0.1, 1.6) 
0.8 (0.4, 1.4) 
1.1 (0.6, 2.1) 
1.4 (1.1, 1.9) 
SLEDAI-2000 score 
   Increase by more than 6 
   Increase by 3 to 6 
   Decrease by 1 to 2 
   Decrease by more than 2 
 
12.3 (2.5, 59.8) 
4.0 (2.1, 7.3) 
1.5 (0.9, 2.3) 
1.4 (0.8, 2.5) 
 
2.5 (0.6, 9.5) 
2.1 (1.1, 4.1) 
1.7 (1.2, 2.3) 
1.9 (1.3, 2.7) 
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Table 6-24: Comparison of the ability of change in BILAG-2004 score and Model D of 
change in SLEDAI-2000 score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall BILAG-2004 score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
10.8 (3.8, 30.4) 
6.1 (3.6, 10.3) 
0.6 (0.2, 2.0) 
0.6 (0.3, 0.9) 
 
0.6 (0.1, 2.7) 
1.2 (0.7, 2.0) 
1.7 (0.9, 3.3) 
1.5 (1.1, 2.0) 
SLEDAI-2000 score 
   Increase to score of > 7 
   Increase to score of 3 to 7 
   Decrease to score of 3 to 7 
   Decrease to score of < 3 
 
4.8 (1.7, 13.1) 
2.2 (1.3, 3.6) 
2.3 (1.1, 5.1) 
0.6 (0.3, 1.3) 
 
1.3 (0.5, 3.7) 
1.2 (0.7, 2.1) 
1.5 (0.9, 2.7) 
1.6 (1.2, 2.4) 
 
Table 6-25: Comparison of the ability of change in Classic BILAG score and change in 
SLEDAI-2000 score (continuous variable) in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall Classic BILAG score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
22.3 (7.7, 64.6) 
5.5 (3.5, 8.8) 
1.3 (0.5, 3.7) 
0.7 (0.5, 1.2) 
 
1.0 (0.2, 4.4) 
1.0 (0.6, 1.8) 
1.2 (0.6, 2.4) 
1.3 (1.0, 1.7) 
Change in SLEDAI-2000 score 
(continuous variable) 
1.1 (1.1, 1.2) 0.9 (0.9, 1.0) 
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Table 6-26: Comparison of the ability of change in Classic BILAG score and change in 
SLEDAI-2000 score (continuous variable) with previous visit SLEDAI-2000 score, in 
predicting changes in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall Classic BILAG score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
16.1 (5.3, 48.7) 
5.6 (3.4, 9.1) 
0.5 (0.2, 1.5) 
0.7 (0.4, 1.1) 
 
1.0 (0.2, 4.5) 
1.0 (0.6, 1.8) 
1.2 (0.6, 2.3) 
1.3 (1.0, 1.7) 
Change in SLEDAI-2000 score 
(continuous variable) 
Previous visit SLEDAI-2000 score 
1.2 (1.2, 1.3) 
 
1.2 (1.2, 1.3) 
0.9 (0.9, 1.0) 
 
1.0 (1.0, 1.1) 
 
Table 6-27: Comparison of the ability of change in Classic BILAG score and Model A of 
change in SLEDAI-2000 score in predicting changes in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall Classic BILAG score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
24.0 (8.1, 71.4) 
5.1 (3.2, 8.1) 
0.8 (0.3, 2.3) 
0.6 (0.4, 1.0) 
 
0.9 (0.2, 4.1) 
0.9 (0.5, 1.6) 
1.2 (0.6, 2.3) 
1.2 (0.9, 1.6) 
SLEDAI-2000 score 
    Increase (≥ 2) 
    Decrease (≥ 2) 
 
2.7 (1.9, 4.0) 
1.6 (1.1, 2.5) 
 
1.3 (0.9, 1.8) 
2.0 (1.5, 2.7) 
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Table 6-28: Comparison of the ability of change in Classic BILAG score and Model B of 
change in SLEDAI-2000 score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall Classic BILAG score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
21.8 (7.6, 62.6) 
4.8 (3.0, 7.8) 
0.8 (0.3, 2.3) 
0.6 (0.4, 1.0) 
 
0.9 (0.2, 3.9) 
0.9 (0.5, 1.5) 
1.2 (0.6, 2.3) 
1.3 (1.0, 1.7) 
SLEDAI-2000 score 
    Increase (≥ 3) 
    Decrease (≥ 1) 
 
5.8 (3.3, 10.2) 
1.4 (0.9, 2.1) 
 
2.0 (1.1, 3.7) 
1.8 (1.4, 2.4) 
 
Table 6-29: Comparison of the ability of change in Classic BILAG score and Model C of 
change in SLEDAI-2000 score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall Classic BILAG score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
21.2 (7.4, 60.9) 
5.0 (3.1, 8.1) 
0.8 (0.3, 2.4) 
0.6 (0.4, 1.0) 
 
0.9 (0.2, 4.0) 
0.9 (0.5, 1.5) 
1.2 (0.6, 2.3) 
1.2 (0.9, 1.6) 
SLEDAI-2000 score 
   Increase by more than 6 
   Increase by 3 to 6 
   Decrease by 1 to 2 
   Decrease by more than 2 
 
18.2 (4.0, 82.9) 
4.5 (2.5, 8.2) 
1.3 (0.8, 2.1) 
1.5 (0.8, 2.6) 
 
2.2 (0.5, 8.8) 
2.0 (1.0, 3.8) 
1.7 (1.2, 2.4) 
2.0 (1.4, 2.8) 
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Table 6-30: Comparison of the ability of change in Classic BILAG score and Model D of 
change in SLEDAI-2000 score in predicting change in therapy (n=1414). 
Changes in Score Increase in Therapy 
Odds Ratio (95% CI) 
Decrease in Therapy 
Odds Ratio (95% CI) 
Overall Classic BILAG score 
   Increase to Grade A  
   Increase to Grade B 
   Decrease to Grade B 
   Decrease to Grade C/D     
 
21.5 (7.5, 61.9) 
5.1 (3.1, 8.3) 
0.9 (0.3, 2.5) 
0.7 (0.4, 1.1) 
 
0.9 (0.2, 4.2) 
0.9 (0.5, 1.5) 
1.4 (0.7, 2.7) 
1.3 (1.0, 1.7) 
SLEDAI-2000 score 
   Increase to score of > 7 
   Increase to score of 3 to 7 
   Decrease to score of 3 to 7 
   Decrease to score of < 3 
 
8.7 (3.4, 22.1) 
2.2 (1.3, 3.7) 
2.2 (1.0, 4.7) 
0.6 (0.3, 1.4) 
 
1.3 (0.5, 3.8) 
1.3 (0.7, 2.2) 
1.6 (0.9, 2.9) 
1.7 (1.2, 2.5) 
 
6.6.5 Relationship between SLEDAI-2000 with the BILAG-2004 and Classic 
BILAG indices 
(Tables 6-31 to 6-38 at the end of section) 
 
In view of the non-overlapping relationship between change in SLEDAI-2000 score 
and change in BILAG-2004 score with change in therapy, exploratory analysis of this 
relationship was performed. Several thresholds for definition of change in SLEDAI-2000 
score were used in the analysis for comparison (Tables 6-31 to 6-34). 
For increase in therapy, a consistent increase in both BILAG-2004 and SLEDAI-2000 
scores had the strongest effect, with an increase in BILAG-2000 score only and an increase in 
SLEDAI-2000 score only having lesser effects which could not be differentiated statistically. 
This applied across the four thresholds of increase in SLEDAI-2000 scores. Increase in 
SLEDAI-2000 score of at least 3 performed the best when compared to the other three 
thresholds as it had the strongest association with increase in therapy. 
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As for decrease in therapy, the strongest association occurred when there was decrease 
in the scores of both indices. Decrease in SLEDAI-2000 score on its own had a similar effect 
to decrease in BILAG-2004 score only. The results were similar for the four thresholds of 
decrease in SLEDAI-2000 score. Therefore, when the BILAG-2004 index is to be used in 
combination with SLEDAI-2000 index, the optimal performance was with the use of minimal 
increase of 3 and minimal decrease of 1 or 2 in the definition of change in SLEDAI-2000 
score. 
Similar analysis was performed to define the relationship between Classic BILAG 
index and SLEDAI-2000 (Tables 6-35 to 6-38). The results were similar to the BILAG-2004 
index in which the best performance for the combination of Classic BILAG and SLEDAI-
2000 indices was when minimal increase of 3 and minimal decrease of 1 or 2 was used in the 
definition of change in SLEDAI-2000 score. 
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Table 6-31: Relationship between change in SLEDAI-2000 score (minimal change of 1) 
and change in BILAG-2004 score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 1) in SLEDAI-
2000 score only 
207 2.3 (1.4, 3.6) 1.3 (0.9, 1.9) 
Increase in BILAG-2004 
score only (exclude D to C) 
58 8.6 (4.1, 18.2) 1.3 (0.7, 2.6) 
Increase in both BILAG-
2004 and SLEDAI-2000 
scores 
137 17.9 (10.3, 31.1) 1.2 (0.6, 2.4) 
Decrease (≥ 1) in SLEDAI-
2000 score only 
207 1.9 (1.2, 3.0) 1.7 (1.2, 2.5) 
Decrease in BILAG-2004 
score only  
169 0.7 (0.4, 1.3) 1.4 (1.0, 2.0) 
Decrease in both SLEDAI-
2000 and BILAG-2004 
scores 
202 0.7 (0.3, 1.3) 2.6 (1.8, 3.8) 
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Table 6-32: Relationship between change in SLEDAI-2000 score (minimal change of 2) 
and change in BILAG-2004 score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 2) in SLEDAI-
2000 score only 
183 2.3 (1.4, 3.7) 1.4 (1.0, 2.1) 
Increase in BILAG-2004 
score only (exclude D to C) 
63 7.6 (3.8, 15.2) 1.3 (0.6, 2.4) 
Increase in both BILAG-
2004 and SLEDAI-2000 
scores 
132 18.8 (10.5, 33.4) 1.3 (0.6, 2.8) 
Decrease (≥ 2) in SLEDAI-
2000 score only 
195 1.9 (1.2, 3.0) 1.9 (1.3, 2.7) 
Decrease in BILAG-2004 
score only  
176 0.7 (0.4, 1.2) 1.4 (1.0, 1.9) 
Decrease in both SLEDAI-
2000 and BILAG-2004 
scores 
195 0.6 (0.3, 1.3) 2.9 (2.0, 4.2) 
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Table 6-33: Relationship between change in SLEDAI-2000 score (minimal change of 3) 
and change in BILAG-2004 score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 3) in SLEDAI-
2000 score only 
52 6.9 (3.3, 14.7) 2.0 (0.9, 4.4) 
Increase in BILAG-2004 
score only (exclude D to C) 
105 9.0 (5.3, 15.3) 1.0 (0.5, 1.8) 
Increase in both BILAG-
2004 and SLEDAI-2000 
scores 
90 20.8 (9.6, 45.0) 1.7 (0.6, 4.3) 
Decrease (≥ 3) in SLEDAI-
2000 score only 
77 2.1 (1.1, 3.9) 1.9 (1.1, 3.3) 
Decrease in BILAG-2004 
score only  
246 0.7 (0.4, 1.1) 1.6 (1.2, 2.2) 
Decrease in both SLEDAI-
2000 and BILAG-2004 
scores 
125 0.5 (0.2, 1.1) 2.3 (1.5, 3.5) 
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Table 6-34: Relationship between change in SLEDAI-2000 score (minimal change of 4) 
and change in BILAG-2004 score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 4) in SLEDAI-
2000 score only 
44 5.5 (2.6, 11.6) 1.5 (0.7, 3.5) 
Increase in BILAG-2004 
score only (exclude D to C) 
110 8.8 (5.3, 14.8) 0.9 (0.5, 1.7) 
Increase in both BILAG-
2004 and SLEDAI-2000 
scores 
85 20.9 (9.3, 47.3) 1.8 (0.7, 4.8) 
Decrease (≥ 4) in SLEDAI-
2000 score only 
70 1.9 (1.0, 3.6) 1.8 (1.0, 3.3) 
Decrease in BILAG-2004 
score only  
256 0.7 (0.5, 1.2) 1.6 (1.2, 2.2) 
Decrease in both SLEDAI-
2000 and BILAG-2004 
scores 
115 0.3 (0.1, 0.8) 2.2 (1.5, 3.4) 
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Table 6-35: Relationship between change in SLEDAI-2000 score (minimal change of 1) 
and change in Classic BILAG score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 1) in SLEDAI-
2000 score only 
218 2.9 (1.9, 4.6) 1.2 (0.8, 1.8) 
Increase in Classic BILAG 
score only (exclude D to C) 
71 8.9 (4.7, 16.6) 1.0 (0.5, 2.1) 
Increase in both Classic 
BILAG and SLEDAI-2000 
scores 
126 17.9 (10.3, 31.1) 1.1 (0.5, 2.2) 
Decrease (≥ 1) in SLEDAI-
2000 score only 
221 1.9 (1.2, 3.1) 1.8 (1.3, 2.6) 
Decrease in Classic BILAG 
score only  
156 0.9 (0.5, 1.5) 1.2 (0.8, 1.8) 
Decrease in both SLEDAI-
2000 and Classic BILAG 
scores 
188 0.8 (0.4, 1.5) 2.3 (1.6, 3.3) 
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Table 6-36: Relationship between change in SLEDAI-2000 score (minimal change of 2) 
and change in Classic BILAG score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 2) in SLEDAI-
2000 score only 
194 2.8 (1.8, 4.4) 1.4 (0.9, 2.0) 
Increase in Classic BILAG 
score only (exclude D to C) 
76 7.0 (3.9, 12.5) 0.8 (0.4, 1.6) 
Increase in both Classic 
BILAG and SLEDAI-2000 
scores 
121 21.0 (11.8, 37.4) 1.4 (0.7, 2.8) 
Decrease (≥ 2) in SLEDAI-
2000 score only 
210 1.9 (1.2, 3.1) 2.1 (1.4, 3.0) 
Decrease in Classic BILAG 
score only  
164 0.9 (0.5, 1.5) 1.2 (0.8, 1.7) 
Decrease in both SLEDAI-
2000 and Classic BILAG 
scores 
180 0.7 (0.4, 1.4) 2.5 (1.7, 3.7) 
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Table 6-37: Relationship between change in SLEDAI-2000 score (minimal change of 3) 
and change in Classic BILAG score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 3) in SLEDAI-
2000 score only 
64 8.3 (4.3, 16.2) 1.8 (0.9, 3.9) 
Increase in Classic BILAG 
score only (exclude D to C) 
119 8.5 (5.3, 13.6) 0.8 (0.4, 1.5) 
Increase in both Classic 
BILAG and SLEDAI-2000 
scores 
78 25.1 (11.4, 54.8) 1.6 (0.6, 4.2) 
Decrease (≥ 3) in SLEDAI-
2000 score only 
81 2.3 (1.2, 4.6) 1.9 (1.1, 3.2) 
Decrease in Classic BILAG 
score only  
223 0.9 (0.5, 1.4) 1.3 (1.0, 1.8) 
Decrease in both SLEDAI-
2000 and Classic BILAG 
scores 
121 0.5 (0.2, 1.2) 2.1 (1.4, 3.2) 
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Table 6-38: Relationship between change in SLEDAI-2000 score (minimal change of 4) 
and change in Classic BILAG score in explaining change in therapy (n=1414). 
Change in  Score Number of 
Observation
Increase in Therapy 
Odds Ratio  
(95% CI) 
Decrease in Therapy
Odds Ratio  
(95% CI) 
Increase (≥ 4) in SLEDAI-
2000 score only 
57 6.8 (3.5, 13.3) 1.5 (0.7, 3.4) 
Increase in Classic BILAG 
score only (exclude D to C) 
125 8.2 (5.2, 13.1) 0.8 (0.5, 1.5) 
Increase in both Classic 
BILAG and SLEDAI-2000 
scores 
72 25.2 (10.9, 58.3) 1.6 (0.6, 4.4) 
Decrease (≥ 4) in SLEDAI-
2000 score only 
74 1.8 (0.9, 3.7) 1.8 (1.0, 3.2) 
Decrease in Classic BILAG 
score only  
233 0.9 (0.5, 1.4) 1.4 (1.0, 1.9) 
Decrease in both SLEDAI-
2000 and Classic BILAG 
scores 
111 0.5 (0.2, 1.1) 2.1 (1.4, 3.2) 
 
6.7 Discussion 
This large multi-centre prospective longitudinal study had demonstrated that the 
BILAG-2004 index was sensitive to change as changes in the score correlated well with the 
corresponding change in therapy. The analysis on the subgroups of changes in overall 
BILAG-2004 score showed that there was a differential effect of the different subgroups of 
changes in its association with change in therapy. This effect was hierarchical with greater 
change in categories having greater predictive power which indicated that the changes in the 
scoring of the index were performing as expected. 
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The robust external responsiveness method was used in this study to assess the 
sensitivity to change of the disease activity indices. This method examines how the changes in 
the score of the index over time, relate to the corresponding changes in an external reference 
measure. It is imperative that the selected external reference measure represents an accepted 
indicator of change in the patient’s status. As such, change in therapy was chosen as the 
external reference for disease activity for this study, in the absence of a gold standard. 
Therefore, the clinically meaningful change of the indices was studied. Physician’s global 
assessment (PGA) could have been used, but this had been shown to have unsatisfactory 
performance with poor agreement between physicians in several studies (Gladman et al. 1994; 
Guzman et al. 1992; Gladman et al. 1992). It is important that the change in the index over 
time reflects actual change in the clinical status of the patient when the index is used to 
measure transition in clinical states, and this affects the number of patients that are required to 
detect significant differences between treatment arms in a clinical trial. Hence, the results of 
this study are highly relevant and applicable to clinical practice and longitudinal studies of 
SLE disease activity. 
Although the BILAG-2004 and Classic BILAG indices were based on the principle of 
the physician’s intention to treat, using change in therapy as the external reference should not 
explicitly bias the analysis in favour of these two indices as change in treatment did not 
determine the scoring. Only the presence of manifestations of active disease would determine 
the scoring. Furthermore, the scoring of these two indices was not available to the physician 
when the treatment decision was made and it was difficult to work out the scoring of the 
BILAG-2004 and Classic BILAG indices in routine clinical practice without the appropriate 
reference documentations. 
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This study also showed that Classic BILAG and SLEDAI-2000 indices were sensitive 
to change. In fact, this is the first study to assess the sensitivity to change of SLEDAI-2000 
index since it was revised from SLEDAI index. This result is consistent with previous studies 
which showed that both Classic BILAG and SLEDAI indices are sensitive to change (Chang 
et al. 2002a; Fortin et al. 2000; Ward et al. 2000; Brunner et al. 1999; Gladman et al. 1994; 
Liang et al. 1989).  
Although the optimal minimal change in SLEDAI-2000 score that is associated with 
change in therapy is 1 or 2, a higher threshold for increase in score of 3 or 4 is recommended 
as it is better at predicting increase in therapy (due to its superior PPV) but with a resultant 
decrease in the sensitivity. This is similar to the results of two previous works with SLEDAI 
index (Gladman et al. 2000b; Petri et al. 1991) but the study by Liang et al with SLEDAI 
index suggested a much higher cut-off (increase in score of at least 8 for flare of disease 
activity and decrease in score of at least 6 for improvement in disease activity) (Liang et al. 
2004). This discrepancy could be explained by the different study design employed, with the 
study by Liang et al being an internet survey of lupus experts using abstracted case histories 
while this study is based on actual clinical practice. 
Interestingly, change in SLEDAI-2000 score on its own is inadequate in explaining 
change in therapy. The score from which it has changed from is also equally important. This 
is not surprising as the score from the previous assessment put the change in score into 
context, for example a change from score of 18 to 15 may not constitute significant change as 
the patient continues to have very active disease, whereas a change of similar magnitude from 
6 to 3 would most likely indicate improvement in disease activity. The result suggests that 
analysing change in SLEDAI-2000 score as a single cut-off would be insufficient. This has 
led to the use of alternative models of change in SLEDAI-2000 scores in the analysis. The 
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resultant alternative models showed some improvement in the performance. Nevertheless, the 
best model to explain change in therapy is with change in SLEDAI-2000 score (as a 
continuous variable) and the SLEDAI-2000 score of the previous visit included. 
The comparison of the three indices did not show that any of the three indices was 
clearly superior with regards to sensitivity to change. The BILAG-2004 index had similar 
performance to Classic BILAG index. It would have been expected that the changes from 
Classic BILAG index to the BILAG-2004 index would have made the BILAG-2004 index 
more sensitive to change. However, this could not be demonstrated as the main difference 
between the indices was the addition of gastro-intestinal and ophthalmic manifestations of 
active disease. Unfortunately, these manifestations were uncommon in this study with only 13 
assessments having some activity in Gastro-intestinal system and only 19 assessments with 
activity in Ophthalmic system. The other changes would not have made a big impact in the 
sensitivity to change analysis of the index and these were: 
1. Improvement in terminology, definitions and glossary of the index 
2. Refinement in the scoring scheme whereby improvement from Grade A reduces the 
score to Grade B instead of  Grade C 
The results of the comparison between Classic BILAG and SLEDAI-2000 indices 
were in contrast to previous studies which compared Classic BILAG index with SLEDAI 
index that showed Classic BILAG index to be superior (Ward et al. 2000; Brunner et al. 1999; 
Liang et al. 1989). The most likely reason for this is the different statistical methods used with 
external responsiveness being used in this study while previous works have used methods of 
internal responsiveness. External responsiveness analysis is a much more robust method as it 
not only determines if the index changes over time but also relates it to the corresponding 
change in an external reference (Husted et al. 2000). With the external reference being change 
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in therapy, it is the clinically meaningful change of the index over time that is being assessed. 
On the other hand, internal responsiveness methods (such as effect size, standardized response 
means and Guyatt’s responsiveness index) that have been used in previous studies only assess 
the ability of the index to change over time. As they do not relate to change in an external 
reference, significant change in the index may occur without corresponding change in the 
clinical status. Furthermore, comparison across studies is difficult with internal 
responsiveness analysis as the statistics used are highly dependent on study design. This is not 
an issue with external responsiveness method as the statistics used are independent of study 
design, making the results generalisable across studies which allows for comparison (Husted 
et al. 2000). Apart from that, this study has involved far more patients and assessments than 
previous studies (less than 40 patients in all of them). Therefore, the result of the comparison 
of the sensitivity to change performance of the three indices in this study is highly relevant to 
clinical practice. 
In view of the non-overlapping relationship with change in therapy when SLEDAI-
2000 index was compared with the BILAG-2004 and Classic BILAG indices, further analysis 
was performed to define this relationship using different cut-offs in the definition of change in 
SLEDAI-2000 score. When used in combination with either the BILAG-2004 or Classic 
BILAG indices, change in SLEDAI-2000 score with single cut-off of minimal increase of 3 
and minimal decrease of 1 had the best performance. This combination may be useful in the 
analysis of longitudinal outcome studies of SLE when both SLEDAI-2000 and the BILAG-
2004 or Classic BILAG indices are used. 
  For the purpose of validation, overall disease activity with the BILAG-2004 and 
Classic BILAG indices was used, as represented by the highest score achieved by any system 
within the respective index (overall score). This is logical as any patient with any system 
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scoring a Grade A or B should be categorised as having active disease (requiring therapy in 
principle) regardless of how many systems have a score of A or B. However, this may put the 
BILAG-2004 and Classic BILAG indices at a disadvantage in the analysis due to the ceiling 
effect that this imposes and may underestimate the severity of the illness. For example, a 
patient with 3 systems scoring Grade B (and no system scoring Grade A) on one assessment 
which subsequently improved to just one system scoring Grade B (and no system scoring 
Grade A) in the next assessment would be considered as having no change in activity (and not 
as improved) between the two assessments, with this analysis. Further study would be 
required to assess the impact of this ceiling effect, using the changes in the score of individual 
systems in the BILAG-2004 and Classic BILAG indices in the analysis. Nevertheless, it will 
be important to consider the changes in the score of individual systems during data analysis in 
the setting of clinical trials and outcome studies. 
A few other issues with the face and content validity of the index were identified 
during the course of this study. These were: 
1. The definition of myositis and its differentiation between severe and mild based on 
Bohan and Peter’s criteria (diagnostic criteria for polymyositis/dermatomyositis) was 
not appropriate. A definition based on serum muscle enzymes, muscle weakness and 
myalgia would be more suitable. 
2. There was a potential for recording error with the item pleuropericardial pain as it 
could be recorded in patients with pleuritic-like chest pain, in which the physician was 
not convinced it was pleurisy. In order to avoid this, it was recommended that the 
terminology be changed to pleurisy/pericarditis and the definition to be updated to 
include only convincing features that the physician would consider treating and not to 
record if the physician was uncertain. 
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3. Over-scoring of Mucocutaneous system was noted with malar rash. As transient malar 
rash that resolved after a few days would usually require no intervention, it was 
recommended that for malar rash to be recorded, it needed to have been observed by a 
physician and to have persisted for at least one week before it could be considered 
sufficiently significant to be recorded. 
4. An additional criterion for improvement was recommended to include manifestations 
that had completely resolved for at least 1 week. 
5. One of the Renal system Grade A criterion for deteriorating renal function was 
‘Glomeular filtration rate (GFR) having fallen to < 67% of previous value’ and it was 
noted that this could be achieved even when the GFR was within normal range. This 
would potentially lead to a score of at least Grade B which is inappropriate as such a 
change in the GFR does not reflect significant disease activity. Indeed, none of the 
assessment in this study with GFR that fell to less than 67% of previous value but was 
still within normal range was attributed to disease activity. To avoid the possibility of 
over-scoring of the Renal system, it was recommended that this criterion be changed 
to require that the GFR not only be less than 67% of previous value but that it should 
also be below the normal range (below 80 ml/min per 1.73 m2). 
These changes were agreed by consensus of members of BILAG and were incorporated into 
the index after the completion of this longitudinal study (Appendix 7). Although most of the 
changes were not taken into account in the present analysis, these changes would not have a 
major effect on the results of this study but might possibly improve on it. 
In conclusion, the BILAG-2004, Classic BILAG and SLEDAI-2000 indices are 
sensitive to change and are suitable for use in longitudinal studies of SLE. As SLEDAI-2000 
index has non-overlapping relationship with the BILAG-2004 and Classic BILAG indices 
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respectively, it may complement the BILAG-2004 or Classic BILAG indices in the analysis 
of SLE disease activity in a longitudinal study.   
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Chapter 7     Rasch Analysis 
 
 
7.1 Abstract 
Objective:  
To assess the BILAG-2004 index empirically using the Rasch model 
Methods:  
SLE patients were recruited into a multi-centre longitudinal study and disease activity was 
assessed using the BILAG-2004 index. Grades D and E were combined for the analysis as 
both indicate inactivity, hence this index has 9 systems (items) with 4 possible scores (A, B, C 
or D) for each item. Analysis was with the Rasch partial credit model using RUMM2020. Fit 
to the model using chi-square statistic and differential item functioning (DIF) with regards to 
sex, race, age and disease duration using analysis of variance were assessed. DIF is a form of 
bias in which different groups within the sample respond differently to an individual item, 
given the same level of disease activity. Significance level for DIF was set at 0.0003 after 
Bonferroni correction. Unidimensionality was confirmed by principal component analysis 
(PCA) of the residuals. Assessments from the first visit were used for primary analysis while 
those from the second visit were used as the validation sample. 
Results:  
A total of 353 SLE patients were recruited (93% females, 58% Caucasian, 20% Afro-
Caribbean, 19% South Asian). Rescoring of all the systems in the index (items) was required 
due to clustering of inactivity in all the systems, with low frequency of active disease scores 
(A or B). Most of the rescoring involved combining Grade A with B and Grade C with D/E. 
After rescoring, there was a good fit to the Rasch model: mean item fit residual -1.1 (SD 1.4), 
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mean person fit residual -0.3 (SD 0.4) and non-significant item-trait interaction (p=0.011). 
There was no significant DIF with regards to age, sex, ethnicity and disease duration. Person 
separation index (ability of the index to discriminate patients) was low at 0.36. 
Unidimensionality was confirmed by PCA with non-significant independent t-test of the 
residuals. Analysis of the validation sample was consistent with the primary analysis. 
Conclusions:  
The BILAG-2004 index, with some modification to the scoring, fits the Rasch model. This 
indicates that the index is a unidimensional ordinal scale index with internal construct 
validity. The low person separation index is consistent with clustering of patients with 
minimal disease activity (Grades C or D or E). 
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7.2 Objective 
 To assess the BILAG-2004 index empirically using the Rasch model. 
 
7.3 Introduction 
The Rasch model is a probabilistic mathematical model that is used to assess 
measurement scale empirically (Andrich 1988; Rasch 1980). It assumes that the probability of 
a particular response in an item is a logistic function of the severity or difficulty of the item 
and the patient’s disease activity. Its most basic model is the dichotomous model as 
represented by the following equation: 
logit = ln ⎟⎠
⎞⎜⎝
⎛
− P
P
1
= β - δ 
where P is the probability of a patient’s given response to an item, β is the patient’s disease 
activity and δ is the severity of the item. An implicit assumption of this model is that there is a 
hierarchical ordering of the items in the index which means that the data forms an ordinal 
scale. This model has the properties of fundamental measurement which are ‘additivity’ of 
measurement units (logit), and specific objectivity as the equation allows for item severity and 
patient’s disease activity to be independent of each other (item-person separation). Where data 
fit model assumptions and expectations, it also confers unidimensionality whereby the index 
measures only one attribute at a time. As such, this model enables assessment of internal 
construct validity of the index as unidimensionality infers that the items in the index are 
measuring the same attribute.  
In this chapter, data from the longitudinal study was used to determine if the BILAG-
2004 index fits the Rasch model. 
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7.4 Methods 
The dataset from the longitudinal study (sensitivity to change study) was used in this 
analysis. This was a multi-centre longitudinal study in which recruited SLE patients were 
followed up prospectively and data were collected for all consecutive visits or encounters 
(inpatient or outpatient) that the patients had with the physician, as described in Chapter 6. 
Data were collected on disease activity as assessed using the BILAG-2004 index.  
 
7.5 Analysis 
Analysis was with Rasch partial credit model using RUMM2020 software (RUMM 
Laboratory, Perth, Australia). For the purpose of this analysis, BILAG-2004 Grades D and E 
were combined as both indicate inactivity. Therefore, the BILAG-2004 index had 9 items 
(representing the 9 systems in the index) with four possible categorical scores (A, B, C and D) 
for each item. 
The fit of the data to the model was assessed by determining the overall fit of the scale 
and the individual item fit. The overall fit of the scale was given by the item-trait interaction 
which was reported as a chi-square statistic and this provided an indication of the deviation of 
the data from the Rasch model. An insignificant chi-square statistic would indicate that the 
data met model expectations and the items in the scale fit together to form a hierarchical and 
unidimensional scale.  
Individual item fit was assessed by a number of indicators which included threshold 
ordering, item fit residuals and a chi-square test. Threshold refers to the point between two 
adjacent response categories where the probability of either response is equal. It would be 
expected that the thresholds would increase systematically in a logical progression from 
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Grade D to Grade A. Disordered thresholds occur when the scoring categories are not 
progressing in a logical order. The item fit residual is the standardised deviation from the 
model for the item and the desired range for the residual is that of between ± 2.5. Values 
outside this range would suggest misfit to the model. The fit of the item is further examined 
by a chi-square test, with a significant test indicating misfit of the item to the model 
expectations. 
Differential item functioning (DIF) with regards to person factors, specifically sex, 
ethnicity (Caucasian versus non-Caucasian), age (age below 40 years versus 40 years and 
above) and disease duration (below 7 years versus 7 years and above), was also assessed as 
this could affect item fit. DIF is a form of bias in which different groups within the sample 
respond differently to an individual item, given the same level of the underlying attribute. For 
example, non-Caucasians may be more likely to have severe renal involvement compared to 
Caucasians, given the same level of disease activity. There are two forms of DIF, uniform and 
non-uniform. Uniform DIF is where there is a consistent systematic difference in the response 
between groups across the range of disease activity being measured. This difference varies in 
non-uniform DIF. Analysis of variance was used to determine the presence of DIF. 
Apart from the fit statistics above, the reliability of the scores of the index (Person 
Separation Index) was estimated, and this provided an indication of the ability of the index to 
discriminate amongst the patients. This is based on Cronbach’s α estimation but instead of 
using the raw scores, the estimates on the logit scale for each patient were used to calculate 
the reliability. An acceptable value for person separation index is that of at least 0.70 
(Nunnally et al. 1994). 
In the analysis, the patients were grouped by their level of trait, which in this study 
was disease activity. Given the large sample size, the number of class intervals was set to 10 
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for the analysis. Significance level was set at 0.01 but for DIF this was set at 0.0003 after 
Bonferroni correction. A test of unidimensionality utilising principal component analysis 
(PCA) of the residuals with independent t-test, was used. 
Primary analysis was with assessments from the first visit. Confirmation of this result 
was made using the validation sample that comprised assessments from the second visit. 
 
7.6 Results 
A total of 353 SLE patients were recruited into this study. The demographics of the 
patients are summarised in Table 7-1. There were 353 assessments from the first visit that 
were available for the primary analysis. The distribution of disease activity according to the 
BILAG-2004 index across the 9 systems is summarised in Table 7-2. 
Table 7-1: Demographics of patients recruited into the study (n=353). 
Patient Characteristics  
Female sex (%) 
Mean age in years (SD) 
Ethnicity (%) 
    Caucasian 
    Afro-Caribbean 
    South Asian 
    Oriental 
    Others 
Mean disease duration in years (SD) 
92.9 
40.9 (12.9) 
 
58.1 
20.1 
19.0 
1.4 
1.4 
8.3 (7.9) 
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Table 7-2: Distribution of disease activity across 9 systems according to the BILAG-2004 
index (n=353). 
BILAG-2004 Score System 
A B C D or E 
Constitutional 2 11 18 322 
Mucocutaneous 7 64 82 200 
Neuropsychiatric 5 4 1 343 
Musculoskeletal 10 37 109 197 
Cardiorespiratory 4 13 13 323 
Gastro-intestinal 0 0 3 350 
Ophthalmic 0 2 1 350 
Renal 11 11 10 321 
Haematological 5 9 154 185 
 
Initial Fit of Data 
There were 66 patients with minimum or extreme scores (Grade D or E in all 
systems). Initial analysis revealed that the data did not fit the Rasch model with a mean item 
fit residual of -1.668 (SD 1.232), mean person location of -2.452, mean person fit residual of -
0.369 (SD 0.416) and significant item-trait interaction (p<0.001). Individual item fit is 
summarised in Table 7-3. Person separation index was low at 0.46. 
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Table 7-3: Individual Item Fit of the BILAG-2004 Index with initial Rasch analysis. 
System Fit Residual P value 
Constitutional -4.213 <0.001 
Mucocutaneous -1.371 0.001 
Neuropsychiatric -1.920 0.391 
Musculoskeletal -1.256 0.013 
Cardiorespiratory -2.056 0.276 
Gastrointestinal -0.538 0.877 
Ophthalmic -0.602 0.867 
Renal -2.710 0.016 
Haematological -0.371 0.002 
 
Threshold Ordering 
There were disordered threshold in all systems except Musculoskeletal system. The 
clustering of patients with Grade D or E in all the systems was contributory, necessitating 
grades with low frequency to be combined with the adjacent grade (Table 7-4). Threshold 
ordering was corrected with this rescoring (Figure 7-1). Despite having ordered threshold, 
Musculoskeletal system had to be rescored as it did not fit into the model with the original 
scoring scheme.  
Figure 7-1: Threshold Map of Items in the BILAG-2004 Index after rescoring. 
 
* items sorted according to location order with the easiest item to achieve at the top and the 
most difficult item to achieve at the bottom 
 
 170
Differential Item Functioning (DIF) 
There was no DIF with regards to sex, ethnicity, age and disease duration. 
 
Final Fit of Data 
There was a good fit to the Rasch model with a mean item fit residual of -1.108 (SD 
1.421), mean person location of -3.353, mean person fit residual of -0.336 (SD 0.428) and 
non-significant item-trait interaction (p=0.011). Person separation index remained low at 0.36. 
Unidimensionality was confirmed by PCA with non-significant independent t-test of the 
residuals. Final individual item fit is summarised in Table 7-4. 
The person-item threshold distribution graph (Figure 7-2) shows the patient’s disease 
severity and item difficulty level on the same linear (logit) scale. This indicates that the index 
is not appropriately targeted at the population being assessed as the majority of the patients 
are located towards the lower end (less disease activity) of the scale.  
Table 7-4:Final Individual Item Fit of the BILAG-2004 Index. 
System Rescoring Fit Residual P value 
Constitutional A and B combined 
C and D combined 
-3.274 0.017 
Mucocutaneous A and B combined 
C and D combined 
0.603 0.078 
Neuropsychiatric A and B combined 
C and D combined 
-1.504 0.494 
Musculoskeletal B and C combined -0.181 0.772 
Cardiorespiratory B and C combined -2.094 0.018 
Gastrointestinal B and C combined -0.986 0.807 
Ophthalmic C and D combined -0.514 0.736 
Renal A and B combined 
C and D combined 
-2.769 0.011 
Haematological B and C combined 0.742 0.476 
 171
Figure 7-2: Person-Item threshold distribution of the BILAG-2004 index with Rasch 
analysis. 
 
 
Validation Analysis 
A total of 347 patients had assessment on their second visit which was available for 
this validation analysis. The distribution of disease activity according to the BILAG-2004 
index across the 9 systems in this validation sample is summarised in Table 7-5. 
Table 7-5: Distribution of disease activity across 9 systems according to the BILAG-2004 
index in the validation sample (n=347). 
BILAG-2004 Score System 
A B C D or E 
Constitutional 2 1 13 331 
Mucocutaneous 5 44 75 223 
Neuropsychiatric 1 1 3 342 
Musculoskeletal 6 25 90 226 
Cardiorespiratory 1 12 5 329 
Gastro-intestinal 0 3 0 344 
Ophthalmic 0 1 4 342 
Renal 5 14 9 319 
Haematological 2 8 164 173 
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Using the rescoring scheme from the primary analysis, there was no disordered 
threshold or DIF with regards to sex, ethnicity, age and disease duration. There was a good fit 
to the Rasch model with a mean item fit residual of -1.161 (SD 1.115), mean person location 
of  -3.956, mean person fit residual of -0.326 (SD 0.357) and non-significant item-trait 
interaction (p=0.016). Person separation index was low at 0.32. Unidimensionality was 
confirmed by PCA with non-significant independent t-test of the residuals. The individual 
item fit is summarised in Table 7-6. This result is consistent with the results from the primary 
analysis and hence, validates the primary results. 
Table 7-6: Individual Item Fit of the BILAG-2004 Index with the validation sample. 
System Fit Residual P value 
Constitutional -3.274 0.017 
Mucocutaneous 0.603 0.078 
Neuropsychiatric -1.504 0.494 
Musculoskeletal -0.181 0.772 
Cardiorespiratory -2.094 0.018 
Gastrointestinal -0.986 0.807 
Ophthalmic -0.514 0.736 
Renal -2.769 0.011 
Haematological 0.742 0.476 
 
7.7 Discussion 
The results of this study showed that the BILAG-2004 index, with some modifications 
to the scoring, had a good fit to the Rasch model. This confirms that the index is performing 
as an ordinal scale index with hierarchical ordering of the system scores, in the way it is 
designed. It also indicates that this index is unidimensional, in which all the system scores are 
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measuring a single latent trait (that is disease activity), and has internal construct validity 
whereby all the system scores correlate well with each other in measuring disease activity.  
It is apparent that there is a mismatch between the difficulty of the index and disease 
activity of the population under study as indicated by the mean patient location which is well 
below zero, and the person-item threshold distribution graph (Figure 7-2). This indicates that 
the index is designed to capture much more severe disease activity (hence much more difficult 
items in the index to achieve) than the population studied. This is not unexpected as many of 
the patients have low level of disease activity. Even in patients with active disease, most have 
only one system involved while the other systems are usually unaffected or minimally 
affected. 
It is the clustering of patients with minimal disease activity that has resulted in low 
patient separation index (reliability) whereby the BILAG-2004 index is not able to 
differentiate between patients within this group. However, differentiation within this group of 
patients with minimal disease activity is not clinically important as it would have little or no 
impact on the management of the disease. Therefore, although the low patient separation 
index is not ideal, it is acceptable considering the circumstances. 
In the analysis, all of the systems in the index required rescoring to enable the index to 
fit to the Rasch model. Once again, this is most likely related to the clustering of Grade D or E 
scores in all the systems while there was low frequency of Grade A and B scores. As a result, 
the grades with low frequencies had to be combined with the adjacent grade. It is reassuring 
that the rescoring scheme is relevant from clinical viewpoint as the majority of combinations 
of categories are that of active disease (combination of Grades A and B) or minimal disease 
activity (combination of Grades C and D). As the scoring in all the systems are not uniform 
following rescoring, linear transformation of the ordinal scale using the Rasch model is not 
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suitable for use outside of this study. If linear transformation using the Rasch model that is 
generally applicable is required, a uniform scoring across all the system is essential. This 
would involve a study with targeted recruitment of patients with active disease, hence 
increasing the frequency of Grades A and B, and reducing the clustering of patients in Grades 
D or E. 
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Chapter 8     Final Discussion 
 
 
The development and validation process for the BILAG-2004 index had led to major 
changes in the content of the index and its supporting documentation as compared to its 
predecessor, the Classic BILAG index. The major improvement had been in the terminology 
and definitions of most items, which was reflected in the glossary of 18 pages for the BILAG-
2004 index (Appendix 7). In contrast, the Classic BILAG index had a 2-page glossary and as 
such, relied mainly on the judgement of the individual physician who was completing the 
index (Appendix 2). This may have resulted in less than optimal standardisation across 
different physicians and introduce user-related errors in studies involving more than one 
physician. This issue was recognised and for clinical trials, a longer and more detailed 
glossary had been developed for the Classic BILAG index, whereas the detailed glossary for 
the BILAG-2004 index was developed from the start, with the aim of ensuring greater 
standardisation amongst users of the index. Explicit and clear definitions/qualifications for the 
majority of the items in the index were incorporated. In addition, overly subjective definitions 
were avoided and at the same time, definitions were checked to ensure that they were not too 
restrictive or stringent so that the index remained comprehensive (able to capture all aspects 
of disease activity and severity). Items that were difficult to attribute to disease activity with 
certainty such as fatigue, mood disorder, anxiety disorder and migraine/tension/cluster 
headache, were removed. Despite these changes, the BILAG-2004 index still requires an 
element of physician’s subjective judgement in deciding the attribution to SLE disease 
activity for certain manifestations that are difficult to differentiate from other conditions, such 
as lupus pancreatitis, lupus cholecystitis, cognitive dysfunction and lupus abdominal 
peritonitis/serositis. 
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This research on the validation of the BILAG-2004 index represents the largest multi-
centre validation study to-date of a clinical disease activity index in SLE. The major strength 
of these validation studies is in the involvement of several physicians (from different centres) 
who have recruited a large number of patients (and assessments). Furthermore, the data were 
collected prospectively in routine clinical setting that should be applicable to routine practice 
and clinical trials. Previous validation studies of other disease activity indices have involved 
rather small sample sizes (usually less than 50 patients) and/or retrospective assessment or 
abstracted case histories (Gladman et al. 2002; Bae et al. 2001; Fortin et al. 2000; Ward et al. 
2000; Brunner et al. 1999; Gladman et al. 1994; Hay et al. 1993; Bombardier et al. 1992; Petri 
et al. 1992; Gladman et al. 1992; Liang et al. 1989).  
This index had undergone a thorough examination, with robust statistical methods 
being used in the analysis. The reference standard for disease activity of change in therapy 
used in the criterion validity and sensitivity to change analyses might not be perfect but 
remains the best benchmark. This was chosen in preference to physician’s global assessment 
of disease activity as this had been shown in several studies to have unsatisfactory 
performance and poor agreement between expert physicians, making it unsuitable for such a 
purpose (Wollaston et al. 2004; Brunner et al. 1999; Gladman et al. 1994; Gladman et al. 
1992). The definition used for change in therapy in this research was meticulous and robust. 
There was no issue with circularity even though the index was based on the principle of the 
physicians’ intention to treat, as the treatment was not taken into account in the scoring. 
Furthermore, the treatment decisions made in the clinic were not based on the score of the 
index, as the score was not available to the physician when the treatment decisions were 
made. Most of the participating physicians were not familiar with the scoring scheme, 
although some of them had helped in the initial development of the index (during the 
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consensus building process). With change in therapy as the external standard, the results of 
the criterion validity and sensitivity to change analyses are clinically meaningful. Therefore, 
the results from this validation process will be highly relevant and applicable to clinical 
practice.  
There is a possibility that the effect of using these indices may have influenced and 
changed the way in which the physicians assessed the patients. Physicians have to be 
thorough in their assessment and this may have been much more meticulous than in routine 
practice. As a result, subtle changes in the patients’ status would be detected earlier leading to 
change in treatment (occurring earlier than would have been expected in routine practice). 
Although it is difficult to prove, this positive effect is one that is welcomed and should not 
have an effect on the results as the trigger to a change in treatment is the detection of change 
in clinical status rather than completion of the indices. 
The reliability study has clearly demonstrated the importance of training before 
physicians start using a composite clinical disease activity index. It must be emphasised that 
one cannot assume that physicians, without any form of training, will use composite clinical 
disease activity indices as designed. Training can be considered to be equivalent to 
standardisation of equipment whereby the equipment in this setting is the combination of the 
user (physician) and the disease activity index. It is important to realise that how the index is 
completed will affect the result and if done incorrectly, will lead to unacceptable user-related 
error which cannot be controlled statistically. This is a significant issue in this complex multi-
system disease that requires multiple domains to be considered (such as disease activity, 
damage, health status and intercurrent illness), but only features attributable to SLE disease 
activity are to be recorded in the index. The reliability study highlighted this issue of 
attribution in the first exercise which was significantly reduced with training prior to the 
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second exercise. Therefore, the aims of the training are twofold. Firstly, it is to familiarise the 
physician (user) with the index and the definitions used in the index (not only of the items in 
the index but also what is meant by ‘new’, ‘improved’, ‘worse’ and ‘unchanged’) so that the 
physician will be competent in completing the index correctly. In addition, the training is to 
increase the awareness of the physician on the issue of attribution of manifestations when 
assessing SLE patients and to record only manifestations that are due to SLE disease activity 
in the index. Apart from that, it is essential for trial monitors to be vigilant and meticulous on 
this issue of attribution in clinical trials setting. In the reliability study, the training was not 
performed in a formal setting due to logistic reasons. However, formal training with the use of 
paper cases would be recommended in future studies involving the BILAG-2004 index. The 
pharmaceutical companies that are engaged in current clinical trials in SLE are aware of the 
importance of this issue and have organised formal training for investigators prior to the start 
of the trial.   
One of the limitations in the analyses is with the use of overall score for the BILAG-
2004 index to represent overall disease activity, in the cross sectional and sensitivity to 
change studies. The overall score for the index was determined by the highest score achieved 
by any system within the index. The use of this overall score is logical and sufficient for the 
purpose of validation. However, it possibly have under-estimated the ability of the index due 
to the ceiling effect imposed by the overall score and this may have an impact in the analyses 
comparing the performance of the three indices (the BILAG-2004, Classic BILAG and 
SLEDAI-2000 indices). Therefore, further analysis using all the individual system scores is 
warranted.  
In the cross sectional and longitudinal (sensitivity to change) studies, all patients were 
assessed simultaneously using the BILAG-2004, Classic BILAG and SLEDAI-2000 indices. 
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Although these three indices have similar items for several manifestations of active disease, 
there are differences in the definitions used across the indices. Hence, there is a possibility 
that the same definition had been used unintentionally across the 3 indices for similar items, 
but this is difficult to prove. This is especially so with the BILAG-2004 and Classic BILAG 
indices which are quite similar. An example of this is with inflammatory arthritis, in which 
the definition according to the three indices is summarised in Table 8-1.  
Table 8-1: Definition for inflammatory arthritis according to the BILAG-2004, Classic 
BILAG and SLEDAI-2000 indices. 
Index Definition for inflammatory arthritis 
SLEDAI-2000 ≥ 2 joints with pain and signs of inflammation (tenderness, swelling or  
 effusion) 
BILAG-2004 (a) Severe arthritis     
       Observed active synovitis ≥ 2 joints with marked loss of functional range  
       of movements and significant impairment of activities of daily living,  
       that has been present on several days (cumulatively) over the last 4 weeks 
 
(b) Moderate arthritis or Tendonitis or Tenosynovitis 
       Tendonitis/tenosynovitis or active synovitis ≥ 1 joint (observed or  
       through history) with some loss of functional range of movements, that  
       has been present on several days over the last 4 weeks 
 
(c) Mild arthritis or Arthralgia or Myalgia  
       Inflammatory type of pain (worse in the morning with stiffness, usually  
       improves with activity & not brought on by activity) over joints/muscle  
       and/or inflammatory arthritis which does not fulfil the above criteria for  
       moderate or severe arthritis 
Classic BILAG (a) Severe polyarthritis with loss of function 
       Active joint inflammation with clinically significant loss of the functional 
range of movement of the involved joints. 
 
(b) Arthritis  
       Active joint inflammation without loss of functional range of motion 
 
(c) Arthralgia 
 
Both the BILAG-2004 and Classic BILAG indices have three items for inflammatory arthritis, 
dividing it into three levels of severity (mild, moderate and severe) while SLEDAI-2000 has 
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only one item for the same manifestation. It is apparent that the criteria used by the three 
indices for inflammatory is quite different. Even though both the Classic BILAG and BILAG-
2004 indices have similar division of inflammatory arthritis into three levels of severity, what 
could be recorded as severe arthritis in Classic BILAG index may only be recorded as 
moderate arthritis in the BILAG-2004 index, due to the different criteria used in the 
definition. Similarly, the same definitions for improvement in a manifestation and for new 
manifestation may have been used for both the BILAG-2004 and Classic BILAG indices. The 
improvement criteria in the BILAG-2004 index incorporate 2 parameters which include the 
amount of improvement and the duration of improvement, whereas there is no specific 
definition for improvement in Classic BILAG index (it is based solely on the physician’s 
judgement). There is also a slight difference in the definition of new manifestation between 
the BILAG-2004 and Classic BILAG indices, in which new manifestation that has also 
improved is recorded as improved in the BILAG-2004 index (but not in Classic BILAG 
index) and this difference could be overlooked. One possible way around this problem of 
using the same definition across the indices is for different indices to be completed by 
different physicians. However, this will require a patient to be seen by 3 physicians at every 
assessment, which is not practical or feasible in a large multi-centre study such as the cross 
sectional and sensitivity to change studies. 
This index has not been tested through its full range due to clustering of observations 
with low level of disease activity, which has been highlighted in the Rasch analysis. This is 
particularly evident in the Gastrointestinal and Ophthalmic systems. A better distribution of 
disease activity with more Grades A and B in all of the systems would have been ideal, but 
this has proved difficult to achieve despite recruitment being targeted at patients with active 
disease. Indeed, manifestations of active disease in the Gastrointestinal and Ophthalmic 
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systems were rare in the cross sectional and longitudinal studies. However, these 
manifestations are associated with significant morbidity and mortality (requiring change in 
therapy), hence it is important to be able to record them whenever they occur. 
Although the validation studies had a good case-mix of patients with broad 
representation of the three main ethnic groups in United Kingdom (Caucasians, Afro-
Caribbeans and South Asians), this index had not been used in other ethnic groups (such as 
Orientals and Hispanics) and in the setting outside of United Kingdom (particularly in 
countries where English is not the first language). It remains to be seen if the results are 
applicable in a different setting and to these other ethnic groups, although it is not anticipated 
to perform differently providing that the physicians are experienced in the management of 
lupus, able to speak English fluently and appropriately trained to use the index. There may be 
a need for translation and validation of this index in other languages to optimise its use in 
non-English speaking countries. 
Unfortunately, the predictive validity of this index has yet to be demonstrated. A 
multi-centre longitudinal study designed to determine if disease activity according to the 
BILAG-2004 index predicts development of organ damage in an inception cohort of newly 
diagnosed patients, is on-going. Patients who are within 12 months of achieving the 4th ACR 
classification criteria of SLE are recruited and followed up prospectively. Development of 
damage is assessed using ACR/SLICC damage index. Recruitment into this study began in 
March 2005 and as of 30th April 2007, 83 patients had been recruited. However, the data 
currently are inadequate for any conclusive analysis to be made as far fewer patients have 
developed damage than expected. This reflects the improvement in the management of SLE 
patients, as the initial calculation of the number of patients required for this study (n=60) is 
based on a study that was performed in the early 1990s (Stoll et al. 1996). Clearly, more 
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patients and much longer follow-up are required. This study is continuing and it has been 
extended for another 5 years with ethical approval. 
The results presented in this thesis have shown that the BILAG-2004 index is a 
comprehensive index that is valid for use to assess SLE disease activity. It should be suitable 
for use in clinical trials. The ability of this index to provide disease activity score across 
different systems will be useful in the assessment of therapeutic agents, in particular those that 
may only be helpful for disease activity in certain systems (such as musculoskeletal) but not 
others. This index has been well accepted by the international rheumatology community and 
several clinical trials in SLE are using this index as an outcome measure. Apart from clinical 
trials, this index will be useful in daily clinical setting. With the arrival of newer and 
expensive therapies, health resource planning especially budgeting for these therapies will be 
essential. Similar to the usage of biological therapy for rheumatoid arthritis, I envisage that 
standardised objective assessment of disease activity will become a requirement to 
demonstrate eligibility and response to these expensive therapies. It has been argued that this 
index may be too complicated and difficult to complete but this has not been the case from the 
validation studies. It only takes a few minutes to complete the index once the physician is 
familiar with the items in the index and the glossary definitions for them, as most patients 
have very few items to record and the time required to complete the index mirrors the 
complexity of the case. The difficult part is the scoring of the index, which in fact is the most 
complicated part of the index. Fortunately, a purpose-built database incorporating the BILAG-
2004 index is under development, which will facilitate data management and analyses.  
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8.1 Future Research 
As discussed earlier, the use of the overall score for both the BILAG-2004 and Classic 
BILAG indices in the validation analyses may have under-estimated the ability of these two 
indices. Apart from that, the results of the sensitivity to change analysis revealed that there 
was a non-overlapping relationship with change in therapy when SLEDAI-2000 index was 
compared with the BILAG-2004 and Classic BILAG indices. This suggests that there is a role 
of combining the SLEDAI-2000 with either the BILAG-2004 or Classic BILAG indices in the 
analysis of longitudinal outcome studies in SLE. As the analysis was undertaken using overall 
score for both the BILAG-2004 and Classic BILAG indices, further analysis which takes into 
account all of the individual system scores is required as this would provide a better 
understanding of how the individual system scores would relate to treatment decision and 
would better define the relationship between the BILAG-2004, Classic BILAG and SLEDAI-
2000 indices. 
Furthermore, the definition of flare based on the BILAG-2004 index has not been 
addressed. Flare is used in longitudinal studies to indicate deterioration or worsening of 
disease activity between two time points, such as a change from Grade D to A. The difficulty 
is in the differentiation of flare from persistent activity. For the majority of the items in the 
index, an improvement will result in a drop of one category in the score. If the manifestation 
remained unchanged subsequently, the score will increase back to its initial score, giving an 
impression that the patient had flared (which is incorrect as the manifestation has not 
worsened) when in fact this increase in score is due to persistent activity. It should be pointed 
out that this change in score is appropriate in reflecting the need for treatment as the 
manifestation is no longer improving, but it is the interpretation of the change in score that 
one needs to be careful with in terms of defining flare. As an illustration, a new subacute 
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cutaneous lupus rash affecting 10% of body surface area would result in a Mucocutaneous 
system score of B (Visit 1). With treatment, the rash improved to affect only 4% of body 
surface area and the Mucocutaneous system score dropped to Grade C (Visit 2). In the 
following month, if the rash remained unchanged, the Mucocutaneous system score would go 
back up to Grade B (Visit 3). Therefore, the Mucocutaneous system score had changed from 
Grade B to C between the first two visits (Visit 1 and 2) and from Grade C to B between latter 
two visits (Visit 2 and 3). At face value, the change in the Mucocutaneous system scores 
between Visit 2 and 3 will be classified incorrectly as a flare. This issue with flare definition 
is not unique to the BILAG-2004 index but is universal across all other indices. The beauty of 
being a transitional index (both the BILAG-2004 and Classic BILAG indices) is that it is able 
to differentiate whether a manifestation has improved, worsened or stayed unchanged, which 
will allow the issue of flare definition to be addressed. As the status of the manifestation 
(‘new’, ‘improved’, ‘worsened’ or ‘unchanged’) is recorded in the index, it can be used to 
identify persistent activity (whereby the manifestation has stayed unchanged) as opposed to 
flare (whereby the manifestation is new or has worsened). However, this is very difficult to  
address with non-transitional indices especially global score indices, which by design are 
unable to differentiate between the changing status of a manifestation (improved, worsened or 
unchanged). Using the earlier clinical scenario of subacute cutaneous rash, SLEDAI-2000 
index score is the same (score of 2) for all three visits and similarly, the score would remain 
the same even if the rash has worsened to involve 40% of body surface area. 
As the BILAG-2004 index is designed as an ordinal scale, it is recommended that it 
should be analysed as such. However, there are some restrictions to the way analysis can be 
performed, as there are limited statistical methods that can accommodate ordinal data. Hence, 
it would be useful if the BILAG-2004 index score could be converted into a continuous 
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numerical score for use in certain statistical circumstances where analysis as ordinal data is 
not feasible. This is possible using the Rasch model to transform the data into a linear scale 
but it would require another study, with targeted recruitment of patients with active disease 
that has good distribution across the different scoring categories in all the 9 systems. Another 
possibility is to develop an additive numerical scoring scheme by modelling change in therapy 
using the scores of the individual systems with regression analysis. The coefficients from the 
fitted model can be used to define the numerical values of each categorical score. 
Finally, there is a need for a disease activity index that has been validated for use in 
pregnancy. In the past, pregnancy in SLE was considered to be a serious problem, not 
infrequently resulting in significant risk of mortality to mother and baby. Over the last 2 to 3 
decades, the survival and treatment of SLE have improved considerably resulting in more 
SLE patients getting pregnant. This poses a special problem as pathophysiological changes of 
pregnancy may mimic or confound disease activity. Although several of the indices that are 
developed for use in non-pregnant state have been modified for use in pregnancy, none of 
them have been formally validated. Only the modification of LAI for use in pregnancy (LAI-
P) had undergone validation in the form of criterion validity and sensitivity to change (Ruiz-
Irastorza et al. 2004). This study involved 38 patients with 158 assessments and LAI-P was 
only compared with physician’s global assessment in both the criterion validity and sensitivity 
to change analyses, which was not ideal due to the drawback of using physician’s global 
assessment (discussed earlier). Apart from that, the sensitivity to change analysis used the less 
robust method of internal responsiveness in the form of standardised response mean (see 
Section 1.8.4 for more details on methods of sensitivity to change analysis). A disease activity 
index for use in pregnancy based on the BILAG-2004 index has been developed 
(BILAG2004-Pregnancy index). This has involved modifications that take into account 
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pathophysiological changes of pregnancy that may be confused with disease activity. This 
index is currently undergoing validation which commenced in February 2006 and is 
anticipated to be completed in late 2008. 
 
8.2 Conclusion 
In conclusion, the results of the research studies presented in this thesis have achieved 
most of the objectives of the thesis as set out, which is to develop and validate the BILAG-
2004 index for the assessment of SLE disease activity. Only the predictive validity of this 
index remains outstanding, but the study is on-going. 
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Appendix 1    BILAG-2004 Index 
BILAG-2004 INDEX ASSESSMENT 
Only features attributable to SLE are to be recorded and refer to the last 4 weeks 
compared with the previous 4 weeks.         
                     ♦♦ THIS SHOULD BE USED WITH THE GLOSSARY ♦♦ 
 
Scoring for features:    ND  Not Done 
            1      Improving 
        2      Same        
3      Worse 
        4      New 
        Yes/No OR Value           
   indicate if feature not due to lupus 
     (default is 0 = not present) 
 
CONSTITUTIONAL 
1. Pyrexia (documented)                  (                     ) 
2. Weight loss - unintentional > 5%                 (           ) 
3. Lymphadenopathy/splenomegaly                 (           ) 
4. Fatigue/malaise/lethargy                  (           ) 
5. Anorexia                    (           ) 
 
MUCOCUTANEOUS 
6. Skin eruption - severe                  (           ) 
7. Skin eruption - mild                  (           ) 
8. Angio-oedema - severe                  (           ) 
9. Angio-oedema - mild                  (           ) 
10. Mucosal ulceration - severe                 (           ) 
11. Mucosal ulceration - mild                  (           ) 
12. Panniculitis/Bullous lupus - severe                (           ) 
13. Panniculitis/Bullous lupus - mild                 (           ) 
14. Cutaneous vasculitis/thrombosis                 (           ) 
15. Digital infarcts/nodular vasculitis                 (           ) 
16. Alopecia - severe                   (           ) 
17. Alopecia - mild                   (           ) 
18. Peri-ungual erythema/chilblains                 (           ) 
19. Splinter haemorrhages                  (           ) 
 
NEUROPSYCHIATRY 
20. Aseptic meningitis                  (           ) 
21. Cerebral vasculitis                  (           ) 
22. Demyelinating syndrome                  (           ) 
23. Myelopathy                   (           ) 
24. Acute confusional state                  (           ) 
25. Psychosis                    (           ) 
26. Acute inflammatory demyelinating polyradiculoneuropathy             (           ) 
27. Mononeuropathy (single/multiplex)                (           ) 
28. Cranial neuropathy                  (           ) 
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29. Plexopathy                   (           ) 
30. Polyneuropathy                   (           ) 
31. Seizure disorder                   (           ) 
32. Status epilepticus                   (           ) 
33. Cerebrovascular disease (not due to vasculitis)                                (           )  
34. Cognitive dysfunction                  (           ) 
35. Movement disorder                  (           ) 
36. Autonomic disorder                  (           ) 
37. Cerebellar ataxia                   (           ) 
38. Headache, severe, unremitting                  (           ) 
39. Headache - migraine/cluster/tension                    (                     ) 
40. Headache from IC hypertension                     (                     ) 
41. Mood disorder (depression/mania)                    (                     ) 
42. Anxiety disorder                       (                     ) 
 
MUSCULOSKELETAL 
43. Definite myositis (Bohan & Peter)     (           ) 
44. Myositis with incomplete criteria      (           ) 
45. Severe polyarthritis       (           ) 
46. Arthritis/Tendonitis       (           ) 
47. Arthralgia/Myalgia       (           ) 
 
CARDIORESPIRATORY 
48. Myocarditis - mild       (           ) 
49. Myocarditis/Endocarditis + Cardiac failure    (           ) 
50. Arrhythmia         (           ) 
51. New valvular dysfunction                  (           ) 
52. Serositis (pleuro-pericardial pain) - mild      (           ) 
53. Cardiac tamponade       (           ) 
54. Pleural effusion with dyspnoea      (           ) 
55. Pulmonary haemorrhage/vasculitis     (           ) 
56. Interstitial alveolitis/pneumonitis      (           ) 
57. Shrinking lung syndrome       (           ) 
58. Aortitis         (           ) 
59. Coronary vasculitis       (           ) 
 
GASTROINTESTINAL 
60. Peritonitis         (           ) 
61. Abdominal serositis or ascites      (           ) 
62. Lupus enteritis/colitis       (           ) 
63. Malabsorption        (           ) 
64. Protein losing enteropathy      (           ) 
65. Intestinal pseudo-obstruction      (           ) 
66. Hepatitis         (           ) 
67. Acute cholecystitis       (           ) 
68. Acute pancreatitis        (           ) 
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OPHTHALMIC 
69. Orbital inflammation/myositis/proptosis     (           ) 
70. Keratitis - severe        (           ) 
71. Keratitis - mild        (           ) 
72. Anterior uveitis        (           ) 
73. Posterior uveitis/retinal vasculitis - severe    (           ) 
74. Posterior uveitis/retinal vasculitis - mild     (           ) 
75. Episcleritis        (           ) 
76. Scleritis - severe        (           ) 
77. Scleritis - mild        (           ) 
78. Retinal/choroidal vaso-occlusive disease     (           ) 
79. Isolated cotton-wool spots (cytoid bodies)    (           ) 
80. Optic neuritis        (           ) 
81. Anterior ischaemic optic neuropathy     (           ) 
 
RENAL  
82. Systolic blood pressure (mm Hg)      value   (                     )  
83. Diastolic blood pressure (mm Hg)     value   (                     )  
84. Accelerated hypertension                   Yes/No (                     )   
85. Urine dipstick                        (-=0,+=1, ++=2, +++=3) (                     )  
86. Urine albumin-creatinine ratio       mg/mmol   (                     )  
87. Urine protein-creatinine ratio         mg/mmol       (                     )  
88. 24 hour urine protein (g)       value   (                     )  
89. Nephrotic syndrome                           Yes/No (                     )   
90. Creatinine (plasma/serum)                 μmol/l   (                     )  
91. GFR (calculated)                                ml/min  (                     )  
92. Active urinary sediment                     Yes/No (                     )   
93. Active nephritis                                  Yes/No (                     )   
 
HAEMATOLOGICAL 
94. Haemoglobin (g/dl)                     value   (           )   
95. Haematocrit                      value   (           )   
96. Total white cell count (x 109/l)             value   (           )   
97. Neutrophils (x 109/l)                     value   (           )   
98. Lymphocytes (x 109/l)                     value   (           )   
99. Platelets (x 109/l)                      value   (           )   
100. TTP                   (           ) 
101. Evidence of active haemolysis        Yes/No (           ) 
102. Coombs’ test positive (isolated)        (           ) 
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BILAG2004 INDEX GLOSSARY 
 
• all features must be attributable to SLE and refer to the last 4 weeks compared with the  
    previous 4 weeks 
 
• in some manifestations, it may be difficult to differentiate SLE from other causes as there  
    may not be any specific test and the decision would then lies with the physician’s  
    judgement on the balance of probabilities 
 
• definition of improvement:  (a) the amount of improvement is sufficient for consideration of  
      reduction in therapy  
 
(b) improvement must be present ≥ 2 weeks of the previous 4    
      weeks 
 
• most are self-explanatory but definitions are available for most descriptors 
 
• ophthalmic manifestations need to be assessed by ophthalmologist 
 
 
 
CONSTITUTIONAL 
 
1. Pyrexia      temperature > 37.5˚C documented 
 
2. Unintentional weight loss > 5% 
3. Lymphadenopathy    palpable lymph node more than 1 cm diameter 
 
4. Fatigue or malaise or lethargy 
5. Anorexia     
 
 
MUCOCUTANEOUS 
 
6. Severe eruption     > 18% body surface area 
                        includes discoid lesion 
 
body surface area (BSA) is defined using the 
rules of nines (used to assess extent of burns) as 
follows: 
 
palm (excluding fingers) = 1% BSA 
            each lower limb = 18% BSA 
              each upper limb = 9% BSA 
               torso (front) = 18% BSA 
               torso (back) = 18% BSA 
               head = 9% BSA 
               genital (male) = 1% BSA 
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7. Mild eruption     ≤ 18% body surface area 
                                includes discoid lesion 
 
8. Angio-oedema     potentially life-threatening eg: stridor 
 
9. Severe mucosal ulceration   disabling extensive &/or deep ulceration 
 
10. Mild mucosal ulceration   localised non-disabling ulceration 
 
11. Severe panniculitis   any one: 
     affecting the face  
     > 9% body surface area 
     threatens integrity of epithelium &/or  
      subcutaneous tissue 
 
12. Mild panniculitis ≤ 9% body surface area and does not fulfill any 
criteria for severe panniculitis 
 
13. Cutaneous vasculitis/thrombosis  resulting in gangrene or ulceration or skin  
infarction 
 
14. Digital infarct/nodular vasculitis  localised single or multiple infarct(s) over  
digit(s) or tender erythematous nodule(s) 
 
15. Severe alopecia    clinically detectable diffuse or patchy hair loss  
with scalp inflammation 
 
16. Mild alopecia    not clinically detectable and little/no scalp  
inflammation (may be diffuse & must be 
spontaneous) 
 
17. Peri-ungual erythema or chilblains 
18. Splinter haemorrhages 
 
 
NEUROPSYCHIATRIC 
 
19. Aseptic meningitis   criteria (all): acute/subacute onset 
           headache 
            photophobia 
          neck stiffness 
     fever 
     signs of meningeal irritation 
     abnormal CSF but negative cultures 
 
exclude CNS/meningeal infection, intracranial    
haemorrhage 
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20. Cerebral vasculitis   should be present with features of vasculitis  
in another system and supportive imaging &/or  
biopsy findings 
 
21. Demyelinating syndrome   discrete white matter lesion with associated   
       neurological deficit not recorded elsewhere 
 
there must have been at least one previously 
recorded event 
 
exclude multiple sclerosis 
 
22. Myelopathy    acute onset of rapidly evolving paraparesis or  
quadriparesis and/or sensory level 
 
exclude intramedullary and extramedullary  
space occupying lesion 
 
23. Acute confusional state   acute disturbance of consciousness or level of  
arousal with reduced ability to focus, maintain or 
shift attention 
 
includes hypo- and hyperaroused states and 
encompasses the spectrum from delirium to 
coma 
 
24. Psychosis     delusion or hallucinations    
 
      does not occur exclusively during course of a  
delirium 
 
exclude drugs, substance abuse, primary  
psychotic disorder 
 
25. Acute inflammatory demyelinating criteria: 
       polyradiculoneuropathy       progressive polyradiculoneuropathy 
          loss of reflexes 
          symmetrical involvement 
          increased CSF protein without pleocytosis 
    supportive abnormal nerve conduction study 
 
26. Mononeuropathy (single/multiplex) nerve conduction study not essential 
 
27. Cranial neuropathy   except optic neuropathy which is classified  
elsewhere 
 
28. Plexopathy    disorder of brachial or lumbosacral plexus  
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resulting in neurological deficit not  
corresponding to territory of single root or nerve 
 
positive electrophysiology study required 
 
29. Polyneuropathy    symmetrical distal sensory and/or motor deficit 
 
      positive electrophysiology study required 
 
30. Seizure disorder independent description of seizure by reliable 
witness 
 
31. Status epilepticus    a seizure or series of seizures lasting ≥ 30  
minutes without full recovery to baseline 
 
32. Cerebrovascular disease   any one with supporting imaging: 
       (not due to vasculitis)      stroke syndrome 
         transient ischaemic attack 
         intracranial haemorrhage 
       
exclude hypoglycaemia, cerebral sinus 
thrombosis, vascular malformation, tumour, 
abscess 
 
cerebral sinus thrombosis not included as  
definite thrombosis not considered part of lupus 
activity 
 
33. Cognitive dysfunction   significant deficits in any cognitive functions: 
         simple attention 
         complex attention 
         memory 
         visual-spatial processing 
         language 
         reasoning/problem solving 
         psychomotor speed 
         executive functions 
 
      neuropsychological testing should be done if  
possible or corroborating history from third party  
that it is interfering with daily activities 
 
      exclude substance abuse 
 
34. Movement disorder   exclude drugs 
 
35. Autonomic disorder   any one: 
         fall in blood pressure to standing > 30/15 mm  
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   Hg (systolic/diastolic) 
 
   increase in heart rate to standing ≥ 30 bpm 
 
   loss of heart rate variation with respiration   
   (max – min < 15 bpm, expiration:inspiration  
   ratio < 1.2, Valsalva ratio < 1.4) 
 
   loss of sweating over body and limbs  
   (anhidrosis) by sweat test 
 
      exclude drugs and diabetes mellitus 
 
36. Cerebellar ataxia 
37. Severe headache (unremitting) disabling headache unresponsive to narcotic 
analgesia & lasting ≥ 3 days 
 
exclude intracranial space occupying lesion  
and CNS infection 
 
38. Migraine with/without aura  recurrent attacks of headache lasting  4 - 72  
hours 
 
may be preceded by neurological aura (lasting  
up to 1 hour) 
 
39. Tension headache    recurrent episodes of headaches lasting minutes  
to days 
 
40. Cluster headache    attacks of severe unilateral headache lasting 15  
- 180 minutes 
 
attacks at least once every other day and up to 8 
times a day  
 
attacks occur in clusters (series of weeks or  
months) separated by remissions of usually  
months or years 
 
41. Headache from IC hypertension  exclude cerebral sinus thrombosis 
 
42. Mood disorder (depression/mania) prominent & persistent disturbance in mood 
characterised by depressed mood or markedly 
diminished interest or pleasure in almost all 
activities or elevated, expansive or irritable mood 
 
 should result in significant distress or impaired 
functioning 
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43. Anxiety disorder    prominent anxiety, panic disorder, panic attacks  
or obsessions or compulsions resulting in 
clinically significant distress or impaired 
functioning 
 
 
MUSCULOSKELETAL 
 
44. Definite myositis    ≥ 3 Bohan & Peter criteria: 
      proximal muscle weakness 
      elevated muscle enzymes 
      positive muscle biopsy 
      abnormal EMG 
 
45. Incomplete myositis   2 Bohan & Peter criteria 
 
46. Severe polyarthritis   observed active synovitis ≥ 2 joints with  
significant impairment of activities of daily 
living and has been present on several days 
(cumulatively) over the last 4 weeks 
 
47. Arthritis or Tendonitis tendonitis or active synovitis ≥ 1 joint with some 
impairment of function, which has been present 
on several days over the last 4 weeks 
 
48. Arthralgia or Myalgia inflammatory joint or muscle pain which does 
not fulfill the above criteria for arthritis or 
myositis 
 
 
CARDIORESPIRATORY 
 
49. Mild myocarditis    inflammation of myocardium with raised  
cardiac enzymes &/or ECG changes and without 
resulting cardiac failure, arrhythmia or valvular 
dysfunction 
 
50. Cardiac failure cardiac failure due to myocarditis or non-
infective inflammation of endocardium or 
cardiac valves (endocarditis) 
 
51. Arrhythmia arrhythmia (except sinus tachycardia) due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
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52. New valvular dysfunction new cardiac valvular dysfunction due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
 
53. Mild serositis (pleuro-pericardial pain) in absence of cardiac tamponade or pleural 
effusion with dyspnoea 
 
54. Cardiac tamponade 
55. Pleural effusion with dyspnoea 
56. Pulmonary haemorrhage/vasculitis inflammation of pulmonary vasculature with  
haemoptysis &/or dyspnoea &/or pulmonary 
hypertension 
 
supporting imaging &/or histological diagnosis 
 
57. Interstitial alveolitis/pneumonitis  radiological features of alveolar infiltration not  
due to infection or haemorrhage 
 
reduced corrected gas transfer Kco (< 70% 
normal) 
 
58. Shrinking lung syndrome   reduced lung volumes (< 70% predicted) in  
presence of normal corrected gas transfer Kco 
with dysfunctional diaphragmatic movements 
 
59. Aortitis     inflammation of aorta with or without  
dissection with supporting imaging abnormalities  
 
accompanied by > 10 mm Hg difference in BP 
between arms &/or claudication of extremities 
&/or vascular bruits 
 
60. Coronary vasculitis   inflammation of coronary vessels with  
radiographic evidence of non-atheromatous 
narrowing, obstruction or aneurismal changes 
 
 
GASTROINTESTINAL 
 
61. Peritonitis     serositis presenting as acute abdomen with  
rebound/guarding 
 
62. Serositis     not presenting as acute abdomen 
 
63. Lupus enteritis or colitis vasculitis or inflammation of small or large 
bowel with supportive imaging &/or biopsy 
findings 
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64. Malabsorption    diarrhoea with abnormal D- xylose absorption  
test or increased faecal fat excretion after 
exclusion of coeliac’s disease (poor response to 
gluten-free diet) and gut vasculitis 
 
65. Protein-losing enteropathy  diarrhoea with hypoalbuminaemia or increased  
fecal excretion of iv radiolabeled albumin after 
exclusion of gut vasculitis 
 
66. Intestinal pseudo-obstruction  subacute intestinal obstruction due to intestinal  
hypomotility 
 
67. Hepatitis     raised transaminases in absence of  
autoantibodies specific to autoimmune hepatitis 
(eg: anti-smooth muscle, anti-liver cytosol 1) 
&/or biopsy appearance of chronic active 
hepatitis 
 
68. Acute cholecystitis   after exclusion of gallstones and infection 
 
69. Acute pancreatitis    usually associated multisystem involvement 
 
  
RENAL 
 
70. Systolic blood pressure 
71. Diastolic blood pressure 
72. Accelerated hypertension   blood pressure rising to > 170/110 mm Hg  
within 1 month with grade 3 or 4 Keith-
Wagener-Barker retinal changes (flame-shaped 
haemorrhages or cotton-wool spots or 
papilloedema) 
 
73. Urine dipstick 
74. Urine albumin-creatinine ratio  on freshly voided urine sample 
 
75. Urine protein-creatinine ratio  on freshly voided urine sample 
 
76. 24 hour urine protein 
77. Nephrotic syndrome   criteria: 
heavy proteinuria (> 50 mg/kg/day or >    
  3.5 g/day or protein-creatinine ratio > 350  
  mg/mmol or albumin-creatinine ratio > 350  
  mg/mmol) 
 
           hypoalbuminaemia  
           oedema 
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78. Plasma/Serum creatinine 
79. GFR      MDRD formula: 
GFR = 170 x [serum creatinine(mg/dl)]-0.999 x   
              [age]-0.176 x [serum urea(mg/dl]-0.17 x   
              [serum albumin(g/dl)]0.318 x [0.762 if  
              female] x [1.180 if black] 
 
conversion: 
    serum creatinine  -   mg/dl = (μmol/l)/88.5 
    serum urea          -  mg/dl = (mmol/l) x 2.8 
 
creatinine clearance not recommended as it is not 
reliable 
 
80. Active urinary sediment   Uncentrifuged specimen: pyuria (> 5  
WCC/hpf), haematuria (> 5 RBC/hpf) or red cell 
casts in absence of other causes 
 
81. Histology of active nephritis WHO Class III, IV or V 
 
 within last 3 months or since previous 
assessments if seen less than 3 months ago 
 
glomerular sclerosis without inflammation not 
counted 
 
 
OPHTHALMIC 
 
82. Orbital inflammation 
83. Severe keratitis     sight threatening 
includes:  corneal melt 
    peripheral ulcerative keratitis 
 
84. Mild keratitis    not sight threatening 
 
85. Anterior uveitis 
86. Severe posterior uveitis &/or retinal  sight-threatening &/or retinal vasculitis 
       vasculitis     not due to vaso-occlusive disease 
 
87. Mild posterior uveitis &/or retinal not sight-threatening 
       vasculitis       
not due to vaso-occlusive disease 
 
88. Episcleritis 
89. Severe scleritis    necrotising anterior scleritis 
anterior &/or posterior scleritis requiring  
  systemic steroids/immunosuppression &/or not    
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  responding to NSAIDs 
 
90. Mild scleritis anterior &/or posterior scleritis not requiring 
systemic steroids 
       
      excludes necrotising anterior scleritis 
 
91. Retinal/choroidal vaso-occlusive   includes: retinal arterial & venous occlusion 
disease         serous retinal &/or retinal pigment  
     epithelial detachments secondary to    
     choroidal vasculopathy 
 
92. Isolated cotton-wool spots  also known as cytoid bodies   
 
93. Optic neuritis    excludes anterior ischaemic optic neuropathy 
 
94. Anterior ischaemic optic neuropathy visual loss with pale swollen optic disc due to 
occlusion of posterior ciliary arteries 
 
 
HAEMATOLOGICAL 
 
95. Haemoglobin 
96. White cell count 
97. Neutrophil count 
98. Lymphocyte count 
99. Platelet count 
100. Evidence of active haemolysis positive Coomb’s test & evidence of haemolysis 
(raised bilirubin or raised reticulocyte count or 
reduced haptoglobulins) 
 
101. Isolated positive Coomb’s test 
 
 
ADDITIONAL ITEMS 
 
These items are required mainly for calculation of GFR 
 
      i.  Date of Birth 
      ii.  Weight 
      iii.  Black       
      iv.  Serum urea 
      v.  Serum albumin 
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BILAG2004 INDEX SCORING 
 
    • scoring based on the principle of physician’s intention to treat 
 
Grade 
 
Definition 
 
A Severe disease activity requiring any of the following treatment: 
 
1. systemic high dose oral corticosteroids (equivalent to  
     prednisolone > 20 mg/day) 
 
2. intravenous pulse corticosteroids (equivalent to pulse  
     methylprednisolone  ≥ 500 mg) 
 
3. systemic immunosuppressives 
4. therapeutic high dose anticoagulation 
      eg: warfarin with target INR 3 - 4 
 
B 
 
Moderate disease activity requiring any of the following treatment: 
 
1. systemic low dose oral corticosteroids (equivalent to prednisolone  
      ≤ 20 mg/day) 
 
2. intramuscular or intra-articular or soft tissue corticosteroids  
      injection (equivalent to methylprednisolone < 500mg) 
 
3. topical corticosteroids 
4. topical immunosuppressants 
5. antimalarials 
6. symptomatic therapy 
      eg: NSAIDs for inflammatory arthritis 
            antipsychotic for psychosis 
 
C 
 
Stable mild disease 
D 
 
Inactive disease but previously affected 
E System never involved 
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CONSTITUTIONAL 
 
Grade A: 
Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  AND  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Fatigue/malaise/lethargy 
  Anorexia 
 
Grade B: 
Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  OR  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Fatigue/malaise/lethargy 
  Anorexia 
 
BUT do not fulfil criteria for Grade A 
 
Grade C 
Pyrexia recorded as 1 (improving)  OR 
 
One or more of the following recorded as > 0:  
 
Weight loss 
  Lymphadenopathy/Splenomegaly 
  Fatigue/malaise/lethargy 
  Anorexia 
 
BUT does not fulfil criteria for Grade A or B 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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MUCOCUTANEOUS 
 
Grade A   
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Skin eruption - severe  
Angio-oedema - severe 
  Mucosal ulceration - severe 
  Panniculitis/Bullous lupus - severe 
Cutaneous vasculitis/thrombosis 
 
Grade B  
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Skin eruption - mild 
Panniculitis/Bullous lupus - mild 
  Digital infarcts/nodular vasculitis 
  Alopecia - severe 
   
Grade C   
Any Grade B features recorded as 1 (improving) OR 
 
Any of the following recorded as > 0: 
 
  Angio-oedema - mild 
  Mucosal ulceration - mild 
  Alopecia - mild 
Periungual erythema/chilblains 
Splinter haemorrhages 
 
Grade D  
Previous involvement 
 
Grade E  
No previous involvement 
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NEUROLOGICAL 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Aseptic meningitis 
Cerebral vasculitis 
Demyelinating syndrome 
Myelopathy 
Acute confusional state 
Psychosis 
Acute inflammatory demyelinating polyradiculoneuropathy 
Mononeuropathy (single/multiplex) 
Cranial neuropathy 
Plexopathy 
Polyneuropathy 
Status epilepticus 
Cerebellar ataxia 
 
Grade B 
Any Grade A features recorded as 1 (improving) OR 
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Seizure disorder  
Cerebrovascular disease (not due to vasculitis) 
Cognitive dysfunction 
Movement disorder 
Autonomic disorder  
Headache severe unremitting 
Headache due to raised intracranial hypertension 
Mood disorder 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR 
 
Any of the following recorded as > 0: 
 
Headache - migraine/cluster/tension 
 
Grade D  
Previous involvement 
 
Grade E  
No previous involvement 
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MUSCULOSKELETAL 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
 Definite Myositis (Bohan and Peter) 
Severe polyarthritis 
 
Grade B 
Any Grade A features recorded as 1 (improving)  OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
 Myositis with incomplete criteria  
Arthritis/Tendonitis 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
 Arthralgia/Myalgia 
   
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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CARDIORESPIRATORY 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Myocarditis/Endocarditis + Cardiac failure 
  Arrhythmia 
  New valvular dysfunction 
Cardiac tamponade 
  Pleural effusion with dyspnoea 
  Pulmonary haemorrhage/vasculitis  
Interstitial alveolitis/pneumonitis  
Shrinking lung syndrome 
Aortitis 
Coronary vasculitis 
 
Grade B 
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Serositis (pleuro-pericardial pain) - mild  
Myocarditis - mild 
 
Grade C 
Any Grade B features recorded as 1 (improving) 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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GASTROINTESTINAL 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Peritonitis 
Lupus enteritis/colitis 
Intestinal pseudo-obstruction  
Acute cholecystitis 
Acute pancreatitis 
 
Grade B 
Any Grade A feature recorded as 1 (improving) OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
Abdominal serositis and/or ascites  
Malabsorption 
Protein losing enteropathy 
Hepatitis 
 
Grade C 
Any Grade B features recorded as 1 (improving)  
 
Grade D  
Previous involvement 
 
Grade E   
No previous involvement 
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OPHTHALMIC 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Orbital inflammation/myositis/proptosis 
Keratitis - severe 
Posterior uveitis/retinal vasculitis - severe 
Scleritis - severe 
Retinal/choroidal vaso-occlusive disease 
Optic neuritis 
Anterior ischaemic optic neuropathy  
 
Grade B 
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Keratitis - mild 
Anterior uveitis 
Posterior uveitis/retinal vasculitis - mild 
Scleritis - mild 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
Episcleritis 
Isolated cotton-wool spots (cytoid bodies) 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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RENAL 
 
Grade A 
Two or more of the following providing 1, 4 or 5 is included: 
 
1. Deteriorating proteinuria (severe) defined as   
 
      (a) urine dipstick increased by ≥ 2 levels; or  
      (b) 24 hour urine protein rising from < 0.20 g to > 1 g; or 
      (c) 24 hour urine protein rising from > 1 g by ≥ 100%; or 
      (d) newly documented 24 hour urine protein of > 1 g; or 
      (e) urine protein-creatinine ratio rising from < 20 mg/mmol to > 100 mg/mmol; or  
      (f) urine protein-creatinine ratio rising from > 100 mg/mmol by ≥ 100%; or 
      (g) newly documented urine protein-creatinine ratio of > 100 mg/mmol; or             
      (h) urine albumin-creatinine ratio rising from < 20 mg/mmol to > 100 mg/mmol ; or  
      (i) urine albumin-creatinine ratio rising from > 100 mg/mmol  by ≥ 100%; or 
      (j) newly documented urine albumin-creatinine ratio of > 100 mg/mmol 
 
2. Accelerated hypertension  
3. Deteriorating renal function (severe) defined as  
 
      (a) plasma creatinine > 130 μmol/l and having risen to > 130% of previous value; or  
      (b) GFR having fallen to < 67% of previous value; or  
      (c) GFR < 50 ml/min, and last time was > 50 ml/min or was not measured. 
 
4. Active urinary sediment 
5. Histological evidence of active nephritis within last 3 months  
6. Nephrotic syndrome 
 
Grade B 
One of the following: 
 
1. One of the Grade A feature 
 
2. Deteriorating proteinuria (mild) defined as 
 
(a) urine dipstick which has risen by 1 level to at least 2+; or  
(b) 24 hour urine protein rising from > 1 g by > 50% but < 100%; or 
(c) urine protein-creatinine ratio rising from > 100 mg/mmol by > 50% but < 100%; or  
(d) urine albumin-creatinine ratio rising from > 100 mg/mmol by > 50% but < 100%                             
 
3. Plasma creatinine > 130 μmol/l and having risen to ≥ 115% but ≤ 130% of previous value 
 
Grade C 
One of the following: 
 
1. Mild/Stable proteinuria defined as 
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      (a) urine dipstick ≥ 1+ but has not fulfilled criteria for Grade A & B; or 
      (b) 24 hour urine protein > 0.25 g but has not fulfilled criteria for Grade A & B ; or 
      (c) urine protein-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Grade A  
             & B; or  
 
      (d) urine albumin-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Grade A  
 & B 
 
2. Rising blood pressure (providing the recorded values are > 140/90 mm Hg) which has not 
fulfilled criteria for Grade A & B, defined as 
  
(a) systolic rise of ≥ 30 mm Hg; and  
(b) diastolic rise of ≥ 15mm Hg  
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
 
 
Note: although albumin-creatinine ratio and protein-creatinine ratio are different, the same  
           cut-off values are used for both in this index 
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HAEMATOLOGICAL 
 
Grade A 
TTP recorded as 2 (same), 3 (worse) or 4 (new)   OR 
 
Any of the following: 
   
Haemoglobin   < 8 g/dl 
Haematocrit  < 24 % 
White cell count  < 1.0 x 109/l 
Neutrophil count  < 0.5 x 109/l  
Platelet count   < 25 x 109/l 
 
Grade B 
TTP recorded as 1 (improving)   OR 
 
Any of the following:  
 
Haemoglobin   8 - 9.9 x 109/l 
Haematocrit  24 - 29 % 
White cell count  1 - 2.4 x 109/l 
Neutrophil count  0.5 - 1.4 x 109/l 
Platelet count   25 - 99 x 109/l 
Evidence of active haemolysis 
 
Grade C 
Any of the following: 
 
Haemoglobin   10 - 10.9 g/dl  
Haematocrit  30 - 32 % 
White cell count  2.5 - 3.9 x 109/l 
Neutrophil count  1.5 - 1.9 x 109/l 
Lymphocyte count  < 1.0 x 109/L 
Platelet count  100 - 149 x 109/l 
Isolated Coombs’ test positive  
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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Appendix 2    Classic BILAG Index 
All features must be attributable to SLE and refer to last 4 weeks compared with prior 
disease activity  
 
Indicate features which are present:  1) Improving 
    2) Same 
    3) Worse 
    4) New 
    Or Y/N or value (where indicated) 
    (default is 0 = not present) 
 
GENERAL 
1. Pyrexia (documented)  (        ) 
2. Weight loss - unintentional > 5%  (        ) 
3. Lymphadenopathy/splenomegaly  (        ) 
4. Fatigue/malaise/lethargy  (        ) 
5. Anorexia/nausea/vomiting  (        ) 
   
MUCOCUTANEOUS   
6. Maculopapular eruption - severe, active (or discoid/bullous)  (        ) 
7. Maculopapular eruption - mild  (        ) 
8. Active discoid lesions – generalised or extensive  (        ) 
9. Active discoid lesions - localised  (including lupus profundus)  (        ) 
10. Alopecia (severe, active)  (        ) 
11. Alopecia (mild)  (        ) 
12. Panniculitis (severe)  (        ) 
13. Angio-oedema  (        ) 
14. Extensive mucosal ulceration  (        ) 
15. Small mucosal ulcers  (        ) 
16. Malar erythema  (        ) 
17. Subcutaneous nodules  (        ) 
18. Perniotic skin lesions  (        ) 
19. Peri-ungual erythema  (        ) 
20. Swollen fingers      Y/N (        ) 
21. Sclerodactyly Y/N (        ) 
22. Calcinosis Y/N (        ) 
23. Telangiectasia Y/N (        ) 
   
NEUROLOGICAL   
24. Deteriorating level of  consciousness  (        ) 
25. Acute psychosis or delirium or confusional state  (        ) 
26. Seizures  (        ) 
27. Stroke or stroke syndrome  (        ) 
28. Aseptic meningitis  (        ) 
29. Mononeuritis multiplex  (        ) 
30. Ascending or transverse myelitis  (        ) 
31. Peripheral or cranial neuropathy  (        ) 
32. Disc swelling/cytoid bodies  (        ) 
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33. Chorea  (        ) 
34. Cerebellar ataxia  (        ) 
35. Headache severe, unremitting  (        ) 
36. Organic depressive illness  (        ) 
37. Organic brain syndrome including pseudotumor cerebri  (        ) 
38. Episodic migraine headaches  (        ) 
   
MUSCULOSKELETAL   
39. Definite myositis (Bohan & Peter)  (        ) 
40. Severe polyarthritis - with loss of function  (        ) 
41. Arthritis  (        ) 
42. Tendonitis  (        ) 
43. Mild chronic myositis  (        ) 
44. Arthralgia  (        ) 
45. Myalgia  (        ) 
46. Tendon contractures and fixed deformity Y/N (        ) 
47. Aseptic necrosis Y/N (        ) 
   
CARDIOVASCULAR & RESPIRATORY   
48. Pleuropericardial pain  (        ) 
49. Dyspnoea  (        ) 
50. Cardiac failure  (        ) 
51. Friction rub   (        ) 
52. Effusion (pericardial or pleural)  (        ) 
53. Mild or intermittent chest pain  (        ) 
54. Progressive Chest X-ray changes-lung fields Y/N (        ) 
55. Progressive Chest X-ray changes-heart size Y/N (        ) 
56. ECG evidence of pericarditis or myocarditis Y/N (        ) 
57. Cardiac arrhythmias including tachycardia> 100 in absence of 
        fever 
Y/N (        ) 
58. Pulmonary function fall by > 20% Y/N  
59. Cytohistological evidence of inflammatory lung disease Y/N (        ) 
   
VASCULITIS   
60. Major cutaneous vasculitis including ulcers  (        ) 
61. Major abdominal crisis due to vasculitis  (        ) 
62. Recurrent thromboembolism (excluding strokes)  (        ) 
63. Raynaud’s  (        ) 
64. Livedo reticularis  (        ) 
65. Superficial phlebitis  (        ) 
66. Minor cutaneous vasculitis(nail fold vasculitis, digital  
         vasculitis, purpura, urticaria) 
 (        ) 
67. Thromboembolism (excluding stroke) - 1st episode Y/N (        ) 
   
RENAL   
68. Systolic blood pressure (mm Hg) value (        ) 
69. Diastolic blood pressure (mm Hg) value (        ) 
70. Accelerated hypertension Y/N (        ) 
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71. Urine dipstick protein (+ = 1, ++ = 2, +++ = 3) value (        ) 
72. 24 hour urinary protein (g) value (        ) 
73. Newly documented proteinuria > 1g / 24hrs Y/N (        ) 
74. Nephrotic syndrome Y/N (        ) 
75. Creatinine (plasma/serum) value (        ) 
76. Creatinine clearance/GFR  ml/min value (        ) 
77. Active urinary sediment Y/N (        ) 
78. Histological evidence of active nephritis - within 3 months Y/N (        ) 
   
HAEMATOLOGY   
79. Haemoglobin g/dl value (        ) 
80. Total white cell count x 109/l value (        ) 
81. Neutrophils x 109/L value (        ) 
82. Lymphocytes x 109/L value (        ) 
83. Platelets x 109/L value (        ) 
84. Evidence of active haemolysis Y/N (        ) 
85. Coomb’s test positive Y/N (        ) 
86. Evidence of circulating anticoagulant Y/N (        ) 
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CLASSIC BILAG GLOSSARY 
 
It is implicit in this scoring system that all features scored are considered to be due to active 
lupus. 
 
GENERAL 
 
1. Pyrexia: temperature > 37.5oC documented 
2. Weight loss unintentional more than 5% 
3. Lymphadenopathy: palpable lymph nodes > 1cm in diameter 
4. Fatigue or malaise or lethargy 
5. Anorexia or nausea or vomiting  
 
MUCOCUTANEOUS 
 
6. Maculopapular eruption – severe: active maculopapular or bullous eruption; extensive (> 
18% of body surface area), scarring or causing disability. 
7. Maculopapular eruption – mild ( ≤ 18% body surface area), non-scarring, non-disabling 
8. Active discoid lesions – generalised or extensive, > 18% surface area 
9. Active discoid lesions – localised ie ≤ 18% surface area 
10. Alopecia – severe, active: abnormal diffuse hair loss which is clinically detectable with 
scalp inflammation. 
11. Alopecia (mild): limited relatively inactive:  abnormal diffuse hair loss with little or no 
detectable scalp inflammation. 
12. Panniculitis: extensive, painful, erythematous subcutaneous nodules associated with fat 
necrosis resolve with scarring, or lupus profundus: erythematous elevated plaques with 
an overlying discoid skin lesion 
13. Angio-oedema: potentially life threatening eg stridor 
14. Extensive mucosal ulceration: severe, deep, disabling ulcers. 
 
NEUROLOGICAL 
 
24. Acute deteriorating level of consciousness by any accepted clinical criteria 
25. Acute psychosis or delirium or confusional state: severe disturbance in the perception of 
reality characterised by: delusions, hallucinations, incoherence, marked illogical 
thinking, bizarre or catatonic behaviour 
35. Headache severe, unremitting: continuous headache not relieved by narcotic analgesia 
36. Organic depressive illness: associated with somatic symptoms and severe enough to 
merit treatment with anti-depressive medication  
37. Organic brain syndrome:  impaired orientation, memory or other intellectual function in 
the absence of metabolic, psychiatric or pharmacological causes 
Clinical features develop over a short period (usually hours to days) and tend to fluctuate 
over the course of the day: 
a. Clouding of consciousness with reduced capacity to focus and sustain attention to 
environment. 
b. i. Perceptual disturbance: misinterpretations, illusions or hallucinations  
                   ii.    incoherent speech 
iii. insomnia or daytime drowsiness 
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iv. increased or decreased psychomotor activity 
c.   Disorientation and recent memory impairment    
 
MUSCULOSKELETAL 
 
39. Myositis:  at least three of – proximal muscle weakness, elevated muscle enzymes, 
positive muscle biopsy and abnormal EMG. 
40. Polyarthritis with loss of function: active joint inflammation with clinically significant 
loss of the functional range of movement of the involved joints. 
41. Arthritis: active joint inflammation without loss of functional range of motion 
 
CARDIO RESPIRATORY 
 
48. Pleuropericardial pain: localised sharp or dull pain in the chest aggravated by respiration. 
49. Dyspnoea: on exercise (not orthopnoea alone).  
53. Mild intermittent chest pain: non-specific (not clearly pleuritic, pericardial, 
musculoskeletal or angina). 
58. Pulmonary function fall by > 20%: >20% of expected (predicted for height, weight, sex 
and age) or > 20% fall in total lung capacity (forced vital capacity) and/or DLCO.  
 
VASCULAR SYSTEM 
 
59. Major cutaneous vasculitis including ulcers: extensive gangrene and/or ulceration 
66. Minor cutaneous vasculitis eg digital vasculitis with nail fold infarcts 
 
RENAL 
 
70. Accelerated hypertension: BP rising to >170/110 (5th phase) within one month, if 
accompanied by Grade IV retinal changes (ie haemorrhage, exudates).   
77. Active urinary sediment:  on uncentrifuged specimen.  Pyuria (> 5wc/hpf), haematuria 
(>5rbc/hpf) or red cell casts in the absence of infection or any other cause 
78. Histological evidence of active nephritis: according to WHO criteria.  Sclerosis alone 
(without inflammation) will not be regarded as active nephritis 
 
HAEMATOLOGY 
 
79. Evidence of circulating lupus anticoagulant or other antiphospholipid antibody.    
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CLASSIC BILAG INDEX SCORING 
 
General 
 
Category A 
Pyrexia scoring 2 (same), 3 (worse) or 4 (new)   AND 
≥ 2 others scoring 2 (same), 3 (worse) or 4 (new) 
 
Category B 
Pyrexia scoring 2 (same), 3 (worse) or 4 (new)   OR 
≥ 2 others scoring 2 (same), 3 (worse) or 4 (new)    
 
BUT do not fulfill criteria for Category A 
 
Category C 
Pyrexia scoring 1 (improving)    OR 
One or more of others scoring > 0 
 
BUT do not fulfill criteria for Category A or B 
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
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Mucocutaneous 
 
Category A 
Any one of the following scoring 2 (same), 3 (worse) or 4 (new):    
 
Maculopapular/Bullous eruption - severe 
Discoid lesions – extensive 
Angio-oedema 
Extensive mucosal ulceration 
 
Category B 
Any one of the following scoring 2 (same), 3 (worse) or 4 (new) 
 
Malar erythema 
Maculopapular eruption - mild 
Panniculitis 
Discoid lesions - localised 
Alopecia - severe 
Subcutaneous nodules 
Perniotic skin lesions 
 
Category C 
Any Category A or Category B criteria scoring 1 (improving)   OR 
 
Any one of the following scoring > 0: 
 
Peri-ungual erythema 
Swollen fingers 
Sclerodactyly 
Calcinosis 
Telangiectasia 
Alopecia - mild 
Mucosal ulceration -small 
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
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Neurological  
 
Category A 
Any one of the following scoring 3 (worse) or 4 (new): 
 
Deteriorating level of consciousness 
Acute psychosis or delirium or confusional state 
Seizures 
Stroke or stroke syndrome 
Aseptic meningitis 
Mononeuritis multiplex 
Ascending or transverse myelitis 
Peripheral or cranial neuropathy 
Chorea 
Cerebellar ataxia 
 
Category B 
Any one of the following scoring 3 (worse) or 4 (new): 
 
Headache (severe unremitting) 
Organic depressive illness 
Organic brain syndrome including pseudotumor cerebri 
Disc swelling or cytoid bodies  
 
OR 
 
Any of the following scoring 2 (same) or 1 (improving): 
  
Deteriorating level of consciousness 
Acute psychosis or delirium or confusional state 
Seizure 
 
Category C 
 
Episodic migraine headaches scoring > 0      OR 
 
Any one of the following scoring 2 (same) or 1 (improving) 
 
Stroke or stroke syndrome 
Aseptic meningitis 
Mononeuritis multiplex 
Ascending or transverse myelitis 
Peripheral or cranial neuropathy 
Chorea 
Cerebellar ataxia 
Headache (severe unremitting) 
Organic depressive illness 
Organic brain syndrome including pseudotumor cerebri 
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Disc swelling or cytoid bodies  
 
Category D  
Previous involvement 
 
Category E  
No previous involvement 
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Musculoskeletal 
 
Category A 
One or more of the following scoring > 1: 
 
Definite myositis (Bohan and Peter) 
Severe polyarthritis  
 
Category B 
One or more of the following scoring > 1: 
Arthritis (definite synovitis) 
Tendonitis 
 
Category C 
Any Category A or Category B criteria scoring 1     OR 
 
One or more of the following scoring > 0 (or Yes) 
 
Arthralgia 
Myalgia 
Tendon contractures and fixed deformity 
Aseptic necrosis 
Mild chronic myositis 
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
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Cardiorespiratory 
 
Category A 
Cardiac failure scoring >1 plus ≥ 2 other criteria listed below scoring >1 
 
OR 
 
Symptomatic effusion scoring > 1 plus ≥ 2 other criteria listed below scoring >1 
 
OR 
 
Four of the criteria listed below each scoring > 1 
 
Pleuropericardial pain 
Dyspnoea 
Friction Rub 
Progressive Chest X-ray changes – lung fields 
Progressive Chest X-ray changes – heart size 
ECG evidence of pericarditis or myocarditis 
Cardiac arrhythmias including tachycardia - >100 in absence of fever 
Deteriorating lung function: <20% of expected or >20% fall 
Cytohistological evidence of inflammatory lung disease 
 
Category B 
Two of the criteria listed below each scoring > 1: 
 
Pleuropericardial pain 
Dyspnoea 
Friction Rub 
Progressive Chest X-ray changes – lung fields 
Progressive Chest X-ray changes – heart size 
ECG evidence of pericarditis or myocarditis 
Cardiac arrhythmias including tachycardia - >100 in absence of fever 
Deteriorating lung function: <20% of expected or >20% fall 
Cytohistological evidence of inflammatory lung disease 
 
Category C 
One of the criteria listed below each scoring > 0: 
 
Mild intermittent chest pain 
Pleuropericardial pain 
Dyspnoea 
Friction Rub 
Progressive Chest X-ray changes – lung fields 
Progressive Chest X-ray changes – heart size 
ECG evidence of pericarditis or myocarditis 
Cardiac arrhythmias including tachycardia - >100 in absence of fever 
Deteriorating lung function: <20% of expected or >20% fall 
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Cytohistological evidence of inflammatory lung disease 
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
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Vasculitis 
 
Category A 
Any of the following scoring > 1: 
 
Major cutaneous vasculitis  
Major abdominal crisis due to vasculitis 
Recurrent thromboembolism (excluding strokes) 
 
Category B 
Any of the following scoring > 1: 
 
Minor cutaneous vasculitis 
Superficial phlebitis 
Thromboembolism (excluding strokes), first episode 
 
Category C 
 
Any Category A or Category B criteria scoring 1 
Raynaud’s phenomenon, scoring > 0 
Livedo reticularis, scoring > 0 
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
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Renal 
 
Category A 
Two or more of the following providing 1, 4 or 5 is included: 
1. Proteinuria, defined as 
(a) urinary dipstick increased by 2 or more levels; or 
(b) 24 urinary protein rising from < 0.20g to > 1g; or 
(c) 24 hour urinary protein rising from > 1g by 100%; or 
(d) newly documented proteinuria of > 1g 
 
2. Accelerated hypertension 
3. Deteriorating renal function, defined as  
(a) plasma creatinine >130 μmol/l and having risen to >130% of previous  
       value; or  
(b) creatinine clearance having fallen to < 67% of previous value; or  
(c) creatinine clearance < 50 ml/min, and last time was > 50 ml/min or was  
       not measured 
 
4. Active urinary sediment  
5. Histological evidence of active nephritis  
 
Category B 
One of the following: 
1. Any one of the Category A criteria above 
2. Proteinuria 
(a) urinary dipstick which has risen by 1+ or more to at least 2+, or  
(b) 24 hour urinary protein rising from > 1g by >50% but <100% 
 
3. Plasma creatinine > 130 μmol/l and having risen to 115% of previous value 
 
Category C 
One of the following: 
 
24 hour urinary protein > 0.25g 
Urinary dipstick 1+ or more 
Rising blood pressure, defined as 
(i) systolic rise of > 30mm and 
(ii) diastolic rise of >15mm and 
(iii) the recorded values are > 140/90) 
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
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Haematological 
 
Category A 
One of the following: 
 
White cell count < 1000 
Platelet count < 25 
Haemoglobin < 8 
 
Category B 
One of the following: 
 
White cell count < 2500 
Platelet count < 100 
Haemoglobin < 11 
Coombs Test positive and evidence of active haemolysis, e.g. 
  raised bilirubin +/- increased Reticulocyte Count 
 
Category C 
One of the following: 
 
White cell count < 4000 
Platelet count < 150 
Lymphocyte count < 1500 
Coombs Test positive but no evidence of active haemolysis 
Evidence of circulating lupus anticoagulant or other antiphospholipid  
  antibody 
 
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
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Appendix 3    SLEDAI-2000 Index 
 (Circle in SLEDAI Score column if descriptor is present at the time of the visit or in the   
   preceding 10 days) 
 
Item SLEDAI 
SCORE 
Descriptor Definition 
1 8 Seizure Recent onset, exclude metabolic, infectious or drug causes 
2 8 Psychosis Altered ability to function in normal activity due to severe 
disturbance in the perception of reality. Include hallucinations, 
incoherence, marked loose associations, impoverished thought 
content, marked illogical thinking, bizarre, disorganised, or catatonic 
behaviour. Exclude uraemia and drug causes 
3 8 Organic brain 
syndrome 
Altered mental function with impaired orientation, memory, or other 
intellectual function, with rapid onset and fluctuating clinical 
features, inability to sustain attention to environment, plus at least 2 
of the following: perceptual disturbance, incoherent speech, 
insomnia or daytime drowsiness, or increased or decreased 
psychomotor activity. Exclude metabolic, infectious or drug causes 
4 8 Visual 
disturbance 
Retinal changes of SLE. Include cytoid bodies, retinal hemorrhages, 
serous exudates or hemorrhages in the choroid, or optic neuritis. 
Exclude hypertension, infection, or drug causes 
5 8 Cranial nerve 
disorder 
New onset of sensory or motor neuropathy involving cranial nerves 
6 8 Lupus 
headache 
Severe, persistent headache; may be migrainous, but must be non-
responsive to narcotic analgesia 
7 8 CVA New onset Cerebrovascular accident(s). Exclude arteriosclerosis 
8 8 Vasculitis Ulceration, gangrene, tender finger nodules, periungual infarction, 
splinter hemorrhages or biopsy or angiogram proof of vasculitis 
9 4 Arthritis ≥ 2 joints with pain and signs of inflammation (i.e. tenderness, 
swelling or effusion) 
10 4 Myositis Proximal muscle aching/weakness, associated with elevated 
creatinine phosphokinase (CK)/aldolase, or EMG changes or a 
biopsy showing myositis 
11 4 Urinary casts Heme-granular or RBC casts 
12 4 Hematuria > 5 RBC/high power field. Exclude stone, infection or other cause 
13 4 Proteinuria > 0.5 gram/24 hours 
14 4 Pyuria > 5 WBC/high power field. Exclude infection 
15 2 Rash Inflammatory type rash 
16 2 Alopecia Abnormal, patchy or diffuse loss of hair 
17 2 Mucosal 
ulcers 
Oral or nasal ulcerations 
18 2 Pleurisy Pleuritic chest pain with pleural rub or effusion, or pleural thickening 
19 2 Pericarditis Pericardial pain with at least 1 of the following: rub, effusion or ECG 
or echocardiogram confirmation 
20 2 Low 
complement 
Decrease in CH50, C3 or C4 below lower limit of normal for testing 
laboratory  
21 2 Increased 
DNA binding 
Increased DNA binding above normal range for testing laboratory 
22 1 Fever > 38ºC. Exclude infectious cause 
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23 1 Thrombocyto
penia 
< 100 x 109 platelets/L, exclude drug causes 
24 1 Leukopenia < 3 x 109 WBC/L, exclude drug causes 
 
TOTAL SCORE:    
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Appendix 4    SLICC/ACR Damage Index 
Damage (non-reversible change, not related to active inflammation) occurring since 
diagnosis of lupus, ascertained by clinical assessment and present for at least 6 months 
unless otherwise stated.  Repeat episodes must occur at least 6 months apart to score 2.  
The same lesion cannot be scored twice.  
OCULAR  
Any cataract ever (documented by ophthalmoscopy)   
Retinal change OR Optic atrophy (documented by ophthalmoscopy)  
  
Score 
1 
1 
NEUROPSYCHIATRIC 
Cognitive impairment (eg memory deficit, difficulty with calculation, poor 
concentration, difficulty in spoken or written language, impaired performance level) 
OR Major psychosis    
Seizures requiring therapy for 6 months       
Cerebrovascular accident or surgical resection (for non-malignant causes)  (score 2 if 
>1) 
Cranial or peripheral neuropathy (excluding optic)     
Transverse myelitis          
 
 
 
1 
1 
1     2 
 
1 
1 
RENAL 
Estimated/Measured GFR < 50%       
Proteinuria ≥ 3.5g/24 hours       
OR  
End-stage renal failure (regardless of dialysis or transplantation)   
 
1 
1 
 
3 
PULMONARY 
Pulmonary hypertension (right ventricular prominence or loud P2)    
Pulmonary fibrosis (physical & radiograph)      
Shrinking lung (radiograph) 
Pleural fibrosis (radiograph) 
Pulmonary infarction (radiograph) or resection (for non-malignant causes) 
 
1 
1 
1 
1 
1 
CARDIOVASCULAR 
Angina OR Coronary artery bypass 
Myocardial infarction                                                                             (score 2 if > 1) 
Cardiomyopathy (ventricular dysfunction) 
Valvular disease (diastolic, murmur, or systolic murmur > 3/6) 
Pericarditis for 6 months OR Pericardiectomy 
 
1 
1     2 
1 
1 
1 
PERIPHERAL VASCULAR 
Claudication for 6 months 
Minor tissue loss (pulp space) 
Significant tissue loss (eg loss of digit or limb)                                      (score 2 if > 1) 
Venous thrombosis with swelling ulceration OR Venous stasis  
 
1 
1 
1     2 
1 
GASTROINTESTINAL 
Infarction or resection of bowel below duodenum, spleen, liver or gallbladder for any 
cause                                                                                                        (score 2 if > 1) 
Mesenteric insufficiency 
Chronic peritonitis 
Stricture OR Upper gastrointestinal surgery 
Pancreatic insufficiency requiring enzyme replacement 
 
1     2 
 
1 
1 
1 
1 
MUSCULOSKELETAL  
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Muscle atrophy or weakness 
Deforming or erosive arthritis (including reversible deformities, excluding avascular 
necrosis) 
Osteoporosis with fracture or vertebral collapse (excluding avascular necrosis) 
Avascular necrosis (imaging)                                                                  (score 2 if > 1) 
Osteomyelitis (supported by culture evidence) 
Tendon rupture 
1 
1 
 
1 
1     2 
1 
1 
SKIN 
Scarring chronic alopecia 
Extensive scarring or panniculum other than scalp and pulp space 
Skin ulceration for > 6 months (excluding thrombosis)  
 
1 
1 
1 
PREMATURE GONADAL FAILURE (secondary amenorrhoea before age 40) 1 
DIABETES MELLITUS (regardless of treatment) 1 
MALIGNANCY (exclude dysplasia)                                             (score 2 if > 1 site) 1     2 
 
 230
Appendix 5    Agreement Tables from Reliability Study 
 
1) Constitutional 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 0 0 0 1 1
B 0 3 1 7 11
C 0 2 15 34 51
 
 
Rater 1 
D 0 1 4 29 34
Total 0 6 20 71 97
 
 
 
 
 
 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 1 0 0 0 1
B 0 3 2 3 8
C 0 4 13 27 44
 
 
Rater 1 
D 0 0 3 25 28
Total 1 7 18 55 81
 
 
 
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 48.45 37.20 0.18 
Weighted 69.59 62.95 0.18 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 53.61 38.72 0.24 
Weighted 75.26 64.08 0.31 
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2) Mucocutaneous 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 2 0 2 1 5
B 1 11 2 5 19
C 1 4 11 9 25
 
 
Rater 1 
D 0 1 4 43 48
Total 4 16 19 58 97
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 69.07 38.08 0.50 
Weighted 80.41 56.44 0.55 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 0 1 0 0 1
B 0 13 3 2 18
C 0 6 22 4 32
 
 
Rater 1 
D 0 3 1 26 30
Total 0 23 26 32 81
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 72.16 32.96 0.58 
Weighted 84.28 55.36 0.65 
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3) Neuropsychiatric 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 3 0 0 5 8
B 0 0 0 1 1
C 0 0 8 16 24
 
 
Rater 1 
D 0 0 3 61 64
Total 3 0 11 83 97
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 74.23 59.52 0.36 
Weighted 84.02 74.35 0.38 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 2 1 0 0 3
B 0 2 0 2 4
C 0 0 5 8 13
 
 
Rater 1 
D 1 1 0 59 61
Total 3 4 5 69 81
 
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 79.38 62.96 0.44 
Weighted 85.82 73.09 0.47 
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4) Musculoskeletal 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 1 3 0 0 4
B 0 5 4 4 13
C 0 7 9 25 41
 
 
Rater 1 
D 0 4 0 35 39
Total 1 19 13 64 97
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 51.55 34.86 0.26 
Weighted 72.42 57.49 0.35 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 2 0 1 0 3
B 2 5 4 1 12
C 0 5 14 16 35
 
 
Rater 1 
D 0 2 3 25 30
Total 4 12 22 42 80
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 56.70 34.25 0.34 
Weighted 77.32 57.00 0.47 
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5) Cardiorespiratory 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 0 0 0 3 3
B 1 5 0 2 8
C 0 1 0 0 1
 
 
Rater 1 
D 0 2 0 83 85
Total 1 8 0 88 97
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 90.72 80.21 0.53 
Weighted 92.01 80.98 0.58 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 0 0 0 0 0
B 0 3 0 5 8
C 0 0 1 1 2
 
 
Rater 1 
D 0 0 1 70 71
Total 0 3 2 76 81
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 90.72 83.46 0.44 
Weighted 92.27 85.98 0.45 
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6) Gastrointestinal 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 0 0 0 0 0
B 0 0 0 1 1
C 0 0 0 1 1
 
 
Rater 1 
D 0 1 0 94 95
Total 0 1 0 96 97
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 96.91 96.94 -0.01 
Weighted 97.42 97.45 -0.01 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 0 0 0 0 0
B 0 0 0 1 1
C 0 0 0 0 0
 
 
Rater 1 
D 0 0 0 80 80
Total 0 0 0 81 81
 
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 98.97 98.97 0 
Weighted 98.97 98.97 0 
 236
7) Ophthalmic 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 0 0 0 0 0
B 0 0 0 2 2
C 0 0 0 2 2
 
 
Rater 1 
D 0 0 0 93 93
Total 0 0 0 97 97
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 95.88 95.88 0 
Weighted 96.91 96.91 0 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 0 0 0 0 0
B 0 0 0 1 1
C 0 0 1 0 1
 
 
Rater 1 
D 0 0 0 79 79
Total 0 0 1 80 81
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 98.97 96.94 0.66 
Weighted 98.97 97.96 0.49 
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8) Renal 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 1 0 0 0 1
B 0 7 0 0 7
C 0 0 11 2 13
 
 
Rater 1 
D 0 0 1 75 76
Total 1 7 12 77 97
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 96.91 64.39 0.91 
Weighted 98.45 75.66 0.94 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 4 0 0 0 4
B 0 4 0 0 4
C 0 0 1 4 5
 
 
Rater 1 
D 0 0 0 84 84
Total 4 4 1 88 97
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 95.88 78.96 0.80 
Weighted 97.94 82.19 0.88 
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9) Haematological 
Exercise 1 
 
Rater 2  
A B C D 
Total
A 0 0 0 0 0
B 0 2 1 0 3
C 0 0 43 3 46
 
 
Rater 1 
D 0 0 4 41 45
Total 0 2 48 44 94
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 91.49 47.46 0.84 
Weighted 95.74 72.48 0.85 
 
Exercise 2 
 
Rater 2  
A B C D 
Total
A 0 0 0 0 0
B 0 8 2 0 10
C 0 0 23 1 24
 
 
Rater 1 
D 0 0 8 55 63
Total 0 8 33 56 97
 
 
 
 
 
 
 
 Agreement 
(%) 
Expected 
Agreement (%) 
Kappa 
Unweighted 88.66 46.76 0.79 
Weighted 94.33 67.73 0.82 
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Appendix 6    Revised BILAG-2004 Index (Post-Reliability Study) 
 
BILAG-2004 INDEX 
Only record items due to SLE Disease Activity & assessment refers to manifestations 
occurring in the last 4 weeks (compared with the previous 4 weeks).                         
♦♦ TO BE USED WITH THE GLOSSARY ♦♦ 
 
 Scoring:     ND  Not Done 
       1      Improving 
      2      Same      
3      Worse 
      4      New 
     Yes/No OR Value   (where indicated) 
          indicate if  not due to SLE activity 
    (default is 0 = not present) 
 
CONSTITUTIONAL 
1. Pyrexia - documented > 37.5ºC        (           ) 
2. Weight loss - unintentional > 5%      (           )  
3. Lymphadenopathy/splenomegaly      (           ) 
4. Anorexia         (           ) 
 
MUCOCUTANEOUS 
5. Skin eruption - severe       (           ) 
6. Skin eruption - mild       (           ) 
7. Angio-oedema - severe       (           ) 
8. Angio-oedema - mild        (           ) 
9. Mucosal ulceration - severe      (           ) 
10. Mucosal ulceration - mild       (           ) 
11. Panniculitis/Bullous lupus - severe     (           ) 
12. Panniculitis/Bullous lupus - mild      (           ) 
13. Cutaneous vasculitis/thrombosis      (           ) 
14. Digital infarcts/nodular vasculitis      (           ) 
15. Alopecia - severe        (           ) 
16. Alopecia - mild        (           ) 
17. Peri-ungual erythema/chilblains      (           ) 
18. Splinter haemorrhages       (           ) 
 
NEUROPSYCHIATRIC 
19. Aseptic meningitis       (           ) 
20. Cerebral vasculitis       (           ) 
21. Demyelinating syndrome       (           ) 
22. Myelopathy        (           ) 
23. Acute confusional state       (           ) 
24. Psychosis         (           ) 
25. Acute inflammatory demyelinating polyradiculoneuropathy  (           )   
26. Mononeuropathy (single/multiplex)     (           ) 
27. Cranial neuropathy       (           ) 
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28. Plexopathy        (           ) 
29. Polyneuropathy        (           ) 
30. Seizure disorder        (           ) 
31. Status epilepticus        (           ) 
32. Cerebrovascular disease (not due to vasculitis)    (           )  
33. Cognitive dysfunction       (           ) 
34. Movement disorder       (           ) 
35. Autonomic disorder       (           ) 
36. Cerebellar ataxia (isolated)      (           ) 
37. Lupus headache - severe unremitting      (           ) 
38. Headache from IC hypertension      (           ) 
 
MUSCULOSKELETAL 
39. Definite myositis (Bohan & Peter)     (           ) 
40. Myositis with incomplete criteria      (           ) 
41. Arthritis(severe)        (           ) 
42. Arthritis(moderate)/Tendonitis/Tenosynovitis    (           ) 
43. Arthritis(mild)/Arthralgia/Myalgia      (           ) 
 
CARDIORESPIRATORY 
44. Myocarditis - mild       (           ) 
45. Myocarditis/Endocarditis + Cardiac failure    (           ) 
46. Arrhythmia        (           ) 
47. New valvular dysfunction       (           ) 
48. Serositis (pleuro-pericardial pain) - mild     (           ) 
49. Cardiac tamponade       (           ) 
50. Pleural effusion with dyspnoea      (           ) 
51. Pulmonary haemorrhage/vasculitis     (           ) 
52. Interstitial alveolitis/pneumonitis      (           ) 
53. Shrinking lung syndrome       (           ) 
54. Aortitis         (           ) 
55. Coronary vasculitis       (           ) 
 
GASTROINTESTINAL 
56. Lupus peritonitis        (           ) 
57. Abdominal serositis or ascites      (           ) 
58. Lupus enteritis/colitis       (           ) 
59. Malabsorption        (           ) 
60. Protein losing enteropathy      (           ) 
61. Intestinal pseudo-obstruction      (           ) 
62. Lupus hepatitis        (           ) 
63. Acute lupus cholecystitis       (           ) 
64. Acute lupus pancreatitis       (           ) 
 
OPHTHALMIC 
65. Orbital inflammation/myositis/proptosis     (           ) 
66. Keratitis - severe        (           ) 
67. Keratitis - mild        (           ) 
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68. Anterior uveitis        (           ) 
69. Posterior uveitis/retinal vasculitis - severe    (           ) 
70. Posterior uveitis/retinal vasculitis - mild     (           ) 
71. Episcleritis        (           ) 
72. Scleritis - severe        (           ) 
73. Scleritis - mild        (           ) 
74. Retinal/choroidal vaso-occlusive disease     (           ) 
75. Isolated cotton-wool spots (cytoid bodies)    (           ) 
76. Optic neuritis        (           ) 
77. Anterior ischaemic optic neuropathy     (           ) 
 
RENAL  
78. Systolic blood pressure (mm Hg)      value  (           )   
79. Diastolic blood pressure (mm Hg)     value             (           )   
80. Accelerated hypertension                      Yes/No (           )   
81. Urine dipstick protein              (+=1, ++=2, +++=3) (           )   
82. Urine albumin-creatinine ratio            mg/mmol (           )   
83. Urine protein-creatinine ratio              mg/mmol (           )   
84. 24 hour urine protein (g)       value   (           )   
85. Nephrotic syndrome        Yes/No (           )   
86. Creatinine (plasma/serum)      μmol/l  (           )   
87. GFR (calculated)                          ml/min/1.73 m2  (           )   
88. Active urinary sediment                        Yes/No (           )   
89. Active nephritis         Yes/No (           )   
 
HAEMATOLOGICAL 
90. Haemoglobin (g/dl)       value  (           )   
91. Total white cell count (x 109/l)      value  (           )   
92. Neutrophils (x 109/l)       value  (           )   
93. Lymphocytes (x 109/l)       value  (           )   
94. Platelets (x 109/l)        value  (           )   
95. TTP           (           ) 
96. Evidence of active haemolysis            Yes/No (           ) 
97. Coombs’ test positive (isolated)      Yes/No (           ) 
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BILAG-2004 INDEX GLOSSARY 
 
INSTRUCTIONS 
 
     • only record features that are attributable to SLE disease activity and not due to  
        damage, infection, thrombosis (in absence of inflammatory process) or other  
        conditions 
 
     • assessment refers to manifestations occurring in the last 4 weeks compared with the  
        previous 4 weeks 
 
     • activity refers to disease process which is reversible while damage refers to permanent  
        process/scarring (irreversible) 
 
     • damage due to SLE should be considered as a cause of features that are fixed/persistent  
        (SLICC/ACR damage index uses persistence ≥ 6 months to define damage) 
 
     • in some manifestations, it may be difficult to differentiate SLE from other conditions as  
        there may not be any specific test and the decision would then lies with the physician’s  
        judgement on the balance of probabilities 
 
     • ophthalmic manifestations would usually need to be assessed by ophthalmologist (using  
        the proforma included with this glossary) and these items would need to be recorded  
        retrospectively after receiving the response from ophthalmologist 
 
     • guidance for scoring: 
 
          (4) NEW  
                 • manifestations are recorded as new when it is a new episode occurring in the last   
                    4 weeks (compared to the previous 4 weeks) which has not improved and this  
                    includes new episodes (recurrence) of old manifestations  
 
                 • new episode occurring in the last 4 weeks but also satisfying the criteria for     
                    improvement (below) would be classified as improving instead of new 
 
          (3) WORSE 
                 • this refers to manifestations that have deteriorated in the last 4 weeks compared  
                    to the previous 4 weeks 
 
          (2) SAME 
                 • this refers to manifestations that have been present for the last 4 weeks and the  
                    previous 4 weeks without significant improvement or deterioration (from the  
                    previous 4 weeks) 
 
                 • this also applies to manifestations that have improved over the last 4 weeks  
                    compared to the previous 4 weeks but do not meet the criteria for improvement 
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          (1) IMPROVING 
                 • definition of improvement: (a) the amount of improvement is sufficient for  
                       consideration of reduction in therapy and  
                                                                       would not justify escalation in therapy 
 
                 (b) improvement must be present currently and ≥ 2  
                       weeks of the last 4 weeks 
 
          (0) NOT PRESENT 
 
          (ND) NOT DONE 
                 • it is important to indicate if a test has not been performed (particularly laboratory  
                    investigations) so that this will be recorded as such in the database & not as  
                    normal or absent (which is the default) 
 
           INDICATE (TICK) IF NOT DUE TO SLE ACTIVITY 
                 • for descriptors that are based on measurements (in renal and haematology  
                    systems), it is important to indicate if these are not due to lupus disease activity  
                    (for consideration of scoring) as they are usually recorded routinely into a  
                    database 
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CONSTITUTIONAL 
 
1. Pyrexia      temperature > 37.5˚C documented 
 
2. Unintentional weight loss > 5% 
3. Lymphadenopathy    palpable lymph node more than 1 cm diameter 
 
      exclude infection 
   
4. Anorexia 
 
 
MUCOCUTANEOUS 
 
5. Severe eruption     > 18% body surface area 
                         
any lupus rash except panniculitis, bullous lesion  
& angio-oedema 
 
body surface area (BSA) is estimated using the 
rules of nines (used to assess extent of burns) as 
follows: 
 
palm(excluding fingers) = 1% BSA 
            each lower limb = 18% BSA 
              each upper limb = 9% BSA 
               torso (front) = 18% BSA 
               torso (back) = 18% BSA 
               head = 9% BSA 
               genital (male) = 1% BSA 
 
 
6. Mild eruption     ≤ 18% body surface area 
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any lupus rash except panniculitis, bullous lesion  
& angio-oedema 
 
7. Severe angio-oedema    potentially life-threatening eg: stridor 
 
      angio-oedema is a variant form of urticaria  
                                                                        which affects the subcutaneous, submucosal and  
deep dermal tissues 
 
8. Mild angio-oedema    not life threatening 
 
9. Severe mucosal ulceration   disabling (significantly interfering with oral  
                                                                        intake), extensive & deep ulceration 
       
      must have been observed by a physician 
 
10. Mild mucosal ulceration   localised &/or non-disabling ulceration 
 
11. Severe panniculitis or bullous lupus any one: 
> 9% body surface area 
facial  panniculitis 
     panniculitis that is beginning to ulcerate 
     panniculitis that threatens integrity of  
       subcutaneous tissue (beginning to cause   
       surface depression) on > 9% body surface  
       area 
 
      panniculitis presents as a palpable and tender  
subcutaneous induration/nodule  
 
note that established surface depression and  
atrophy alone is likely to be due to damage 
 
12. Mild panniculitis or bullous lupus ≤ 9% body surface area   
does not fulfill any criteria for severe panniculitis 
(for panniculitis) 
 
13. Cutaneous vasculitis/thrombosis  resulting in extensive gangrene or ulceration or  
skin infarction 
 
14. Digital infarct/nodular vasculitis  localised single or multiple infarct(s) over  
digit(s) or tender erythematous nodule(s) 
 
15. Severe alopecia    clinically detectable (diffuse or patchy) hair loss  
with scalp inflammation (redness over scalp) 
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16. Mild alopecia diffuse or patchy hair loss without scalp 
inflammation (clinically detectable or by history) 
 
17. Peri-ungual erythema or chilblains chilblains are localised inflammatory lesions  
                                                                        (may ulcerate) which are precipitated by  
exposure to cold 
 
18. Splinter haemorrhages 
 
 
NEUROPSYCHIATRIC 
 
19. Aseptic meningitis   criteria (all): acute/subacute onset 
           headache 
       fever 
     abnormal CSF (raised protein &/or  
       lymphocyte predominance) but negative  
       cultures 
 
preferably photophobia, neck stiffness and  
meningeal irritation should be present as well but  
are not essential for diagnosis 
 
      exclude CNS/meningeal infection, intracranial    
haemorrhage 
 
20. Cerebral vasculitis   should be present with features of vasculitis  
in another system  
 
supportive imaging &/or biopsy findings 
 
21. Demyelinating syndrome   discrete white matter lesion with associated   
       neurological deficit not recorded elsewhere 
 
ideally there should have been at least one 
previously recorded event 
 
supportive imaging required 
 
exclude multiple sclerosis 
 
22. Myelopathy    acute onset of rapidly evolving paraparesis or  
quadriparesis and/or sensory level 
 
exclude intramedullary and extramedullary  
space occupying lesion 
 
23. Acute confusional state   acute disturbance of consciousness or level of  
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arousal with reduced ability to focus, maintain or 
shift attention 
 
includes hypo- and hyperaroused states and 
encompasses the spectrum from delirium to 
coma 
 
24. Psychosis     delusion or hallucinations    
 
      does not occur exclusively during course of a  
delirium 
 
exclude drugs, substance abuse, primary  
psychotic disorder 
 
25. Acute inflammatory demyelinating criteria: 
       polyradiculoneuropathy       progressive polyradiculoneuropathy 
          loss of reflexes 
          symmetrical involvement 
          increased CSF protein without pleocytosis 
    supportive electrophysiology study 
 
26. Mononeuropathy (single/multiplex) supportive electrophysiology study required 
 
27. Cranial neuropathy   except optic neuropathy which is classified  
under ophthalmic system 
 
28. Plexopathy    disorder of brachial or lumbosacral plexus  
resulting in neurological deficit not  
corresponding to territory of single root or nerve 
 
supportive electrophysiology study required 
 
29. Polyneuropathy    acute symmetrical distal sensory and/or motor  
                                                                        deficit 
 
      supportive electrophysiology study required 
 
30. Seizure disorder independent description of seizure by reliable 
witness 
 
31. Status epilepticus    a seizure or series of seizures lasting ≥ 30  
minutes without full recovery to baseline 
 
32. Cerebrovascular disease   any one with supporting imaging: 
       (not due to vasculitis)      stroke syndrome 
         transient ischaemic attack 
         intracranial haemorrhage 
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exclude hypoglycaemia, cerebral sinus 
thrombosis, vascular malformation, tumour, 
abscess 
 
cerebral sinus thrombosis not included as  
definite thrombosis not considered part of lupus 
activity 
 
33. Cognitive dysfunction   significant deficits in any cognitive functions: 
         simple attention (ability to register & maintain  
                                                                             information) 
         complex attention 
         memory (ability to register, recall & recognise  
                                                                             information eg learning, recall) 
         visual-spatial processing (ability to analyse,  
                                                                             synthesise & manipulate visual-spatial  
                                                                             information) 
         language (ability to comprehend, repeat &  
                                                                             produce oral/written material eg verbal  
                                                                             fluency, naming) 
         reasoning/problem solving (ability to reason &  
                                                                             abstract) 
         psychomotor speed 
         executive functions (eg planning, organising,  
                                                                             sequencing) 
 
      in absence of disturbance of consciousness or  
level of arousal 
       
      sufficiently severe to interfere with daily  
activities 
     
 neuropsychological testing should be done or  
corroborating history from third party if possible  
 
      exclude substance abuse 
 
34. Movement disorder   exclude drugs 
 
35. Autonomic disorder   any one: 
         fall in blood pressure to standing > 30/15 mm  
   Hg (systolic/diastolic) 
 
   increase in heart rate to standing ≥ 30 bpm 
 
   loss of heart rate variation with respiration   
   (max – min < 15 bpm, expiration:inspiration  
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   ratio < 1.2, Valsalva ratio < 1.4) 
 
   loss of sweating over body and limbs  
   (anhidrosis) by sweat test 
 
      exclude drugs and diabetes mellitus 
 
36. Cerebellar ataxia cerebellar ataxia in isolation of other CNS 
features 
 
 usually subacute presentation 
 
37. Severe lupus headache (unremitting) disabling headache unresponsive to narcotic 
analgesia & lasting ≥ 3 days 
 
exclude intracranial space occupying lesion  
and CNS infection 
 
38. Headache from IC hypertension  exclude cerebral sinus thrombosis 
 
 
MUSCULOSKELETAL 
 
39. Definite myositis    ≥ 3 Bohan & Peter criteria: 
      proximal muscle weakness 
      elevated muscle enzymes (CK or aldolase) 
      positive muscle biopsy 
      EMG characteristic of myositis 
 
40. Incomplete myositis   2 Bohan & Peter criteria 
 
41. Severe arthritis    observed active synovitis ≥ 2 joints with marked   
                                                                        loss of functional range of movements and  
                                                                        significant impairment of activities of daily  
                                                                        living, that has been present on several days  
                                                                        (cumulatively) over the last 4 weeks 
 
42. Arthritis or Tendonitis/Tenosynovitis tendonitis/tenosynovitis or active synovitis ≥ 1 
joint (observed or through history) with some 
loss of functional range of movements, that has 
been present on several days over the last 4 
weeks 
 
43. Arthralgia or Myalgia inflammatory type of pain (worse in the morning 
with stiffness, usually improves with activity & 
not brought on by activity) over joints/muscle or 
joint tenderness which does not fulfill the above 
criteria for arthritis or myositis 
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CARDIORESPIRATORY 
 
44. Mild myocarditis    inflammation of myocardium with raised  
cardiac enzymes &/or ECG changes and without 
resulting cardiac failure, arrhythmia or valvular 
dysfunction 
 
45. Cardiac failure cardiac failure due to myocarditis or non-
infective inflammation of endocardium or 
cardiac valves (endocarditis) 
 
 cardiac failure due to myocarditis is defined by 
left ventricular ejection fraction ≤ 40% & 
pulmonary oedema or peripheral oedema 
 
cardiac failure due to acute valvular regurgitation 
(from endocarditis) can be associated with 
normal left ventricular ejection fraction 
 
 diastolic heart failure is not included 
 
46. Arrhythmia arrhythmia (except sinus tachycardia) due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
 
      confirmation by electrocardiogram required  
(history of palpitations alone inadequate) 
 
47. New valvular dysfunction new cardiac valvular dysfunction due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
 
      supportive imaging required 
 
48. Mild serositis (pleuro-pericardial pain) in absence of cardiac tamponade or pleural 
effusion with dyspnoea 
 
49. Cardiac tamponade   supportive imaging required 
50. Pleural effusion with dyspnoea  supportive imaging required 
51. Pulmonary haemorrhage/vasculitis inflammation of pulmonary vasculature with  
haemoptysis &/or dyspnoea &/or pulmonary 
hypertension 
 
supportive imaging &/or histological diagnosis 
required 
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52. Interstitial alveolitis/pneumonitis  radiological features of alveolar infiltration not  
due to infection or haemorrhage required for 
diagnosis 
 
corrected gas transfer Kco reduced to < 70% 
normal or fall of > 20% if previously abnormal 
 
      on-going activity would be determined by  
clinical findings and lung function tests, and  
repeated imaging may be required in those with  
deterioration (clinically or lung function tests) or 
failure to respond to therapy 
 
53. Shrinking lung syndrome   acute reduction (> 20% if previous measurement  
                                                                        available) in lung volumes (to < 70% predicted)  
                                                                        in the presence of normal corrected gas transfer  
                                                                        (Kco) & dysfunctional diaphragmatic  
movements 
 
54. Aortitis     inflammation of aorta (with or without  
dissection) with supportive imaging 
abnormalities  
 
accompanied by > 10 mm Hg difference in BP 
between arms &/or claudication of extremities 
&/or vascular bruits 
 
      repeated imaging would be required to determine  
on-going activity in those with clinical  
deterioration or failure to respond to therapy 
 
55. Coronary vasculitis   inflammation of coronary vessels with  
radiographic evidence of non-atheromatous 
narrowing, obstruction or aneurysmal changes 
 
 
GASTROINTESTINAL 
 
56. Lupus peritonitis    serositis presenting as acute abdomen with  
rebound/guarding 
 
57. Serositis     not presenting as acute abdomen 
 
58. Lupus enteritis or colitis vasculitis or inflammation of small or large 
bowel with supportive imaging &/or biopsy 
findings 
 
59. Malabsorption    diarrhoea with abnormal D- xylose absorption  
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test or increased faecal fat excretion after 
exclusion of coeliac’s disease (poor response to 
gluten-free diet) and gut vasculitis 
 
60. Protein-losing enteropathy  diarrhoea with hypoalbuminaemia or increased  
faecal excretion of iv radiolabeled albumin after 
exclusion of gut vasculitis and malabsorption 
 
61. Intestinal pseudo-obstruction  subacute intestinal obstruction due to intestinal  
hypomotility 
 
62. Lupus hepatitis    raised transaminases  
 
absence of autoantibodies specific to 
autoimmune hepatitis (eg: anti-smooth muscle, 
anti-liver cytosol 1) &/or biopsy appearance of 
chronic active hepatitis 
 
hepatitis typically lobular with no piecemeal 
necrosis 
 
63. Acute lupus cholecystitis   after exclusion of gallstones and infection 
 
64. Acute lupus pancreatitis   usually associated multisystem involvement 
 
 
OPHTHALMIC 
 
65. Orbital inflammation   orbital inflammation with myositis &/or extra- 
ocular muscle swelling &/or proptosis 
 
      supportive imaging required 
 
66. Severe keratitis     sight threatening 
includes:  corneal melt 
    peripheral ulcerative keratitis 
 
67. Mild keratitis    not sight threatening 
 
68. Anterior uveitis 
69. Severe posterior uveitis &/or retinal  sight-threatening &/or retinal vasculitis 
       vasculitis     not due to vaso-occlusive disease 
 
70. Mild posterior uveitis &/or retinal not sight-threatening 
       vasculitis       
not due to vaso-occlusive disease 
 
71. Episcleritis 
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72. Severe scleritis    necrotising anterior scleritis 
 
anterior &/or posterior scleritis requiring  
systemic steroids/immunosuppression &/or not  
responding to NSAIDs 
 
73. Mild scleritis anterior &/or posterior scleritis not requiring 
systemic steroids 
       
      excludes necrotising anterior scleritis 
 
74. Retinal/choroidal vaso-occlusive   includes: retinal arterial & venous occlusion 
disease         serous retinal &/or retinal pigment  
     epithelial detachments secondary to    
     choroidal vasculopathy 
 
75. Isolated cotton-wool spots  also known as cytoid bodies   
 
76. Optic neuritis    excludes anterior ischaemic optic neuropathy 
 
77. Anterior ischaemic optic neuropathy visual loss with pale swollen optic disc due to 
occlusion of posterior ciliary arteries 
 
 
RENAL 
 
78. Systolic blood pressure 
79. Diastolic blood pressure 
80. Accelerated hypertension   blood pressure rising to > 170/110 mm Hg  
within 1 month with grade 3 or 4 Keith-
Wagener-Barker retinal changes (flame-shaped 
haemorrhages or cotton-wool spots or 
papilloedema) 
 
81. Urine dipstick 
82. Urine albumin-creatinine ratio  on freshly voided urine sample 
 
83. Urine protein-creatinine ratio  on freshly voided urine sample 
 
84. 24 hour urine protein 
85. Nephrotic syndrome   criteria: 
heavy proteinuria (> 50 mg/kg/day or >    
  3.5 g/day or protein-creatinine ratio > 350  
  mg/mmol or albumin-creatinine ratio > 350  
  mg/mmol) 
 
           hypoalbuminaemia  
           oedema 
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86. Plasma/Serum creatinine 
87. GFR      MDRD formula: 
GFR = 170 x [serum creatinine (mg/dl)]-0.999 x   
              [age]-0.176 x [serum urea (mg/dl]-0.17 x   
              [serum albumin (g/dl)]0.318 x [0.762 if  
              female] x [1.180 if African ancestry] 
       
         units = ml/min per 1.73 m2 
         normal: male = 130 ± 40 
                       female = 120 ± 40 
 
conversion: 
    serum creatinine  -   mg/dl = (μmol/l)/88.5 
    serum urea          -  mg/dl = (mmol/l) x 2.8 
          serum albumin    -    g/dl    = (g/l)/10 
 
creatinine clearance not recommended as it is not 
reliable 
 
88. Active urinary sediment   pyuria (> 5 WCC/hpf or > 10 WCC/mm3 (μl))  
 
OR 
 
haematuria (> 5 RBC/hpf or > 10 RBC/mm3 (μl)) 
 
OR 
 
red cell casts  
 
in absence of other causes  
 
89. Histology of active nephritis WHO Classification (1995): (any one)  
   Class III – (a) or (b) subtypes 
   Class IV – (a), (b) or (c) subtypes 
   Class V – (a), (b), (c) or (d) subtypes 
   Vasculitis 
 
 OR 
 
 ISN/RPS Classification (2003): (any one) 
    Class III – (A) or (A/C) subtypes 
    Class IV – (A) or (A/C) subtypes 
    Class V 
    Vasculitis 
  
 within last 3 months or since previous 
assessments if seen less than 3 months ago 
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glomerular sclerosis without inflammation not 
included 
 
 
HAEMATOLOGICAL 
 
90. Haemoglobin 
91. White cell count 
92. Neutrophil count 
93. Lymphocyte count 
94. Platelet count    exclude thrombocytopenia of antiphospholipid  
syndrome 
 
95. TTP     thrombotic thrombocytopaenic purpura 
       
clinical syndrome of micro-angiopathic 
haemolytic anaemia and thrombocytopenia in 
absence of any other identifiable cause 
 
96. Evidence of active haemolysis positive Coomb’s test & evidence of haemolysis 
(raised bilirubin or raised reticulocyte count or 
reduced haptoglobulins) 
 
97. Isolated positive Coomb’s test 
 
 
ADDITIONAL ITEMS 
 
These items are required mainly for calculation of GFR 
 
      i.  Weight 
      ii.  African ancestry       
      iii.  Serum urea 
      iv.  Serum albumin 
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BILAG-2004 INDEX SCORING 
 
    • scoring based on the principle of physician’s intention to treat 
 
Grade 
 
Definition 
 
A Severe disease activity requiring any of the following treatment: 
 
1. systemic high dose oral corticosteroids (equivalent to  
     prednisolone > 20 mg/day) 
 
2. intravenous pulse corticosteroids (equivalent to pulse  
     methylprednisolone ≥ 500 mg) 
 
3. systemic immunomodulators (include biologicals,  
     immunoglobulins and plasmapheresis) 
 
4. therapeutic high dose anticoagulation in the presence of high dose  
    corticosteroids or immunomodulators 
      eg: warfarin with target INR 3 - 4 
 
B 
 
Moderate disease activity requiring any of the following treatment: 
 
1. systemic low dose oral corticosteroids (equivalent to prednisolone  
     ≤ 20 mg/day) 
 
2. intramuscular or intra-articular or soft tissue corticosteroids  
     injection (equivalent to methylprednisolone < 500mg) 
 
3. topical corticosteroids 
4. topical immunomodulators 
5. antimalarials or thalidomide or prasterone or acitretin 
6. symptomatic therapy 
      eg: NSAIDs for inflammatory arthritis 
 
C 
 
Stable mild disease 
 
D 
 
Inactive disease but previously affected 
 
E System never involved 
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CONSTITUTIONAL 
 
Grade A: 
Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  AND  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Anorexia 
 
Grade B: 
Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  OR  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Anorexia 
 
BUT do not fulfil criteria for Grade A 
 
Grade C 
Pyrexia recorded as 1 (improving)  OR 
 
One or more of the following recorded as > 0:  
 
Weight loss 
  Lymphadenopathy/Splenomegaly 
  Anorexia 
 
BUT does not fulfil criteria for Grade A or B 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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MUCOCUTANEOUS 
 
Grade A   
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Skin eruption - severe  
Angio-oedema - severe 
  Mucosal ulceration - severe 
  Panniculitis/Bullous lupus - severe 
Cutaneous vasculitis/thrombosis 
 
Grade B  
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Skin eruption - mild 
Panniculitis/Bullous lupus - mild 
  Digital infarcts/nodular vasculitis 
  Alopecia - severe 
   
Grade C   
Any Grade B features recorded as 1 (improving) OR 
 
Any of the following recorded as > 0: 
 
  Angio-oedema - mild 
  Mucosal ulceration - mild 
  Alopecia - mild 
Periungual erythema/chilblains 
Splinter haemorrhages 
 
Grade D  
Previous involvement 
 
Grade E  
No previous involvement 
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NEUROLOGICAL 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Aseptic meningitis 
Cerebral vasculitis 
Demyelinating syndrome 
Myelopathy 
Acute confusional state 
Psychosis 
Acute inflammatory demyelinating polyradiculoneuropathy 
Mononeuropathy (single/multiplex) 
Cranial neuropathy 
Plexopathy 
Polyneuropathy 
Status epilepticus 
Cerebellar ataxia 
 
Grade B 
Any Grade A features recorded as 1 (improving) OR 
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Seizure disorder  
Cerebrovascular disease (not due to vasculitis) 
Cognitive dysfunction 
Movement disorder 
Autonomic disorder  
Headache severe unremitting 
Headache due to raised intracranial hypertension 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR 
 
Grade D  
Previous involvement 
 
Grade E  
No previous involvement 
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MUSCULOSKELETAL 
 
Grade A 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
 Definite Myositis (Bohan and Peter) 
Severe arthritis 
 
Grade B 
Any Grade A features recorded as 1 (improving)  OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
 Myositis with incomplete criteria  
Arthritis/Tendonitis/Tenosynovitis 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
 Arthralgia/Myalgia 
   
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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CARDIORESPIRATORY 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Myocarditis/Endocarditis + Cardiac failure 
  Arrhythmia 
  New valvular dysfunction 
Cardiac tamponade 
  Pleural effusion with dyspnoea 
  Pulmonary haemorrhage/vasculitis  
Interstitial alveolitis/pneumonitis  
Shrinking lung syndrome 
Aortitis 
Coronary vasculitis 
 
Grade B 
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Serositis (pleuro-pericardial pain) - mild  
Myocarditis - mild 
 
Grade C 
Any Grade B features recorded as 1 (improving) 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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GASTROINTESTINAL 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Peritonitis 
Lupus enteritis/colitis 
Intestinal pseudo-obstruction  
Acute lupus cholecystitis 
Acute lupus pancreatitis 
 
Grade B 
Any Grade A feature recorded as 1 (improving) OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
Abdominal serositis and/or ascites  
Malabsorption 
Protein losing enteropathy 
Lupus hepatitis 
 
Grade C 
Any Grade B features recorded as 1 (improving)  
 
Grade D  
Previous involvement 
 
Grade E   
No previous involvement 
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OPHTHALMIC 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Orbital inflammation/myositis/proptosis 
Keratitis - severe 
Posterior uveitis/retinal vasculitis - severe 
Scleritis - severe 
Retinal/choroidal vaso-occlusive disease 
Optic neuritis 
Anterior ischaemic optic neuropathy  
 
Grade B 
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Keratitis - mild 
Anterior uveitis 
Posterior uveitis/retinal vasculitis - mild 
Scleritis - mild 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
Episcleritis 
Isolated cotton-wool spots (cytoid bodies) 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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RENAL 
 
Grade A 
Two or more of the following providing 1, 4 or 5 is included: 
 
1. Deteriorating proteinuria (severe) defined as   
 
      (a) urine dipstick increased by ≥ 2 levels; or  
      (b) 24 hour urine protein > 1 g that has not decreased (improved) by ≥ 50%; or 
      (c) urine protein-creatinine ratio > 100 mg/mmol that has not decreased (improved) by ≥  
             50%; or 
 
      (d) urine albumin-creatinine ratio > 100 mg/mmol that has not decreased (improved) by ≥  
             50% 
 
2. Accelerated hypertension  
3. Deteriorating renal function (severe) defined as  
 
      (a) plasma creatinine > 130 μmol/l and having risen to > 130% of previous value; or  
      (b) GFR having fallen to < 67% of previous value; or  
      (c) GFR < 50 ml/min per 1.73 m2, and last time was > 50 ml/min per 1.73 m2 or was not  
             measured. 
 
4. Active urinary sediment 
5. Histological evidence of active nephritis within last 3 months  
6. Nephrotic syndrome 
 
 
Grade B 
One of the following: 
 
1. One of the Grade A feature 
 
2. Urine dipstick which has risen by 1 level to at least 2+  
 
3. Plasma creatinine > 130 μmol/l and having risen to ≥ 115% but ≤ 130% of previous value 
 
Grade C 
One of the following: 
 
1. Mild/Stable proteinuria defined as 
 
      (a) urine dipstick ≥ 1+ but has not fulfilled criteria for Grade A & B; or 
      (b) 24 hour urine protein > 0.25 g but has not fulfilled criteria for Grade A & B ; or 
      (c) urine protein-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Grade A  
             & B; or  
 
(d) urine albumin-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Grade A  
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       & B 
 
2. Rising blood pressure (providing the recorded values are > 140/90 mm Hg) which has not 
fulfilled criteria for Grade A & B, defined as 
  
(a) systolic rise of ≥ 30 mm Hg; and  
(b) diastolic rise of ≥ 15mm Hg  
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
 
 
Note: although albumin-creatinine ratio and protein-creatinine ratio are different, the same  
           cut-off values are used for both in this index 
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HAEMATOLOGICAL  
 
Grade A 
TTP recorded as 2 (same), 3 (worse) or 4 (new)   OR 
 
Any of the following: 
   
Haemoglobin   < 8 g/dl 
White cell count  < 1.0 x 109/l 
Neutrophil count  < 0.5 x 109/l  
Platelet count   < 25 x 109/l 
 
Grade B 
TTP recorded as 1 (improving)   OR 
 
Any of the following:  
 
Haemoglobin   8 - 9.9 x 109/l 
White cell count  1 - 2.4 x 109/l 
Neutrophil count  0.5 - 1.4 x 109/l 
Platelet count   25 - 49 x 109/l 
Evidence of active haemolysis 
 
Grade C 
Any of the following: 
 
Haemoglobin   10 - 10.9 g/dl  
White cell count  2.5 - 3.9 x 109/l 
Neutrophil count  1.5 - 1.9 x 109/l 
Lymphocyte count  < 1.0 x 109/L 
Platelet count  50 - 149 x 109/l 
Isolated Coombs’ test positive  
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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Appendix 7    Revised BILAG-2004 Index (Post-Longitudinal 
Study) 
BILAG-2004 INDEX 
Only record items due to SLE Disease Activity & assessment refers to manifestations 
occurring in the last 4 weeks (compared with the previous 4 weeks).                         
♦♦ TO BE USED WITH THE GLOSSARY ♦♦ 
 
 Scoring:     ND  Not Done 
       1      Improving 
      2      Same      
3      Worse 
      4      New 
     Yes/No OR Value   (where indicated) 
          indicate if  not due to SLE activity 
    (default is 0 = not present) 
 
CONSTITUTIONAL 
1. Pyrexia - documented > 37.5ºC        (           ) 
2. Weight loss - unintentional > 5%      (           )  
3. Lymphadenopathy/splenomegaly      (           ) 
4. Anorexia         (           ) 
 
MUCOCUTANEOUS 
5. Skin eruption - severe       (           ) 
6. Skin eruption - mild       (           ) 
7. Angio-oedema - severe       (           ) 
8. Angio-oedema - mild        (           ) 
9. Mucosal ulceration - severe      (           ) 
10. Mucosal ulceration - mild       (           ) 
11. Panniculitis/Bullous lupus - severe     (           ) 
12. Panniculitis/Bullous lupus - mild      (           ) 
13. Cutaneous vasculitis/thrombosis      (           ) 
14. Digital infarcts/nodular vasculitis      (           ) 
15. Alopecia - severe        (           ) 
16. Alopecia - mild        (           ) 
17. Peri-ungual erythema/chilblains      (           ) 
18. Splinter haemorrhages       (           ) 
 
NEUROPSYCHIATRIC 
19. Aseptic meningitis       (           ) 
20. Cerebral vasculitis       (           ) 
21. Demyelinating syndrome       (           ) 
22. Myelopathy        (           ) 
23. Acute confusional state       (           ) 
24. Psychosis         (           ) 
25. Acute inflammatory demyelinating polyradiculoneuropathy  (           )   
26. Mononeuropathy (single/multiplex)     (           ) 
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27. Cranial neuropathy       (           ) 
28. Plexopathy        (           ) 
29. Polyneuropathy        (           ) 
30. Seizure disorder        (           ) 
31. Status epilepticus        (           ) 
32. Cerebrovascular disease (not due to vasculitis)    (           )  
33. Cognitive dysfunction       (           ) 
34. Movement disorder       (           ) 
35. Autonomic disorder       (           ) 
36. Cerebellar ataxia (isolated)      (           ) 
37. Lupus headache - severe unremitting      (           ) 
38. Headache from IC hypertension      (           ) 
 
MUSCULOSKELETAL 
39. Myositis - severe        (           ) 
40. Myositis - mild        (           ) 
41. Arthritis(severe)        (           ) 
42. Arthritis(moderate)/Tendonitis/Tenosynovitis    (           ) 
43. Arthritis(mild)/Arthralgia/Myalgia      (           ) 
 
CARDIORESPIRATORY 
44. Myocarditis - mild       (           ) 
45. Myocarditis/Endocarditis + Cardiac failure    (           ) 
46. Arrhythmia        (           ) 
47. New valvular dysfunction       (           ) 
48. Pleurisy/Pericarditis       (           ) 
49. Cardiac tamponade       (           ) 
50. Pleural effusion with dyspnoea      (           ) 
51. Pulmonary haemorrhage/vasculitis     (           ) 
52. Interstitial alveolitis/pneumonitis      (           ) 
53. Shrinking lung syndrome       (           ) 
54. Aortitis         (           ) 
55. Coronary vasculitis       (           ) 
 
GASTROINTESTINAL 
56. Lupus peritonitis        (           ) 
57. Abdominal serositis or ascites      (           ) 
58. Lupus enteritis/colitis       (           ) 
59. Malabsorption        (           ) 
60. Protein losing enteropathy      (           ) 
61. Intestinal pseudo-obstruction      (           ) 
62. Lupus hepatitis        (           ) 
63. Acute lupus cholecystitis       (           ) 
64. Acute lupus pancreatitis       (           ) 
 
OPHTHALMIC 
65. Orbital inflammation/myositis/proptosis     (           ) 
66. Keratitis - severe        (           ) 
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67. Keratitis - mild        (           ) 
68. Anterior uveitis        (           ) 
69. Posterior uveitis/retinal vasculitis - severe    (           ) 
70. Posterior uveitis/retinal vasculitis - mild     (           ) 
71. Episcleritis        (           ) 
72. Scleritis - severe        (           ) 
73. Scleritis - mild        (           ) 
74. Retinal/choroidal vaso-occlusive disease     (           ) 
75. Isolated cotton-wool spots (cytoid bodies)    (           ) 
76. Optic neuritis        (           ) 
77. Anterior ischaemic optic neuropathy     (           ) 
 
RENAL  
78. Systolic blood pressure (mm Hg)      value  (           )   
79. Diastolic blood pressure (mm Hg)     value             (           )   
80. Accelerated hypertension                      Yes/No (           )   
81. Urine dipstick protein              (+=1, ++=2, +++=3) (           )   
82. Urine albumin-creatinine ratio            mg/mmol (           )   
83. Urine protein-creatinine ratio              mg/mmol (           )   
84. 24 hour urine protein (g)       value   (           )   
85. Nephrotic syndrome        Yes/No (           )   
86. Creatinine (plasma/serum)      μmol/l  (           )   
87. GFR (calculated)                          ml/min/1.73 m2  (           )   
88. Active urinary sediment                        Yes/No (           )   
89. Active nephritis         Yes/No (           )   
 
HAEMATOLOGICAL 
90. Haemoglobin (g/dl)       value  (           )   
91. Total white cell count (x 109/l)      value  (           )   
92. Neutrophils (x 109/l)       value  (           )   
93. Lymphocytes (x 109/l)       value  (           )   
94. Platelets (x 109/l)        value  (           )   
95. TTP           (           ) 
96. Evidence of active haemolysis            Yes/No (           ) 
97. Coombs’ test positive (isolated)      Yes/No (           ) 
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BILAG-2004 INDEX GLOSSARY 
 
INSTRUCTIONS 
 
     • only record features that are attributable to SLE disease activity and not due to  
        damage, infection, thrombosis (in absence of inflammatory process) or other  
        conditions 
 
     • assessment refers to manifestations occurring in the last 4 weeks compared with the  
        previous 4 weeks 
 
     • activity refers to disease process which is reversible while damage refers to permanent  
        process/scarring (irreversible) 
 
     • damage due to SLE should be considered as a cause of features that are fixed/persistent  
        (SLICC/ACR damage index uses persistence ≥ 6 months to define damage) 
 
     • in some manifestations, it may be difficult to differentiate SLE from other conditions as  
        there may not be any specific test and the decision would then lies with the physician’s  
        judgement on the balance of probabilities 
 
     • ophthalmic manifestations would usually need to be assessed by ophthalmologist and  
        these items would need to be recorded retrospectively after receiving the response from  
        ophthalmologist 
 
     • guidance for scoring: 
 
          (4) NEW  
                 • manifestations are recorded as new when it is a new episode occurring in the last   
                    4 weeks (compared to the previous 4 weeks) which has not improved and this  
                    includes new episodes (recurrence) of old manifestations  
 
                 • new episode occurring in the last 4 weeks but also satisfying the criteria for     
                    improvement (below) would be classified as improving instead of new 
 
          (3) WORSE 
                 • this refers to manifestations that have deteriorated in the last 4 weeks compared  
                    to the previous 4 weeks 
 
          (2) SAME 
                 • this refers to manifestations that have been present for the last 4 weeks and the  
                    previous 4 weeks without significant improvement or deterioration (from the  
                    previous 4 weeks) 
 
                 • this also applies to manifestations that have improved over the last 4 weeks  
                    compared to the previous 4 weeks but do not meet the criteria for improvement 
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          (1) IMPROVING 
                 • definition of improvement: (a) the amount of improvement is sufficient for  
                       consideration of reduction in therapy and  
                                                                       would not justify escalation in therapy 
 
AND   
               
                                                                 (b) improvement must be present currently and 
                                                                       for at least 2 weeks out of the last 4 weeks 
 
                                                                        OR 
 
                                                                      manifestation that has completely resolved and  
                                                                      remained absent over the whole of last 1 week 
 
          (0) NOT PRESENT 
 
          (ND) NOT DONE 
                 • it is important to indicate if a test has not been performed (particularly laboratory  
                    investigations) so that this will be recorded as such in the database & not as  
                    normal or absent (which is the default) 
 
           INDICATE (TICK) IF NOT DUE TO SLE ACTIVITY 
                 • for descriptors that are based on measurements (in renal and haematology  
                    systems), it is important to indicate if these are not due to lupus disease activity  
                    (for consideration of scoring) as they are usually recorded routinely into a  
                    database 
 
          CHANGE IN SEVERITY CATEGORY 
                 • there are several items in the index which have been divided into categories of  
                    mild and severe (depending on definition). It is essential to record mild and  
                    severe items appropriately if the manifestations fulfill both criteria during the last  
                    4 weeks 
 
                 • if a mild item deteriorated to the extent that it fulfilled the definition of severe  
                    category (ie changed into severe category) within the last 4 weeks: 
       severe item scored as new (4)  
                    AND  mild item scored as worsening (3) 
 
                 • if a severe item improved (fulfilling the improvement criteria) to the extent that it  
                    no longer fulfilled the definition of severe category (ie changed into mild  
                    category) within the last 4 weeks: 
                               severe item scored as not present (0) if criteria for severe category has not  
                                                                                              been met over last 4 weeks 
                                                         or as improving (1) if criteria for severe category has been                  
                                                                                             met at some point over last 4 weeks 
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                   AND  
 
                               mild item scored as improving (1) if it is improving over last 4 weeks 
                                                      or as the same (2) if it has remained stable over last 4 weeks 
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CONSTITUTIONAL 
 
1. Pyrexia      temperature > 37.5˚C documented 
 
2. Unintentional weight loss > 5% 
3. Lymphadenopathy    lymph node more than 1 cm diameter 
 
      exclude infection 
   
4. Anorexia 
 
 
MUCOCUTANEOUS 
 
5. Severe eruption     > 18% body surface area 
                         
any lupus rash except panniculitis, bullous lesion  
& angio-oedema 
 
body surface area (BSA) is estimated using the 
rules of nines (used to assess extent of burns) as 
follows: 
 
palm(excluding fingers) = 1% BSA 
            each lower limb = 18% BSA 
              each upper limb = 9% BSA 
               torso (front) = 18% BSA 
               torso (back) = 18% BSA 
               head = 9% BSA 
               genital (male) = 1% BSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Mild eruption     ≤ 18% body surface area 
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any lupus rash except panniculitis, bullous lesion  
& angio-oedema 
 
malar rash must have been observed by a  
physician and has to be present continuously  
(persistent) for at least 1 week to be considered  
significant (to be recorded) 
 
7. Severe angio-oedema    potentially life-threatening eg: stridor 
 
      angio-oedema is a variant form of urticaria  
                                                                        which affects the subcutaneous, submucosal and  
deep dermal tissues 
 
8. Mild angio-oedema    not life threatening 
 
9. Severe mucosal ulceration   disabling (significantly interfering with oral  
                                                                        intake), extensive & deep ulceration 
       
      must have been observed by a physician 
 
10. Mild mucosal ulceration   localised &/or non-disabling ulceration 
 
11. Severe panniculitis or bullous lupus any one: 
> 9% body surface area 
facial  panniculitis 
     panniculitis that is beginning to ulcerate 
     panniculitis that threatens integrity of  
       subcutaneous tissue (beginning to cause   
       surface depression) on > 9% body surface  
       area 
 
      panniculitis presents as a palpable and tender  
subcutaneous induration/nodule  
 
note that established surface depression and  
atrophy alone is likely to be due to damage 
 
12. Mild panniculitis or bullous lupus ≤ 9% body surface area   
does not fulfill any criteria for severe panniculitis 
(for panniculitis) 
 
13. Major cutaneous vasculitis/thrombosis resulting in extensive gangrene or ulceration or  
skin infarction 
 
14. Digital infarct or nodular vasculitis localised single or multiple infarct(s) over  
digit(s) or tender erythematous nodule(s) 
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15. Severe alopecia    clinically detectable (diffuse or patchy) hair loss  
with scalp inflammation (redness over scalp) 
 
16. Mild alopecia diffuse or patchy hair loss without scalp 
inflammation (clinically detectable or by history) 
 
17. Peri-ungual erythema or chilblains chilblains are localised inflammatory lesions  
                                                                        (may ulcerate) which are precipitated by  
exposure to cold 
 
18. Splinter haemorrhages 
 
 
NEUROPSYCHIATRIC 
 
19. Aseptic meningitis   criteria (all): acute/subacute onset 
           headache 
       fever 
     abnormal CSF (raised protein &/or  
       lymphocyte predominance) but negative  
       cultures 
 
preferably photophobia, neck stiffness and  
meningeal irritation should be present as well but  
are not essential for diagnosis 
 
exclude CNS/meningeal infection, intracranial    
haemorrhage 
 
20. Cerebral vasculitis   should be present with features of vasculitis  
in another system  
 
supportive imaging &/or biopsy findings 
 
21. Demyelinating syndrome   discrete white matter lesion with associated   
       neurological deficit not recorded elsewhere 
 
ideally there should have been at least one 
previously recorded event 
 
supportive imaging required 
 
exclude multiple sclerosis 
 
22. Myelopathy    acute onset of rapidly evolving paraparesis or  
quadriparesis and/or sensory level 
 
exclude intramedullary and extramedullary  
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space occupying lesion 
 
23. Acute confusional state   acute disturbance of consciousness or level of  
arousal with reduced ability to focus, maintain or 
shift attention 
 
includes hypo- and hyperaroused states and 
encompasses the spectrum from delirium to 
coma 
 
24. Psychosis     delusion or hallucinations    
 
      does not occur exclusively during course of a  
delirium 
 
exclude drugs, substance abuse, primary  
psychotic disorder 
 
25. Acute inflammatory demyelinating criteria: 
       polyradiculoneuropathy       progressive polyradiculoneuropathy 
          loss of reflexes 
          symmetrical involvement 
          increased CSF protein without pleocytosis 
    supportive electrophysiology study 
 
26. Mononeuropathy (single/multiplex) supportive electrophysiology study required 
 
27. Cranial neuropathy   except optic neuropathy which is classified  
under ophthalmic system 
 
28. Plexopathy    disorder of brachial or lumbosacral plexus  
resulting in neurological deficit not  
corresponding to territory of single root or nerve 
 
supportive electrophysiology study required 
 
29. Polyneuropathy    acute symmetrical distal sensory and/or motor  
                                                                        deficit 
 
      supportive electrophysiology study required 
 
30. Seizure disorder independent description of seizure by reliable 
witness 
 
31. Status epilepticus    a seizure or series of seizures lasting ≥ 30  
minutes without full recovery to baseline 
 
32. Cerebrovascular disease   any one with supporting imaging: 
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       (not due to vasculitis)      stroke syndrome 
         transient ischaemic attack 
         intracranial haemorrhage 
       
exclude hypoglycaemia, cerebral sinus 
thrombosis, vascular malformation, tumour, 
abscess 
 
cerebral sinus thrombosis not included as  
definite thrombosis not considered part of lupus 
activity 
 
33. Cognitive dysfunction   significant deficits in any cognitive functions: 
         simple attention (ability to register & maintain  
                                                                             information) 
         complex attention 
         memory (ability to register, recall & recognise  
                                                                             information eg learning, recall) 
         visual-spatial processing (ability to analyse,  
                                                                             synthesise & manipulate visual-spatial  
                                                                             information) 
         language (ability to comprehend, repeat &  
                                                                             produce oral/written material eg verbal  
                                                                             fluency, naming) 
         reasoning/problem solving (ability to reason &  
                                                                             abstract) 
         psychomotor speed 
         executive functions (eg planning, organising,  
                                                                             sequencing) 
 
      in absence of disturbance of consciousness or  
level of arousal 
       
      sufficiently severe to interfere with daily  
activities 
     
 neuropsychological testing should be done or  
corroborating history from third party if possible  
 
      exclude substance abuse 
 
34. Movement disorder   exclude drugs 
 
35. Autonomic disorder   any one: 
         fall in blood pressure to standing > 30/15 mm  
   Hg (systolic/diastolic) 
 
   increase in heart rate to standing ≥ 30 bpm 
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   loss of heart rate variation with respiration   
   (max – min < 15 bpm, expiration:inspiration  
   ratio < 1.2, Valsalva ratio < 1.4) 
 
   loss of sweating over body and limbs  
   (anhidrosis) by sweat test 
 
      exclude drugs and diabetes mellitus 
 
36. Cerebellar ataxia cerebellar ataxia in isolation of other CNS 
features 
 
 usually subacute presentation 
 
37. Severe lupus headache (unremitting) disabling headache unresponsive to narcotic 
analgesia & lasting ≥ 3 days 
 
exclude intracranial space occupying lesion  
and CNS infection 
 
38. Headache from IC hypertension  exclude cerebral sinus thrombosis 
 
 
MUSCULOSKELETAL 
 
39. Severe myositis    significantly elevated serum muscle enzymes  
       with significant muscle weakness 
 
      exclude endocrine causes and drug-induced  
       myopathy 
 
electromyography and muscle biopsy are used 
for diagnostic purpose and are not required to 
determine level of activity 
 
40. Mild myositis    significantly elevated serum muscle enzymes  
with myalgia but without significant muscle  
weakness 
 
      asymptomatic elevated serum muscle enzymes  
not included 
 
exclude endocrine causes and drug-induced  
       myopathy 
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electromyography and muscle biopsy are used 
for diagnostic purpose and are not required to 
determine level of activity 
 
41. Severe arthritis    observed active synovitis ≥ 2 joints with marked   
                                                                        loss of functional range of movements and  
                                                                        significant impairment of activities of daily  
                                                                        living, that has been present on several days  
                                                                        (cumulatively) over the last 4 weeks 
 
42. Moderate arthritis or Tendonitis tendonitis/tenosynovitis or active synovitis ≥ 1  
       or Tenosynovitis  joint (observed or through history) with some 
loss of functional range of movements, that has 
been present on several days over the last 4 
weeks 
 
43. Mild arthritis or Arthralgia or Myalgia inflammatory type of pain (worse in the morning 
with stiffness, usually improves with activity & 
not brought on by activity) over joints/muscle  
 
inflammatory arthritis which does not fulfill the 
above criteria for moderate or severe arthritis 
 
 
CARDIORESPIRATORY 
 
44. Mild myocarditis    inflammation of myocardium with raised  
cardiac enzymes &/or ECG changes and without 
resulting cardiac failure, arrhythmia or valvular 
dysfunction 
 
45. Cardiac failure cardiac failure due to myocarditis or non-
infective inflammation of endocardium or 
cardiac valves (endocarditis) 
 
 cardiac failure due to myocarditis is defined by 
left ventricular ejection fraction ≤ 40% & 
pulmonary oedema or peripheral oedema 
 
cardiac failure due to acute valvular regurgitation 
(from endocarditis) can be associated with 
normal left ventricular ejection fraction 
 
 diastolic heart failure is not included 
 
46. Arrhythmia arrhythmia (except sinus tachycardia) due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
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      confirmation by electrocardiogram required  
(history of palpitations alone inadequate) 
 
47. New valvular dysfunction new cardiac valvular dysfunction due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
 
      supportive imaging required 
 
48. Pleurisy/Pericarditis convincing history &/or physical findings that 
you would consider treating 
 
 in absence of cardiac tamponade or pleural 
effusion with dyspnoea 
 
                                                                        do not score if you are unsure whether or not it is 
pleurisy/pericarditis 
 
49. Cardiac tamponade   supportive imaging required 
50. Pleural effusion with dyspnoea  supportive imaging required 
51. Pulmonary haemorrhage/vasculitis inflammation of pulmonary vasculature with  
haemoptysis &/or dyspnoea &/or pulmonary 
hypertension 
 
supportive imaging &/or histological diagnosis 
required 
 
52. Interstitial alveolitis/pneumonitis  radiological features of alveolar infiltration not  
due to infection or haemorrhage required for 
diagnosis 
 
corrected gas transfer Kco reduced to < 70% 
normal or fall of > 20% if previously abnormal 
 
      on-going activity would be determined by  
clinical findings and lung function tests, and  
repeated imaging may be required in those with  
deterioration (clinically or lung function tests) or 
failure to respond to therapy 
 
53. Shrinking lung syndrome   acute reduction (> 20% if previous measurement  
                                                                        available) in lung volumes (to < 70% predicted)  
                                                                        in the presence of normal corrected gas transfer  
                                                                        (Kco) & dysfunctional diaphragmatic  
movements 
 
54. Aortitis     inflammation of aorta (with or without  
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dissection) with supportive imaging 
abnormalities  
 
accompanied by > 10 mm Hg difference in BP 
between arms &/or claudication of extremities 
&/or vascular bruits 
 
      repeated imaging would be required to determine  
on-going activity in those with clinical  
deterioration or failure to respond to therapy 
 
55. Coronary vasculitis   inflammation of coronary vessels with  
radiographic evidence of non-atheromatous 
narrowing, obstruction or aneurysmal changes 
 
 
GASTROINTESTINAL 
 
56. Lupus peritonitis    serositis presenting as acute abdomen with  
rebound/guarding 
 
57. Serositis     not presenting as acute abdomen 
 
58. Lupus enteritis or colitis vasculitis or inflammation of small or large 
bowel with supportive imaging &/or biopsy 
findings 
 
59. Malabsorption    diarrhoea with abnormal D- xylose absorption  
test or increased faecal fat excretion after 
exclusion of coeliac’s disease (poor response to 
gluten-free diet) and gut vasculitis 
 
60. Protein-losing enteropathy  diarrhoea with hypoalbuminaemia or increased  
faecal excretion of iv radiolabeled albumin after 
exclusion of gut vasculitis and malabsorption 
 
61. Intestinal pseudo-obstruction  subacute intestinal obstruction due to intestinal  
hypomotility 
 
62. Lupus hepatitis    raised transaminases  
 
absence of autoantibodies specific to 
autoimmune hepatitis (eg: anti-smooth muscle, 
anti-liver cytosol 1) &/or biopsy appearance of 
chronic active hepatitis 
 
hepatitis typically lobular with no piecemeal 
necrosis 
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exclude drug-induced and viral hepatitis 
 
63. Acute lupus cholecystitis   after exclusion of gallstones and infection 
 
64. Acute lupus pancreatitis   usually associated multisystem involvement 
 
 
OPHTHALMIC 
 
65. Orbital inflammation   orbital inflammation with myositis &/or extra- 
ocular muscle swelling &/or proptosis 
 
      supportive imaging required 
 
66. Severe keratitis     sight threatening 
includes:  corneal melt 
    peripheral ulcerative keratitis 
 
67. Mild keratitis    not sight threatening 
 
68. Anterior uveitis 
69. Severe posterior uveitis &/or retinal  sight-threatening &/or retinal vasculitis 
       vasculitis     not due to vaso-occlusive disease 
 
70. Mild posterior uveitis &/or retinal not sight-threatening 
       vasculitis       
not due to vaso-occlusive disease 
 
71. Episcleritis 
72. Severe scleritis    necrotising anterior scleritis 
 
anterior &/or posterior scleritis requiring  
systemic steroids/immunosuppression &/or not    
responding to NSAIDs 
 
73. Mild scleritis anterior &/or posterior scleritis not requiring 
systemic steroids 
       
      excludes necrotising anterior scleritis 
 
74. Retinal/choroidal vaso-occlusive   includes: retinal arterial & venous occlusion 
disease         serous retinal &/or retinal pigment  
     epithelial detachments secondary to    
     choroidal vasculopathy 
 
75. Isolated cotton-wool spots  also known as cytoid bodies   
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76. Optic neuritis    excludes anterior ischaemic optic neuropathy 
 
77. Anterior ischaemic optic neuropathy visual loss with pale swollen optic disc due to 
occlusion of posterior ciliary arteries 
 
 
RENAL 
 
78. Systolic blood pressure 
79. Diastolic blood pressure 
80. Accelerated hypertension   blood pressure rising to > 170/110 mm Hg  
within 1 month with grade 3 or 4 Keith-
Wagener-Barker retinal changes (flame-shaped 
haemorrhages or cotton-wool spots or 
papilloedema) 
 
81. Urine dipstick 
82. Urine albumin-creatinine ratio  on freshly voided urine sample 
 
      conversion: 1 mg/mg = 113 mg/mmol 
 
      it is important to exclude other causes (especially  
infection) when proteinuria is present 
 
83. Urine protein-creatinine ratio  on freshly voided urine sample 
 
      conversion: 1 mg/mg = 113 mg/mmol 
 
      it is important to exclude other causes (especially  
infection) when proteinuria is present 
 
84. 24 hour urine protein   it is important to exclude other causes (especially  
infection) when proteinuria is present 
 
85. Nephrotic syndrome   criteria: 
heavy proteinuria ( ≥ 3.5 g/day or protein-  
  creatinine ratio ≥ 350 mg/mmol or albumin- 
  creatinine ratio ≥ 350 mg/mmol) 
 
           hypoalbuminaemia  
           oedema 
 
86. Plasma/Serum creatinine 
87. GFR      MDRD formula: 
GFR = 170 x [serum creatinine (mg/dl)]-0.999 x   
              [age]-0.176 x [serum urea (mg/dl]-0.17 x   
              [serum albumin (g/dl)]0.318 x [0.762 if  
              female] x [1.180 if African ancestry] 
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         units = ml/min per 1.73 m2 
         normal: male = 130 ± 40 
                       female = 120 ± 40 
 
conversion: 
    serum creatinine  -   mg/dl = (μmol/l)/88.5 
    serum urea          -  mg/dl = (mmol/l) x 2.8 
          serum albumin    -    g/dl    = (g/l)/10 
 
creatinine clearance not recommended as it is not 
reliable 
 
exclude other causes for decrease in GFR 
(especially drugs) 
 
88. Active urinary sediment   pyuria (> 5 WCC/hpf or > 10 WCC/mm3 (μl))  
 
   OR 
 
haematuria (> 5 RBC/hpf or > 10 RBC/mm3 (μl)) 
 
   OR 
 
red cell casts  
 
   OR 
 
white cell casts 
 
in absence of other causes (especially infection,  
vaginal bleed, calculi) 
 
89. Histology of active nephritis WHO Classification (1995): (any one)  
   Class III – (a) or (b) subtypes 
   Class IV – (a), (b) or (c) subtypes 
   Class V – (a), (b), (c) or (d) subtypes 
   Vasculitis 
 
    OR 
 
 ISN/RPS Classification (2003): (any one) 
    Class III – (A) or (A/C) subtypes 
    Class IV – (A) or (A/C) subtypes 
    Class V 
    Vasculitis 
  
 within last 3 months 
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glomerular sclerosis without inflammation not 
included 
 
 
HAEMATOLOGICAL 
 
90. Haemoglobin    exclude dietary deficiency & GI blood loss 
91. White cell count    exclude drug-induced cause 
92. Neutrophil count    exclude drug-induced cause 
93. Lymphocyte count 
94. Platelet count    exclude thrombocytopenia of antiphospholipid  
syndrome & drug-induced cause 
 
95. TTP     thrombotic thrombocytopaenic purpura 
       
clinical syndrome of micro-angiopathic 
haemolytic anaemia and thrombocytopenia in 
absence of any other identifiable cause 
 
96. Evidence of active haemolysis positive Coomb’s test & evidence of haemolysis 
(raised bilirubin or raised reticulocyte count or 
reduced haptoglobulins) 
 
97. Isolated positive Coomb’s test 
 
ADDITIONAL ITEMS 
 
These items are required mainly for calculation of GFR 
 
      i.  Weight 
      ii.  African ancestry       
      iii.  Serum urea 
      iv.  Serum albumin 
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BILAG-2004 INDEX SCORING 
 
    • scoring based on the principle of physician’s intention to treat 
 
Grade 
 
Definition 
 
A Severe disease activity requiring any of the following treatment: 
 
1. systemic high dose oral corticosteroids (equivalent to  
     prednisolone > 20 mg/day) 
 
2. intravenous pulse corticosteroids (equivalent to pulse  
     methylprednisolone  ≥ 500 mg) 
 
3. systemic immunomodulators (include biologicals,  
     immunoglobulins and plasmapheresis) 
 
4. therapeutic high dose anticoagulation in the presence of high dose 
    corticosteroids or immunomodulators 
      eg: warfarin with target INR 3 - 4 
 
B 
 
Moderate disease activity requiring any of the following treatment: 
 
1. systemic low dose oral corticosteroids (equivalent to prednisolone  
     ≤ 20 mg/day) 
 
2. intramuscular or intra-articular or soft tissue corticosteroids  
     injection (equivalent to methylprednisolone < 500mg) 
 
3. topical corticosteroids 
4. topical immunomodulators 
5. antimalarials or thalidomide or prasterone or acitretin 
6. symptomatic therapy 
      eg: NSAIDs for inflammatory arthritis 
 
C 
 
Mild disease 
D 
 
Inactive disease but previously affected 
E System never involved 
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CONSTITUTIONAL 
 
Grade A: 
Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  AND  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Anorexia 
 
Grade B: 
Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  OR  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Anorexia 
 
BUT do not fulfil criteria for Grade A 
 
Grade C 
Pyrexia recorded as 1 (improving)  OR 
 
One or more of the following recorded as > 0:  
 
Weight loss 
  Lymphadenopathy/Splenomegaly 
  Anorexia 
 
BUT does not fulfil criteria for Grade A or B 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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MUCOCUTANEOUS 
 
Grade A   
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Skin eruption - severe  
Angio-oedema - severe 
  Mucosal ulceration - severe 
  Panniculitis/Bullous lupus - severe 
Major cutaneous vasculitis/thrombosis 
 
Grade B  
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Skin eruption - mild 
Panniculitis/Bullous lupus - mild 
  Digital infarcts or nodular vasculitis 
  Alopecia - severe 
   
Grade C   
Any Grade B features recorded as 1 (improving) OR 
 
Any of the following recorded as > 0: 
 
  Angio-oedema - mild 
  Mucosal ulceration - mild 
  Alopecia - mild 
Periungual erythema/chilblains 
Splinter haemorrhages 
 
Grade D  
Previous involvement 
 
Grade E  
No previous involvement 
 
 
 
 
 
 
 
 
 289
NEUROPSYCHIATRIC 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Aseptic meningitis 
Cerebral vasculitis 
Demyelinating syndrome 
Myelopathy 
Acute confusional state 
Psychosis 
Acute inflammatory demyelinating polyradiculoneuropathy 
Mononeuropathy (single/multiplex) 
Cranial neuropathy 
Plexopathy 
Polyneuropathy 
Status epilepticus 
Cerebellar ataxia 
 
Grade B 
Any Grade A features recorded as 1 (improving) OR 
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Seizure disorder  
Cerebrovascular disease (not due to vasculitis) 
Cognitive dysfunction 
Movement disorder 
Autonomic disorder  
Lupus headache - severe unremitting 
Headache due to raised intracranial hypertension 
 
Grade C 
Any Grade B features recorded as 1 (improving) 
 
Grade D  
Previous involvement 
 
Grade E  
No previous involvement 
 
 
 
 
 
 290
MUSCULOSKELETAL 
 
Grade A 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
 Severe Myositis 
Severe Arthritis 
 
Grade B 
Any Grade A features recorded as 1 (improving)  OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
 Mild Myositis 
Moderate Arthritis/Tendonitis/Tenosynovitis 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
 Mild Arthritis/Arthralgia/Myalgia 
   
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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CARDIORESPIRATORY 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Myocarditis/Endocarditis + Cardiac failure 
  Arrhythmia 
  New valvular dysfunction 
Cardiac tamponade 
  Pleural effusion with dyspnoea 
  Pulmonary haemorrhage/vasculitis  
Interstitial alveolitis/pneumonitis  
Shrinking lung syndrome 
Aortitis 
Coronary vasculitis 
 
Grade B 
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Pleurisy/Pericarditis 
Myocarditis - mild 
 
Grade C 
Any Grade B features recorded as 1 (improving) 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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GASTROINTESTINAL 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Peritonitis 
Lupus enteritis/colitis 
Intestinal pseudo-obstruction  
Acute lupus cholecystitis 
Acute lupus pancreatitis 
 
Grade B 
Any Grade A feature recorded as 1 (improving) OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
Abdominal serositis and/or ascites  
Malabsorption 
Protein losing enteropathy 
Lupus hepatitis 
 
Grade C 
Any Grade B features recorded as 1 (improving)  
 
Grade D  
Previous involvement 
 
Grade E   
No previous involvement 
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OPHTHALMIC 
 
Grade A 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Orbital inflammation/myositis/proptosis 
Keratitis - severe 
Posterior uveitis/retinal vasculitis - severe 
Scleritis - severe 
Retinal/choroidal vaso-occlusive disease 
Optic neuritis 
Anterior ischaemic optic neuropathy  
 
Grade B 
Any Grade A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Keratitis - mild 
Anterior uveitis 
Posterior uveitis/retinal vasculitis - mild 
Scleritis - mild 
 
Grade C 
Any Grade B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
Episcleritis 
Isolated cotton-wool spots (cytoid bodies) 
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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RENAL 
 
Grade A 
Two or more of the following providing 1, 4 or 5 is included: 
 
1. Deteriorating proteinuria (severe) defined as   
 
      (a) urine dipstick increased by ≥ 2 levels (used only if other methods of urine protein  
             estimation not available); or  
 
      (b) 24 hour urine protein > 1 g that has not decreased (improved) by ≥ 25%; or 
      (c) urine protein-creatinine ratio > 100 mg/mmol that has not decreased (improved) by ≥  
             25%; or 
 
      (d) urine albumin-creatinine ratio > 100 mg/mmol that has not decreased (improved) by ≥  
              25% 
 
2. Accelerated hypertension  
3. Deteriorating renal function (severe) defined as  
 
      (a) plasma creatinine > 130 μmol/l and having risen to > 130% of previous value; or  
      (b) GFR < 80 ml/min per 1.73 m2 and having fallen to < 67% of previous value; or  
      (c) GFR < 50 ml/min per 1.73 m2, and last time was > 50 ml/min per 1.73 m2 or was not  
             measured. 
 
4. Active urinary sediment 
5. Histological evidence of active nephritis within last 3 months  
6. Nephrotic syndrome 
 
Grade B 
One of the following: 
 
1. One of the Grade A feature 
 
2. Proteinuria (that has not fulfilled Grade A criteria) 
      (a) urine dipstick which has risen by 1 level to at least 2+ (used only if other methods of  
             urine protein estimation not available); or 
 
      (b) 24 hour urine protein ≥ 0.5 g that has not decreased (improved) by ≥ 25%; or 
      (c) urine protein-creatinine ratio ≥ 50 mg/mmol that has not decreased (improved) by ≥  
             25%; or 
 
      (d) urine albumin-creatinine ratio ≥ 50 mg/mmol that has not decreased (improved) by ≥  
             25% 
 
3. Plasma creatinine > 130 μmol/l and having risen to ≥ 115% but ≤ 130% of previous value 
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Grade C 
One of the following: 
 
1. Mild/Stable proteinuria defined as 
 
(a) urine dipstick ≥ 1+ but has not fulfilled criteria for Grade A & B (used only if other 
methods of urine protein estimation not available); or 
 
      (b) 24 hour urine protein > 0.25 g but has not fulfilled criteria for Grade A & B ; or 
      (c) urine protein-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Grade A  
             & B; or  
 
      (d) urine albumin-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Grade A  
             & B 
 
2. Rising blood pressure (providing the recorded values are > 140/90 mm Hg) which has not 
fulfilled criteria for Grade A & B, defined as 
  
(a) systolic rise of ≥ 30 mm Hg; and  
(b) diastolic rise of ≥ 15mm Hg  
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
 
 
Note: although albumin-creatinine ratio and protein-creatinine ratio are different, the same  
          cut-off values are used for both in this index 
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HAEMATOLOGICAL  
 
Grade A 
TTP recorded as 2 (same), 3 (worse) or 4 (new)   OR 
 
Any of the following: 
   
Haemoglobin   < 8 g/dl 
White cell count  < 1.0 x 109/l 
Neutrophil count  < 0.5 x 109/l  
Platelet count   < 25 x 109/l 
 
Grade B 
TTP recorded as 1 (improving)   OR 
 
Any of the following:  
 
Haemoglobin   8 - 8.9 g/dl 
White cell count  1 - 1.9 x 109/l 
Neutrophil count  0.5 - 0.9 x 109/l 
Platelet count   25 - 49 x 109/l 
Evidence of active haemolysis 
 
Grade C 
Any of the following: 
 
Haemoglobin   9 - 10.9 g/dl  
White cell count  2 - 3.9 x 109/l 
Neutrophil count  1 - 1.9 x 109/l 
Lymphocyte count  < 1.0 x 109/L 
Platelet count  50 - 149 x 109/l 
Isolated Coombs’ test positive  
 
Grade D 
Previous involvement 
 
Grade E 
No previous involvement 
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